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Abstract 
 
Nuclear receptors, including the pregnane x receptor (PXR) and the farnesoid x 
receptor (FXR), regulate the expression of genes that maintain bile acid (BA) 
homeostasis. Intrahepatic cholestasis of pregnancy (ICP) is a common gestational 
liver disease and BAs are implicated in its pathogenesis. 
Rodents exhibit maternal liver growth in order to meet the metabolic demands of 
pregnancy. This process is found to precede changes in body weight, occur in the 
presence of raised serum BAs and is likely to be driven by a placental lactogen. 
While the growth is normally achieved by hepatocyte hypertrophy, potentially 
harmful hyperplasia makes a major contribution in mice lacking Fxr.  
Consistent with reports of raised serum BAs in normal pregnant women, hepatic BAs 
are found in association with pro-cholestatic gene expression in normal pregnant 
mice. Gestation could be a state of reduced Fxr function because BA-fed and Fxr-/- 
mice do not develop raised hepatic BAs during pregnancy. Sequencing and 
functional assessment of PXR variants revealed that polymorphisms in this gene are 
unlikely to contribute to the aetiology of ICP. 
Surprisingly, Pxr-/- mice have enhanced hepatic metabolism and are resistant to 
toxicity caused by lithocholic acid (LCA). Furthermore, while hepatic Pxr is 
activated by intraperitoneal injection of LCA, it is not activated by physiologically 
relevant LCA-feeding.  
Summary: Pregnancy causes liver growth, raised hepatic BA and pro-cholestatic 
gene expression in normal mice. In humans, these adaptations may expose 
predisposed individuals to gestational liver disease. Genetic variation in PXR does 
not contribute to ICP and Pxr may play only a limited role in mediating hepatic 
responses to toxic BAs.   
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Nuclear hormone receptor nomenclature 
 
Nuclear hormone receptors were originally named based on the ligand identified to 
activate the receptor (for example, the pregnane x receptor (PXR)) or a description of 
the function of the receptor (for example, the short heterodimer partner (SHP)). 
Recently, the nuclear receptor signalling atlas (NURSA) have agreed a system of 
nomenclature that classifies each receptor within the “NR” family. According to the 
NURSA classification, PXR is now termed NR1I2. To date, the convention is to use 
descriptive names (PXR) when referring to the function of the receptor and the 
NURSA nomenclature (NR1I2) when referring to the gene sequence. This 
convention has been followed in this thesis.    
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1   Introduction 
 
1.1 Overview 
 
Bile acids are the product of hepatic cholesterol catabolism and are essential for the 
solubilization and absorption of dietary fat and fat-soluble vitamins. They are 
hepatotoxic and a complex network of hepatic and intestinal transport proteins, 
hydroxylation enzymes and signalling hormones are required to maintain bile acid 
homeostasis. As ligands for members of the nuclear hormone receptor superfamily of 
transcription factors, bile acids act as signalling molecules that influence not only 
their own homeostasis but also whole body energy, glucose and lipid metabolism.  
 
During normal pregnancy in humans, bile acid homeostasis is apparently perturbed, 
possibly as a result of altered nuclear hormone receptor-dependant bile acid 
signalling. Furthermore, gestational factors can unmask cholestatic disease in 
otherwise normal, but genetically predisposed, individuals.   
 
This introduction will describe several aspects of bile acid and nuclear receptor 
signalling that are of relevance to the findings presented in this thesis. Data on the 
role of the endobiotic and xenobiotic sensor PXR in preventing bile acid-mediated 
hepatotoxicity will be discussed. Furthermore, the effects of gestation on the 
maintenance of bile acid homeostasis will be reviewed in light of the genetic and 
hormonal aetiology of intrahepatic cholestasis of pregnancy.  
 
1.2 The nuclear receptor super-family 
 
Nuclear hormone receptors (NRs) are ligand-activated transcription factors that have 
diverse biological functions including the regulation of bile, lipid and glucose 
homeostasis, reproduction, growth, development and metabolism (Chambon, 2005; 
Evans, 2005). The ability to directly bind DNA in the promoters of target genes is a 
characteristic that differentiates NRs from other classes of receptor that convey their 
effect on the nucleus through signalling cascades requiring many molecules. To date 
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48 members of the NR super-family have been identified in humans, largely on the 
basis of their sequence similarity to other known receptors (Germain et al., 2006).  
 
With some exceptions, NRs share a common structural organisation (Germain et al., 
2006) (Fig. 1.1). The N-terminal domain contains at least one, highly variable and 
constitutionally active transactivation function (AF-1). The primary sequence of NR 
DNA binding domains (DBD) are highly conserved between receptors and between 
species. The DBD structure of a number of receptors has been resolved and this 
region also contains a dimerization domain. DAX1 and SHP are atypical receptors 
that do not harbor a DBD (Kumar et al., 1986). Between the DBD and the ligand-
binding domain (LBD), lies a moderately conserved hinge region. The primary 
sequence of NR LBDs is only modestly conserved between receptors but the 
secondary structure of 12 α-helices is better conserved. The LBD contains a 
dimerization domain, a ligand-binding pocket, a co-regulator binding surface and an 
AF-2 domain that is required for ligand-dependant transcriptional activation (Sonoda 
et al., 2008). The modest inter-species conservation in NR LBD primary sequence 
suggests a strong evolutionary pressure on this domain.  
 
1.2.1 Transcriptional modification by nuclear hormone 
receptors 
 
NRs have transcriptional activation and repression activities and mediate their action 
through genomic, non-genomic, ligand-dependant and ligand-independent 
mechanisms. Furthermore, NRs are targets of signalling pathways that functionally 
modify the receptor post-translationally.  
 
NRs bind DNA in the upstream region of their target genes in one of three ways. 1) 
As a homodimer, to palindromic (inverted repeat) hormone response elements 
(HREs). 2) As a heterodimer with the retinoid acid receptor (RXR) to direct-repeat 
HREs.  3) As a monomer to half site HREs (summarized in Figure 1.2). Many of the 
orphan NRs that are of relevance to this thesis bind to HREs as heterodimers with 
RXR (Kliewer et al., 1992). Indeed, RXR is required for transcriptional activation by 
a number of receptors. Retinoic acid is required for the functional activation of RXR  
 18 
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 20 
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when bound to HREs as a homodimer. However, while retinoic acid enhances the 
transcriptional activity of an RXR-orphan receptor heterodimer, it is not required for 
this complex to become active. Following ligand binding, NRs loose gene expression 
repressive markers such as histone deacetylases and transcriptional co-repressors 
such as SMRT and NCOR. Ligand activated NRs recruit transcriptional co-
activators, such as the steroid receptor co-activator (SRC) and histone acetyl-
transferases, which are necessary for transcriptional activation (summarised in Fig. 
1.3).   
 
A diverse array of compounds bind NRs and affect transcription of their target genes. 
These molecules are typically small and hydrophobic, e.g. steroid hormones, certain 
vitamins and metabolic intermediates. This array of ligands allows these receptors to 
have wide-ranging endocrine and paracrine functions. Because many NRs were 
identified based on sequence similarity with other known receptors, a large 
proportion of NRs were cloned without knowledge of their activating ligands. NRs 
without a known ligand were initially termed “orphan receptors” and subsequently 
“adopted-orphans” upon identification of their activating molecules. Bile acids (BAs) 
are endogenous ligands of a number of adopted-orphan NRs. 
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1.3 Bile acids  
 
Bile acids (BAs), cholesterol, phospholipids and bilirubin are the major constituents 
of bile. Approximately 0.5g of cholesterol is converted to bile each day and this 
process serves as the principal route of cholesterol elimination (Pauli-Magnus et al., 
2005). The constituents of bile are synthesised in the hepatocytes of the liver and are 
actively transported into the bile canaliculi where they drain into the gall bladder. 
Following feeding, the endocrine actions of cholecystokinine cause the gall bladder 
to contract and the bile is pumped into the ileum (Chiang, 1998). In the intestine, 
BAs have a detergent effect and are essential for the solubilization and subsequent 
absorption of dietary cholesterol and fat-soluble vitamins. Bacterial de-hydroxylation 
of BAs occurs in the intestine to form hydrophobic secondary BAs. Approximately 
95% of BAs are re-absorbed in the terminal ileum and transported back to the liver 
via the portal vein, thus completing the entero-hepatic circulation (Einarsson et al., 
1991). 5% of the total BA pool is excreted in the faeces during each cycle of the 
entero-hepatic circulation, and this is the proportion that is replaced each day by de-
novo synthesis. In the liver, secondary BAs are detoxified and re-entered into the 
entero-hepatic circulation or specifically modified for their targeted excretion in the 
urine or faeces. BAs are implicated in the pathogenesis of a number of gastro-
intestinal diseases and, due to their intrinsic toxicity, their synthesis and homeostasis 
are tightly controlled. Recently, BAs have also been identified as signalling 
molecules capable of activating NRs that mediate diverse functions including 
metabolic regulation.     
 
1.3.1 Bile acid biosynthesis 
 
BAs are the product of cholesterol catabolism. The process of conversion of 
cholesterol into BAs is complex and involves at least 14 enzymes (Russell, 2003) 
(Fig. 1.4). There are two major pathways of BA biosynthesis, the “classical” and the  
“alternative” pathway. The classical pathway is present only in the liver, is the major 
route of BA formation and results in the production of the primary BAs cholic acid 
(CA) and chenodeoxycholic acid (CDCA) (Russell, 2003). The rate-limiting step of 
the classical pathway of BA biosynthesis is catalyzed by the cholesterol 7α-
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hydroxylase (CYP7A1). CYP7A1 hydroxylates cholesterol at the C7 position, 
resulting in the formation of 7α-hydroxycholesterol. In a subsequent reaction, the 
function of the sterol 12α-hydroxylase (CYP8B1) determines the ratio of CA to 
CDCA by driving the biosynthetic pathway towards the formation of CA. Following 
a number of subsequent reactions, primary BAs are finally conjugated to either 
taurine or glycine by the action of the BA CoA amino acid N-acetyltransferase 
(BAAT) (Russell, 2003). In the alternative pathway of BA biosynthesis, which forms 
only a minor contribution to the BA pool, cholesterol is first hydroxylated at the C27 
position by the sterol 27α-hydroxylase (CYP27A1). CDCA is the principal BA 
formed by the alternative pathway of biosynthesis (Axelson et al., 2000). The 
chemical structures of the most common bile acids are depicted in Figure 1.5.   
 
The process of BA biosynthesis is regulated by a network of NRs. BAs exert 
negative feedback regulation on their own synthesis, primarily by regulating the 
function of CYP7A1 at the transcriptional and functional level. BAs were identified 
as endogenous ligands of FXR (the farnesoid x receptor (NR1H4)), now considered 
the be the principal bile acid sensor (Makishima et al., 1999; Parks et al., 1999; 
Wang et al., 1999). BA-activated FXR binds to response elements in the promoter of 
the small heterodimer partner (SHP, NR0B2) and induces its expression. In turn, 
SHP interacts with the hepatocyte nuclear factor 4α (HNF4α) and the liver receptor 
homolog-1 (LRH1) to inhibit their binding to the CYP7A1 promoter and hence 
prevents its transcription (Chiang, 2004). In this way, hepatic FXR reduces BA 
biosynthesis by indirectly repressing the expression of CYP7A1 through the 
induction of SHP. Activation of other BA-responsive NRs including the constitutive 
androstane receptor (CAR, NR1I3) and the pregnane x receptor (PXR, NR1I2) have 
recently also been demonstrated to repress BA biosynthesis (Staudinger et al., 
2001b; Miao et al., 2006). However, knockout mice for Fxr and Shp display 
abnormal basal BA homeostasis (Kim et al., 2007; Yang et al., 2007) whereas Pxr-/- 
(Staudinger et al., 2001b) and Car-/-  mice do not.  
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An important alternative method of feedback regulation of BA biosynthesis has been 
elucidated (Holt et al., 2003). FXR is highly expressed in the terminal ileum and 
microarray analysis of mice treated with the specific Fxr agonist GW4064 revealed 
the marked upregulation of intestinal Fgf15 expression (Inagaki et al., 2005). Fgf15 
is a hormone that binds to and activates the FGF receptor (Fgfr4) in the liver and 
represses BA biosynthesis by acting on Cyp7a1 (Inagaki et al., 2005). The human 
ortholog of mouse Fgf15, FGF19, also represses BA biosynthesis in cultures of 
primary human hepatocytes (Song et al., 2009). The mechanism by which Fgf15 
exerts its effects of Cyp7a1 remains poorly understood (Chiang, 2009) but this is an 
active area of research. It is possible that the principal functions of FGF15/19 are the 
control of gallbladder filling and the normal diurnal regulation of BA synthesis 
during the fed state (Choi et al., 2006). Investigations of the relative importance of 
intestinal and hepatic FXR in regulating BA biosynthesis during normal physiology 
and during cholestasis are ongoing. 
 
1.3.2 Intestinal Biotransformation  
 
In the intestine, BAs undergo bacterial modification resulting in the formation of 
secondary BA (Ridlon et al., 2006). BAs undergo dehydroxylation, deconjugation 
and oxidation. The most biologically relevant reactions appear to be the C7 
dehydroxylation that results in the formation of lithocholic acid (LCA) and 
deoxycholic acid (DCA) from CDCA and CA respectively (Begley et al., 2005). 
Secondary BAs are hydrophobic and have strong detergent effects on membranes. As 
a result of their toxicity, secondary BAs are rapidly detoxified by hydroxylation 
enzymes in the enterocytes of the ileum and hepatocytes of the liver. Some 
secondary BAs are poor activators of FXR (Wang et al., 1999) but strongly activate 
the xenobiotic receptors CAR (Zhang et al., 2004a), PXR (Staudinger et al., 2001b) 
and VDR (Makishima et al., 2002).     
1.3.3 Bile acid transport 
 
The maintenance of the entero-hepatic circulation of BAs is complex (Fig. 1.6) and 
requires the function of several membrane bound transporters whose expression are  
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regulated by NRs (Eloranta & Kullak-Ublick, 2005). Following their synthesis and 
conjugation, BAs are actively excreted into the bile canaliculus by the bile salt export 
pump (BSEP) (Gerloff et al., 1998). BAs with other modifications such as sulphation 
and glucuronidation, organic anions, organic cations and reduced glutathione are 
transported by the multidrug resistance-associated protein 2 (MRP2) and the 
multidrug export pump 1a (MDR1A) (Akita et al., 2001). During cholestasis or BA 
overload, a number of alternative BA transporters, located on the basolateral 
membrane of the hepatocyte facilitate the export of BAs from the hepatocyte and 
into the serum (Meier & Stieger, 2002; Trauner & Boyer, 2003). Raised serum BAs 
are therefore indicative of perturbed maintenance of the entero-hepatic circulation 
and are a result of mechanisms induced to prevent the accumulation of BA in the 
hepatocyte. Alternative hepatic BA exporters include MRP3, MRP4, the organic 
anion transporting polypeptide (OATP2) and the heteromeric organic solute 
transporter couplet-α/β (OSTα/β). In the intestine, BAs are absorbed into the 
ileocyte through the apical sodium-dependant bile salt transporter (ASBT) and 
efluxed into the portal vein by Mrp3 and the OST-α/β couplet (Craddock et al., 
1998; Frankenberg et al., 2006). The intracellular ileal BA binding protein (IBABP) 
protects these cells against the detergent actions of the BAs and promotes their 
cellular transit (Alpini et al., 1997). Following their re-absorption from the intestinal 
lumen into the portal vein, BA are transported back to the liver. The principal 
basolateral hepatic import protein is the sodium-taurocholate co-transporting 
polypeptide (NTCP) (Hagenbuch & Meier, 1994). Organic anion transporters 
(OATP1 and OATP4) also contribute to basolateral BA uptake in the hepatocyte 
(Kullak-Ublick et al., 2001), although to a lesser extent than NTCP. Modified BAs 
that have been re-absorbed following a first pass of the entero-hepatic circulation are 
detoxified in the liver and targeted for re-entry into the entero-hepatic circulation or 
excretion into the faeces or urine.   
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NRs drive changes in the expression of the components of the entero-hepatic 
circulation in order to prevent the toxic accumulation of BAs in the liver. 
Hepatoprotection against cholestatic injury is achieved by repression of BA 
biosynthesis, decreased intestinal and hepatic BA absorption, increased BA 
detoxification and increased hepatic BA export. FXR is the principal NR that 
governs the regulation of genes involved in the entero-hepatic circulation of BAs (Tu 
et al., 2000). However, other receptors, including PXR and CAR also regulate these 
processes during cholestatic conditions (Zhang et al., 2004a). 
 
Hydroxylation and sulfation reactions detoxify BAs and target them for excretion in 
the urine and faeces. In the liver and intestine, members of the cytochrome P450 
family of haem-containing monoxygenases catalyze hydroxylation reactions that 
reduce the hydrophobicity of secondary BAs (Paolini et al., 2000). BA sulfation is a 
phase-II conjugation reaction that involves the transfer of a sulfate group from the 
sulfate donor, 3’-phosphoadenosine 5’-phosphosulfate (PAPS), to the BA substrate 
(Alnouti, 2009). Sulfation reactions occur in the liver and are catalyzed by the 
sulfotransferase enzymes (SULTs) (Alnouti, 2009). BA sulfation is a major 
mechanism of adaptive protection against cholestasis because sulfated BAs are 
highly water-soluble and are easily excreted in the urine and faeces (Staudinger et 
al., 2001b). The xenobiotic receptors CAR, PXR and VDR regulate the transcription 
of hydroxylation and sulfation enzymes while the principal BA sensor FXR seems to 
play only a minor role.  
 
1.3.4 Metabolic actions of bile acids 
 
BAs act as signalling molecules by activating nuclear hormone receptors, in 
particular, the principal BA receptor FXR (Wang et al., 1999). However, it has 
recently been demonstrated that BAs are also ligands for a G-protein coupled 
receptor termed TGR5 (Maruyama et al., 2002; Kawamata et al., 2003; Watanabe et 
al., 2006). Through FXR and TGR5, it is now established that BAs play a complex, 
but not fully delineated, role in the maintenance of lipid, energy and glucose 
homeostasis (Thomas et al., 2008).  
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TGR5 mRNA is expressed in a number of tissues including the gall-bladder, liver 
and intestine (Watanabe et al 2008). LCA is the most potent activator of TGR5 but 
several other BAs also serve as ligands at physiologically relevant concentrations 
(Kawamata et al., 2003). The biological consequences of BA-mediated TGR5 
activation remain poorly understood but it appears that its function differs according 
to the tissue in which it is activated. BA-activated TGR5 has immunoregulatory 
effects in monocytes and macrophages, mediates hepatoprotection in the liver, 
regulates incretin release from the intestine and energy expenditure in muscle and 
brown adipose tissue (Kawamata et al., 2003)(Katsuma et al., 2005). Tgr5-/- mice are 
protected against gall stone formation on lithogenic diets (Vassileva et al., 2006). 
Furthermore, Tgr5 regulates the expression of the nitric oxide synthase in response to 
BAs, which protects the liver against lipid peroxidation and hepatotoxicity (Keitel et 
al., 2007).     
 
BAs affect lipid metabolism. Fxr activation prevents BA biosynthesis and as a result 
this, and the fact that bile acid promote reverse hepatic cholesterol transport, serum 
and hepatic low-density lipoprotein (LDL) cholesterol can accumulate (Fig. 1.7) 
(Leiss & von Bergmann, 1982). A number of direct and indirect Fxr target genes 
modulate lipid metabolism. Among these is the sterol regulatory element-binding 
protein 1c (SREBP1c) (Watanabe et al., 2004). SREBP1c is an indirect target gene 
of FXR that is repressed by bile acids. SREBP1c the master regulator of lipid 
metabolism as it regulates the expression of genes involved in lipogenesis, including 
acetyl-CoA carboxylase 1 (ACC1), glucose-6-phosphatase (G6Pase) and fatty acid 
synthase (FAS) (Horton et al., 2002). Thus through actions of hepatic FXR, bile 
acids can affect whole body cholesterol, glucose and energy homeostasis.   
 
The finding that BA supplementation prevents diet-induced obesity (Watanabe et al., 
2006) suggested that BAs influence energy expenditure. These effects were found to 
be Fxr-independent and were modulated by Tgr5 (Watanabe et al., 2006). 
Furthermore, transgenic mice over-expressing Fgf19 are also resistant to weight gain 
due to increased brown adiopse tissue mass and elevated hepatic β-oxidation 
(Tomlinson et al., 2002). Finally, Shp-/- mice are resistant to obesity, apparently due 
to enhanced brown adipose tissue metabolism (Wang et al., 2005). However, due to 
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the low expression of Shp in brown adipose tissue, it remains possible that this 
phenotype is a secondary effect of the high serum BAs in these mice, rather than a 
direct consequence of altered gene regulation in the absence of Shp (Thomas et al., 
2008).  
 
The BA binding resin cholestyramine reduces the BA pool by preventing BA re-
absorption in the intestine. Cholestyramine therapy improves glycemic control in 
patients with type-2 diabetes (Garg & Grundy, 1994). The mechanism by which BAs 
influence glucose homeostasis remains unclear. However, fasting increases Fxr 
expression, which suggests an inhibitory role of insulin on Fxr expression (Zhang et 
al., 2004b). These data remain a mater of debate however because insulin treatment 
increases Fxr levels in a model of diabetes (Duran-Sandoval et al., 2005).  
 
1.3.5 Bile acids in liver regeneration and hepatocellular 
carcinoma 
 
The liver has a remarkable capacity to regenerate in response to injury, a 
phenomenon that occurs in all vertebrate animals (Michalopoulos, 2007). Liver 
regeneration is most commonly studied in rodents by performing partial hepatic 
resection. In this model, hepatocyte proliferation increases the size of the remaining 
lobes until they reach the mass of the original intact tissue. In rats and mice, the 
process of recovery from 2/3 partial hepatectomy is complete within 5-7 days of 
surgery (Dai et al., 2008). Importantly, the mechanism of re-growth is not mediated 
by sub-populations of stem-cell like cells, which is the case in the growth and 
renewal of the skin and small intestine. Rather, mature hepatocytes retain the ability 
to enter the cell cycle and proliferate in response to mitogenic signals.  
 
Transplanting a liver from a small animal into a larger, but compatible, recipient 
results in liver growth characteristic of that following hepatic resection. This finding 
demonstrates that liver regeneration is not necessarily a response to hepatic injury, 
but rather a response to a relative reduction in functional capacity (Michalopoulos, 
2007).  
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The signals that initiate, regulate and terminate hepatocyte proliferation in response 
to partial hepatectomy are complex. Hepatocyte growth factor (HGF), tumour 
necrosis factor (TNF), interlukin 6 (IL6), norepinephrine, seratonin, components of 
complement and leptins are all implicated in these processes (Michalopoulos, 2007). 
Recently, BAs have been implicated in the process of liver regeneration because BA 
feeding induces hepatocyte proliferation and serum BA concentrations rise several 
hours after partial hepatectomy (Huang et al., 2006). Huang et al discovered that 
depletion of the BA pool by cholestyramine treatment impaired hepatic regeneration 
while feeding a BA-supplemented diet increased the rate of re-growth (Huang et al., 
2006). Subsequently, mice deficient of Fxr were found to have delayed re-growth 
following partial hepatectomy (Huang et al., 2006). Mice deficient of the BA 
receptors Car and Pxr also have a slight perturbation in response to partial 
hepatectomy (Huang et al., 2006; Dai et al., 2008). Together, these findings 
demonstrate that NR-dependant BA signalling is required for the normal progression 
of liver regeneration in mice. The interpretation of these findings is that the reduced 
liver mass following partial hepatectomy exposes each individual hepatocyte to a 
higher intracellular concentration of BAs returning form the entero-hepatic 
circulation. These intracellular BAs stimulate proliferation by a mechanism 
involving Fxr (Huang et al., 2006).  
 
In the BA theory of recovery from partial hepatectomy, hepatocyte proliferation is 
apparently terminated when liver mass increases sufficiently to return the 
intracellular BA levels to normal. This concept requires further investigations 
because Huang et. al. did not measure hepatic bile acid levels during the regenerative 
process. However, BA-mediated hepatocyte proliferation is mitogenic and mice fed a 
BA-supplemented diet develop hepatocellular carcinoma in the long-term (Kim et 
al., 2007; Yang et al., 2007). Two genetic models of cholestasis (Fxr-/- and Shp-/- 
mice) also develop hepatocellular carcinoma in later life (Kim et al., 2007; Yang et 
al., 2007; Zhang et al., 2008). For these reasons, BAs represent a potentially harmful 
mechanism of mediating dynamic changes in liver mass in response to changes in 
hepatic metabolic demand.  
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1.4 The pregnane X receptor (NR1I2) 
 
Originally an orphan receptor, PXR (NR1I2) was cloned based on its sequence 
homology to other known NRs and prior to identification of ligand profiles or 
biological function (Kliewer et al., 1998; Lehmann et al., 1998). PXR is highly 
expressed in the liver and intestine. It is now known that PXR is activated by a 
diverse array of structurally distinct compounds, including approximately 50% of 
prescription drugs and numerous endogenous toxic metabolites (Synold et al., 2001). 
PXR target genes are responsible for phase I (detoxification), phase II (conjugation) 
and phase III (export) of toxic metabolites (Lehmann et al., 1998; Runge-Morris, 
1998; Geick et al., 2001).  
 
1.4.1 Genomic organisation of PXR (NR1I2) 
 
The PXR gene spans 35kb of genomic DNA, contains ten exons, nine introns and has 
been mapped to chromosome position 3q13-21(Zhang et al., 2001) (Fig. 1.8). The 
first two exons are used as alternative 5’ ends of the PXR transcript (the human PXR-
2 isoform uses the alternate exon 1b and accounts for less than 10% of transcript in 
the human liver (Zhang et al., 2001). A third variant is formed by an in-frame 
deletion of 111bp at the 5’ end of exon 5, this variant represents less than 1% of the 
human PXR transcripts and is largely unresponsive to ligand in transfection assays 
(Gardner-Stephen et al., 2004). Because this PXR variant is unresponsive to ligand, 
it was suggested that the relative level of these PXR variants may account for inter-
individual differences in PXR target-gene expression. However, two reports have 
found that the level of variant PXR expression does not correlate with the level of 
PXR target-gene expression in humans, suggesting that the variants are not 
functionally impotant (Zhang et al., 2001 Gardner-Stephen et al., 2004).   
 
1.4.2 Protein structure of PXR 
 
PXR has a classical NR structure consisting of activation function domains, a DNA 
binding domain and a ligand-binding domain (Fig. 1.8). The major PXR transcript 
produces a protein of 434 amino acids. The PXR DNA binding domain spans amino 
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acid 41 to 107 and the ligand binding domain spans amino acids 141 to 434 
(Lehmann et al., 1998). PXR differs from most other NRs in that it can bind a 
diverse range of structurally distinct ligands. The crystal structure of the PXR LBD 
bound to a number of ligands has been resolved (Watkins et al., 2001; Watkins et al., 
2003a; Watkins et al., 2003b; Chrencik et al., 2005). Importantly these structural 
data reveal that PXR has an unusually large β-sheet consisting of five, not the usual 
three, strands. This element creates an enlarged ligand-binding pocket that is flexible 
and hydrophobic. Indeed, the most potent activator of hPXR, rifampicin, is one of 
the largest known ligands for any NR. 
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1.4.3 PXR reporter assays 
 
In vitro reporter assays have been extensively used in the study of hPXR function. 
These assays generally involve the transient transfection of immortalized liver cell 
lines with expression and reporter plasmids followed by ligand treatment (Fig. 1.9). 
Plasmids constitutively expressing full-length PXR and RXR (Lehmann et al., 1998) 
are transfected into a suitable liver cell line, commonly HepG2 or Huh7 cells. Two 
reporter plasmids are also transfected, a constitutively active Renilla-expressing 
plasmid that controls for transfection efficiency and a Luciferase-expressing reporter 
(Goodwin et al., 1999) that serves as a measure of PXR function. Most hPXR 
reporter plasmids contain the hPXR recognition sites cloned from the proximal and 
the distal promoter of the CYP3A4 gene, linked to the Luciferase gene (Goodwin et 
al., 1999). Activation of PXR by ligand causes its heterodimerization with RXR, 
binding to the recognition sites in the Luciferase reporter plasmid and activation of 
transcription of the Luciferase gene. The intracellular Luciferase protein is measured 
by an enzyme emission based assay and its levels correlate with PXR function. These 
assays have been widely used to identify PXR ligands and assess the function of 
variant or mutant PXR alleles.  
 
In vitro reporter assays are an important proof-of-principal for the activation of a NR 
by a ligand. However in vivo effects can be complicated by NRs with overlapping 
ligand profiles and enzymes that can modify the ligand and alter its activation 
function. For example, cholic acid is a poor activator of FXR in transactivation 
assays (Parks et al., 1999) but potently activates intestinal and hepatic FXR when 
administered to mice via dietary supplementation (Yang et al., 2007).  
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1.4.4 Allelic variants of PXR (NR1I2) 
 
Inter-individual variability in the expression levels of PXR target genes (Gonzalez, 
1992) has lead to extensive sequencing of the PXR (NR1I2) gene in search of 
possible causes of this variation. Over 80 Single Nucleotide Polymorphisms (SNPs) 
have been identified in the PXR gene, 13 of which are non-synonymous and result in 
an amino acid change (Table 1.1)(Hustert et al., 2001; Zhang et al., 2001; Koyano et 
al., 2002; Lim et al., 2005; Bosch et al., 2006). However these variants do not 
account for the inter-individual differences in target gene expression.  
 
Table 4.1 Summary of all reported coding hPXR variants 
Variant Locationa MAFb Population Reference 
E18K  0.014 African American  Hustert (2001) 
P27S  0.2 African American Zhang (2001) 
  0.149 African American Hustert (2001) 
  0.03 African American King (2007) 
G36R DBD 0.01 Caucasian Zhang (2001) 
  0.03 African American Zhang (2001) 
  0.03 Caucasian Hustert (2001) 
  0.001 Caucasian Bosch (2005) 
  0.05 Caucasian King (2007) 
  0.04 African American King (2007) 
R98C DBD 0.0024 Japanese Koyano (2002) 
R122Q DBD 0.01 Caucasian Zhang (2001) 
  0.05 Caucasian King (2007) 
V140M  0.002 Caucasian Hustert (2001) 
  0.058 Chinese Lim (2005) 
R148Q LBD 0.0024 Japanese Koyano (2002) 
Q158K LBD 0.022 Chinese Lim (2005) 
D163G LBD 0.014 African American Hustert (2001) 
A370T LBD 0.016 African American Hustert (2001) 
C379G LBD 0.005 Caucasian Bosch (2006) 
R381W LBD 0.0024 Japanese Koyano (2002) 
I403V LBD 0.0024 Japanese Koyano (2002) 
a DBD- DNA binding domain, LBD- ligand binding domain 
b MAF- Minor Allele Frequency 
 
The functional effect of coding variation in PXR has been tested in transactivation 
assays in a number of different cell lines (Hustert et al., 2001; Zhang et al., 2001; 
Koyano et al., 2002; Lim et al., 2005; Bosch et al., 2006). Five variants, R98C, 
R122Q, Q158K, R381W and I403V have been reported to reduce hPXR function in 
the presence of ligand (Zhang et al., 2001; Koyano et al., 2004; Lim et al., 2005). 
Variant R98C, which was identified as a heterozygous SNP in a single, apparently 
normal individual, abolished all PXR function. One variant, D163G, increases the 
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ability of hPXR to activate transcription of a CYP3A4 promoter in the presence of 
ligand (Hustert et al., 2001) and one variant, C379G, has not been tested for a 
functional effect.  
 
Inter-laboratory variation in methodology (cell type, ligand, ligand concentration, 
PXR and CYP3A4-reporter construct, incubation time, transfection method) makes 
direct comparison of the functional consequences of coding SNPs difficult. For 
example, despite no changes in protein expression, variant Q158K performs as wild-
type protein in LS174T cells treated with coltrimazole but causes significantly 
reduced transactivation compared to WT PXR in HepG2 cells treated with the same 
ligand (Lim et al., 2005). It is also possible that coding SNPs located in the LBD 
could have a ligand-specific functional effect.  
 
Several rare splice variants have also been reported (10 in total) in PXR (Lamba et 
al., 2004; Lamba et al., 2005). These variants account for a small proportion of 
hPXR transcripts and they have recently been shown to have no influence on PXR 
mediated drug clearance (He et al., 2006).  
 
1.4.5 PXR target genes 
 
PXR regulates the expression of genes involved in the phase-I (hydroxylation), 
phase-II (sulfation/glucuronidation) and phase-III (export) of toxic compounds (Fig. 
1.10). As such, PXR is though to play an important role in the maintenance of the 
entero-hepatic circulation of BAs and hepatoprotection against cholestatic 
compounds (Iyer et al., 2006). Recently however, PXR has also been implicated in 
cholesterol metabolism and lipid homeostasis (Zhou et al., 2009).  
 
The characterisation of bone fide PXR target genes has proved difficult in vivo. 
These difficulties have arisen because PXR has an overlapping ligand and target 
gene profile with other xenobiotic sensing NRs (Sueyoshi et al., 1999; Makishima et 
al., 2002). Furthermore, there are considerable differences between the ligand profile 
of mouse and human PXR (Staudinger et al., 2001b). The strongest activator of 
mouse Pxr causes hepatomegaly (Staudinger et al., 2001a) and Pxr-/- mice express 
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unusually high hepatic levels of a number of apparent Pxr target genes (Staudinger et 
al., 2001b; Teng & Piquette-Miller, 2007; van Waterschoot et al., 2008).  
 
By far the best-characterised PXR target-gene encodes the phase-I detoxification 
enzyme and member of the Cytochrome P450 family of heme-containing 
monoxygenases, CYP3A4 (in mice, Cyp3a11) (Staudinger et al., 2001b; Xie et al., 
2001). This enzyme hydroxylates a diverse array of substrates, including endogenous 
secondary BAs. CYP3A4/Cyp3a11 therefore represents an integral component of the 
defence against toxic insult. CYP3A4 is dramatically up-regulated following 
administration of PXR ligands (Staudinger et al., 2001a; Staudinger et al., 2001b; 
Xie et al., 2001) and this activation forms the basis of in vitro reporter assays for 
hPXR function (Goodwin et al., 1999). However, both CAR and VDR can also 
activate transcription of CYP3A4/Cyp3a11 in the presence of activating ligands 
(Sueyoshi et al., 1999; Makishima et al., 2002), which complicates the interpretation 
of experiment designed to assess the in vivo function of PXR.  
 
The principal phase-II gene that is up-regulated by PXR is the sulphotransferase 
SULT2A1/Sult2a1 (Liu & Klaassen, 1996; Klaassen et al., 1998; Falkner et al., 2001; 
Runge-Morris & Kocarek, 2005). The product of this gene is responsible for 
transfering a sulfate group from the universal sulfate donor 3'-phosphoadenosine 5'-
phosphosulfate (PAPS) to toxic compounds, thus increasing their water solubility 
and their excretion in the urine and faeces (Sonoda et al., 2002; Kim et al., 2004; 
Saini et al., 2004).  
 
Phase-III exporters that are confirmed to be under the control of PXR include 
membrane bound proteins that mediate hepatic efflux of cholestatic metabolites. 
These genes are members of the multidrug resistance proteins (Mrp1 and Mrp2) and 
an organic anion transporter that mediates alternative basolateral hepatic export, 
OATP2 (Staudinger et al., 2001b; Guzelian et al., 2006; Jigorel et al., 2006; Macias 
et al., 2006).  
 
The genes described above are directly regulated by PXR but are also induced by 
other ligand-activated NR including FXR, CAR and VDR. There is currently no gene 
that is under the sole regulation of ligand bound PXR. 
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Recent reports have implicated PXR in the regulation of CYP7A1, the rate-limiting 
enzyme in BA biosynthesis (Staudinger et al., 2001b). This is apparently a SHP-
independent response to BAs that involves the interaction of PXR and PGC1α 
(Bhalla et al., 2004; Li & Chiang, 2005). Furthermore, the finding that BA 
intermediates can activate PXR and repress the alternative route of BA biosynthesis 
via CYP27A1 and induction of the cholesterol efflux genes ABCG5 and ABCG8 has 
provided some, if limited, evidence that PXR also mediates cholesterol homeostasis 
(Li et al., 2007). Further evidence for the role of PXR in lipid and cholesterol 
homeostasis comes from findings that PXR can activate transcription of the free fatty 
acid uptake transporter, CD36, the long chain fatty acid elongase (FAE), the stearoyl 
COA desaturase-1 (SCD-1) and the NR PPARγ (Zhou et al., 2006). The 
physiological significance of the role of PXR in regulating these lipid and cholesterol 
homeostasis genes remains to be elucidated. Perhaps the most convincing finding to 
date is that treatment of humans with the potent PXR activator rifampicin results in 
unexpected hyperlipidemia, demonstrating that the role of this receptor in these 
conditions is not fully understood (Khogali et al., 1974).   
 
Microarray analysis and genome screening analysis for potential PXR recognition 
sites has yielded many more potential PXR target genes that have implicated this 
receptor in the control of processes such as cell cycle control and immune regulation 
(Rosenfeld et al., 2003; Guzelian et al., 2006). However, despite being attempted 
(Kiyosawa et al., 2008), there is insufficient evidence to identify ligand responsive 
PXR-activated genes from microarray data without the use of Pxr-/- mice and the 
confirmation of these data using in vitro approaches.  
 
1.4.6 PXR Ligands 
 
PXR is the most promiscuous NR. High throughput screening has identified a vast 
and diverse array of structurally distinct molecules capable of binding and activating 
PXR (Watkins et al., 2001). For this reason, PXR has been termed the 
generalised/master xenobiotic sensor.  
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Inter-species variation in LBD sequence has resulted in considerable divergence in 
the ligand profile of mouse and human PXR (Staudinger et al., 2001b). hPXR 
ligands have been identified in in vitro reporter assays. However, most of the 
reported hPXR ligands have not been confirmed in primary cells or in humans. For 
this reason, it is surprising that the humanized PXR mouse (Xie et al., 2000) has not 
been more extensively adopted for research. Fewer ligands have been identified for 
mouse PXR than for human, but these have at least been tested in vivo with the aid of 
Pxr-/- animals.  
 
PXR is activated by approximately 50% of prescription drugs and interest in PXR 
from the pharmaceutical industry has therefore stemmed largely from its role in drug 
metabolism and drug-drug interactions. For example, the non-prescription drug St 
John’s Wort is a PXR ligand and enhances the metabolism of reproductive hormones 
administered as oral contraceptives (Wentworth et al., 2000).  
 
Rifampicin is the most potent known activator of hPXR. Despite this, and significant 
in vivo evidence of rifampicin mediated PXR-activation, rifampicin is rarely used to 
treat cholestatic/hepatotoxic diseases. Rifampicin has been effectively used to treat 
intrahepatic cholestasis of pregnancy (Genes and Williamson, 2009) and its mode of 
action is likely to be through potent activation of hepatic PXR. Rifampicin does not 
activate mouse PXR and the most potent activator of mouse PXR pregnenolone-16α-
carbonitrile (PCN) does not activate hPXR (Kocarek et al., 1995; Jones et al., 2000).  
 
In vitro, both mouse and human PXR are activated by the toxic secondary BA 
lithocholic acid (LCA)(Staudinger et al., 2001b). LCA has been proposed to be the 
principal endogenous ligand of PXR in vertebrates (Iyer et al., 2006).  
 
Other ligands of particular interest to this project are the therapeutic drugs that are 
used to treat some cholestatic syndromes. The hydrophilic, non-toxic BA 
ursodeoxycholic acid (UDCA) and the glucocorticoid dexamethasone are used to 
treat intrahepatic cholestasis of pregnancy (Williamson, 2001; Glantz et al., 2005). 
These compounds are weak PXR ligands and a number of mechanisms have been 
proposed for their mode of action. However, activation of PXR could form part of 
their protective effect.  
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The promiscuity of PXR makes it likely that this receptor will be activated by fetal 
metabolites or changes in circulating reproductive hormones/reproductive hormone 
metabolites during pregnancy. The role of PXR in the detoxification of endobiotics 
and its potential roles in lipid and cholesterol homeostasis make it likely that PXR 
has a role in the maintenance of maternal adaptations during gestation.  
 
1.4.7 Pxr-/- and humanized PXR mice.   
 
Pxr-/- mice have been generated by targeted disruption of the Pxr DBD by 
eliminating exon 2 (Staudinger et al., 2001b) or exons 2 and 3 (Xie et al., 2001). 
Both groups were able to confirm the absence of Pxr protein in the liver and intestine 
and a severely attenuated induction of Cyp3a11 in response to the prototypical rodent 
Pxr ligand PCN. Pxr-/- mice are viable and fertile and exhibit no overt phenotype. 
Serum levels of HDL-cholesterol, steroid hormones (progesterone, estradiol, 
testosterone, and corticosterone), triglycerides, transaminases, albumin, total 
bilirubin, and total BAs are not altered in mice lacking Pxr (Staudinger et al., 2001b). 
Therefore, under standard conditions, Pxr is not required for protection against 
endobiotics. Experiments using the double knockout mouse (Pxr-null + Car-null) 
showed that Car plays a compensatory role for the loss of Pxr function (Uppal et al., 
2005). Importantly however, the double knockout was more sensitive to LCA-
mediated toxicity than either individual knockout demonstrating that both of these 
receptors mediate protection against LCA in vivo (Uppal et al., 2005).    
 
For unknown reasons, the Pxr-/- mouse generated by Staudinger et al, but not Xie et 
al, expresses elevated basal levels of the principal Pxr target gene Cyp3a11. The 
reason for this discrepancy in basal Cyp3a11 expression in the two Pxr-/- mice is not 
known. However, a recent study suggested that plant phytoestrogens in chow diet 
can induce hepatic detoxification machinery such that mice lacking intestinal Cyp3a 
protein have a higher hepatic exposure to these chemicals and hence elevated hepatic 
Cyp3a levels than wild type mice (van Waterschoot et al., 2008). It is possible that 
inter laboratory differences in chow diet exposes the liver to varying amounts of 
plant toxins and, due to an intestinal defect in drug metabolism, hepatic Cyp3a11 is 
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induced by Pxr independent mechanisms under one housing condition but not the 
other. Importantly however, the high basal expression of Cyp3a11 in one Pxr-/- 
mouse but not the other, could affect its response to xenobiotics. Indeed, Xie et al 
report increased sensitivity to LCA in his Pxr-/- mouse while Staudinger et al report 
similar sensitivity as in wild-type animals.  
 
Due to the inter-species variation in ligand profile of mouse and human PXR, Xie et 
al generated a transgenic mouse expressing the human form of the receptor that 
responded to rifampicin but not PCN (Xie et al., 2000). However, this transgenic 
animal has not been widely used, probably because of the cost of testing hPXR 
activation in mice compared to in in vitro assays. Furthermore, the target genes 
induced in the humanized Pxr mouse in response to rifampicin were the same as 
those induced in a wild-type mouse in response to PCN, the prototypical mouse Pxr 
ligand (Xie et al., 2000). These factors have limited the relevance of humanized PXR 
mice.     
 
Under standard laboratory conditions, Pxr is not required for the maintenance of 
normal physiology in the mouse. However, pregnancy is a state that requires 
increased detoxification capacity by the maternal liver and it is a period when one 
might expect adaptive activation Car (as a compensatory mechanism) in Pxr-/- 
animals. To date, no studies have been conducted on the Pxr-/- mouse during 
gestation. 
 
1.4.8 The molecular pathogenesis of lithocholic acid toxicity  
 
Lithocholic acid (LCA) is formed in the intestine of mice and humans by the 
bacterial 7α-dehydroxylation of chenodeoxycholic acid (Norman & Shorb, 1962). 
LCA is the most hydrophobic BA, it has strong detergent properties and is highly 
hepatotoxic. While LCA is poorly absorbed from the intestine, administration of a 
relatively mild 0.5% LCA-supplemented diet to mice is sufficient to cause severe 
liver injury within 7-days of treatment (Staudinger et al., 2001b). For comparison, 7-
days of dietary supplementation with 0.5% cholic acid causes only mild 
histopathology (Teng & Piquette-Miller, 2007).  
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Lithocholic acid is a more potent activator of human PXR than mouse Pxr in vitro 
(Staudinger et al., 2001b). However, the primary metabolite of LCA (3-keto LCA) is 
a highly potent activator of mouse Pxr in vitro (Staudinger et al., 2001b) and LCA 
does activate hepatic Pxr in vivo (Staudinger et al., 2001a; Xie et al., 2001). Despite 
a considerable body of research, the in vivo molecular pathogenesis of LCA-
mediated toxicity and the role of PXR in mediating protection against it remains 
poorly understood. This thesis will describe novel aspects of LCA metabolism. 
Therefore, discrepancies in the literature will be discussed in detail here.   
 
Administration of LCA consistently causes histological hepatotoxicity in normal 
mice. However, there are conflicting reports on the effect of LCA administration on 
the induction of drug metabolizing enzymes, on the role of Pxr in mediating these 
responses and on the relative toxicity of LCA in wild-type and Pxr-/- mice (Xie et al., 
2000; Staudinger et al., 2001b; Xie et al., 2001; Kitada et al., 2003; Zhang et al., 
2004a; Uppal et al., 2005; Fickert et al., 2006; Teng & Piquette-Miller, 2007; Scheer 
et al., 2008; Beilke et al., 2009). These conflicting reports are the result of a lack of 
consistency on the dose, time course and route of LCA administration. Furthermore, 
the strain, age, sex and housing conditions of the animals are also likely to dictate, to 
a large extent, the responses to LCA and the toxicity induced by it.  
 
LCA has been administered to mice by intraperitoneal injection (usually suspended 
in corn), by oral gavage (also usually suspended in corn oil) (Xie et al., 2001) or by 
dietary supplementation. Hepatic Cyp3a11 mRNA is reported to be unaffected 
(Kitada et al., 2003; Beilke et al., 2009), induced (Staudinger et al., 2001b; Xie et 
al., 2001; Zhang et al., 2004a; Fickert et al., 2006) and repressed (Uppal et al., 2005) 
by LCA . While there appears to be a trend that intraperitoneal injection of LCA 
induces hepatic Cyp3a11 while feeding does not, this is not consistent because 
Kitada et al, (2003) reported no increase in hepatic Cyp3a11 mRNA following 
injection in wild-type mice. Most of the reports that observed an upregulation of 
Cyp3a11 by LCA also investigated the role of Pxr in mediating this response and all 
found that the effect was Pxr-dependant. Therefore, while LCA does not consistently 
upregulate hepatic Cyp3a11 expression, when it does, it appears to be a Pxr-
dependant process (Staudinger et al., 2001b; Xie et al., 2001; Zhang et al., 2004a; 
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Fickert et al., 2006). Importantly however, intestinal Cyp3a11 is reported to be 
upregulated following LCA-feeding in a Vdr-dependent and Pxr-independent process 
(Makishima et al., 2002). 
 
Cyp3a11 is implicated in hepatoprotection against LCA-mediated toxicity because 
the expression of this gene increased upon LCA administration and is further 
elevated by administration of PCN, which is protective against LCA-induced liver 
damage (Staudinger et al., 2001b). However, several but not all studies have shown 
that Pxr-/- mice express elevated levels of hepatic Cyp3a11. Indeed, the level of 
Cyp3a11 expression in wild-type mice injected with LCA+PCN does not exceed that 
in vehicle or LCA-treated Pxr-/- mice (Staudinger et al., 2001b). Hence, it is likely 
that basal upregulation of Cyp3a11 in Pxr-/- mice could affect the phenotype of these 
animals in response to LCA 
 
There are conflicting reports on BA-mediated toxicity in Pxr-/- mice. While some 
reports demonstrate that Pxr-/- mice are approximately equally sensitive to LCA as 
wild-type animals (Staudinger et al., 2001b), others have reported higher sensitivity 
in Pxr-/- mice than in controls (Xie et al., 2001). Furthermore, and surprisingly, Pxr-/- 
mice were recently found to be resistant to cholic acid-mediated hepatotoxicity 
(Teng & Piquette-Miller, 2007) due to elevated basal expression of the hepatic 
exporter Mdr3. Interestingly however, elevated expression of hepatoprotective genes 
including Cyp3a11 and Mdr3 would be expected to protect Pxr-/- mice against LCA 
as well as against cholic acid.   
 
Overall, the molecular pathology of LCA-mediated hepatotoxicity is poorly 
understood due to inconsistencies in experimental design. Basal gene expression 
differences between wild-type and Pxr-/- mice have complicated understanding of the 
role of this receptor in protection against LCA. Furthermore, high expression of 
LCA-protective genes are apparently not correlated with phenotypes of 
hepatoprotection of Pxr-/- mice against LCA-toxicity.    
 
1.4.9 Interaction of PXR with other nuclear receptors 
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It is clear that PXR interacts with other NRs. The complexity of these interactions is 
becoming increasingly apparent as potential NR binding sites are discovered in the 
PXR promoter, although the biological significance of these interactions remains to 
be elucidated in many cases.  
 
The retinoic acid receptor (RXR) is an obligate heterodimer partner of a number of 
nuclear receptors including PXR (Kliewer et al., 1992) although retinoic acid is not 
required for a functional RXR/PXR interaction. The hepatic nuclear factor 4-alpha 
(HNF4α) induces PXR gene transcription in fetal liver and is required for normal 
hepatic development (Kamiya et al., 2003). Cellular HNF4a expression is also 
required for rifampicin-mediated PXR induction of CYP3A4 in trans-activation 
assays (Tirona et al., 2003). Rifampicin-activated PXR also blocks HNF4α-mediated 
recruitment of the PPARγ co-activator-1-alpha (PGC-1α), resulting in inhibition of 
CYP7A1 and decreased BA synthesis (Abrahamsson et al., 2005; Li & Chiang, 
2006). The small heterodimer partner (SHP) binds to and represses the activity of 
both human and murine PXR in a ligand-dependant manner (Ourlin et al., 2003; Li 
& Chiang, 2006). SHP-mediated inhibition of PXR in the presence of high 
intrahepatic BA concentrations suggests that PXR functions primarily to induce an 
adaptive response to prevent toxicity following exposure to xenobiotics and 
endobiotics.  
 
Importantly, a recent study has described the PXR gene as a target of activated FXR 
(Jung et al., 2006). Activation of Fxr in mice by treatment with the synthetic agonist 
GW4064 leads to robust induction of Pxr expression in wild type but not Fxr-/- mice. 
Functional Fxr response elements were also identified in the human and mouse PXR 
promoter. These findings imply that a number of PXR target genes may be indirect 
targets of FXR, although the physiological significance of this interaction has not yet 
been established during cholestasis or bile acid challenge.    
 
There is clear overlap in ligand and target gene profile between PXR and CAR, and 
these receptors show considerable redundancy, hinting at their importance in 
endobiotic and xenobiotic tolerance and clearance (Zhang et al., 2004a; Uppal et al., 
2005; Reschly & Krasowski, 2006). However, there is no evidence to suggest a 
direct interaction between these NRs. 
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1.5 Pregnancy 
 
Pregnancy is associated with marked maternal physiological adaptations. Some of 
these adaptations are of relevance to this project and are described below.  
 
1.5.1 Gestational insulin resistance  
 
Insulin promotes lipolysis and inhibits hepatic glucose production. During 
pregnancy, a high basal level of glucose production is required for fetal energy 
expenditure. As a result, placental growth hormone, placental lactogens and insulin-
like growth factor-1 act on the maternal liver to cause a state of insulin resistance 
(Weinhaus et al., 1996; Flamez et al., 2002). Pregnancy is therefore associated with 
β-cell proliferation and increased circulating insulin levels (Karnik et al., 2007).  
 
There is some evidence that insulin can affect Fxr function, but these studies remain 
a matter of debate. The total BA pool is increased in a number of mouse models of 
type-1 diabetes (Nervi et al., 1974; Hassan et al., 1980). Furthermore, hepatic 
depletion of the insulin receptor also increases the BA pool size (Michael et al., 
2000). The expression of hepatic Fxr is decreased in models of type-2 diabetes and 
Cyp7a1 expression is increased (Twisk et al., 1995; Duran-Sandoval et al., 2004). 
Together, these findings demonstrate that insulin signalling can affect the BA pool, 
possibly through actions on Fxr. Furthermore, while fasting induces Fxr expression, 
which is supportive of a negative effect of insulin on Fxr function (Zhang et al., 
2004b), direct administration of insulin represses hepatic Fxr expression (Duran-
Sandoval et al., 2005). The effects of the insulin resistant state of pregnancy on FXR 
and the BA pool have not yet been fully investigated.   
 
1.5.2 Cholesterol for fetal development  
 
In many animals, including humans, pregnancy is associated with increased maternal 
serum triglyceride and cholesterol levels (Von Studnitz, 1955; Bosch & Camejo, 
1967; Reyes & Kern, 1979). The developing fetus has a high demand for cholesterol 
for membrane synthesis and the development of the central nervous system. All 
 51 
nucleated cells synthesize cholesterol but the liver and the intestine are the primary 
sites of cholesterol biosynthesis. This raises the question of whether the maternal 
liver synthesises the cholesterol required for fetal development, a process that could 
affect maternal bile acid homeostasis. 
 
There are conflicting reports on whether the fetus relies on a supply of cholesterol 
from the maternal compartment. Maternal serum cholesterol levels increase during 
gestation in many animals including humans (Von Studnitz, 1955), rats (Bosch & 
Camejo, 1967) and hamsters (Reyes & Kern, 1979), but not mice (Sweeney et al., 
2006). Therefore pregnancy in mice is maintained despite no increase in maternal 
serum cholesterol levels. Several studies have concluded that the cholesterol required 
for fetal development is synthesized in the fetal compartment (the fetus and the 
placenta) (Calandra, 1975; Innis, 1986; Belknap & Dietschy, 1988; Woollett, 1996; 
Smith et al., 1998). However, there is continuing debate on source of the cholesterol 
that is required for the growth of the placenta and yolk sack. Hepatic microsomal 
assays from pregnant rats demonstrated reduced function of Hmgcr, the rate-limiting 
enzyme in cholesterol biosynthesis, in the maternal liver during pregnancy (Smith et 
al., 1998). Furthermore, the protein expression of the 3-hydroxy-3-methylglutaryl-
Coenzyme A reductase (Hmgcr) was not affected during gestation and serum levels 
of cholesterol were unaffected during the majority of pregnancy, but were higher at 
term (Smith et al., 1998). In another study in rats, a radiolabel incorporation assay 
demonstrated a significant increase in maternal hepatic cholesterol biosynthesis 
during pregnancy. Also in this study, feeding cholesterol increased serum cholesterol 
levels and inhibited maternal hepatic cholesterol synthesis but had no effect on de 
novo cholesterol synthesis in the fetal compartment. This finding suggests that 
increased maternal hepatic cholesterol synthesis during pregnancy is not a 
requirement for the developing fetus, and that the fetus synthesizes most of its own 
cholesterol.  
 
1.5.3 Gestational liver enlargement 
 
In rodents, the maternal liver increases in size significantly during gestation to 
become almost twice the weight of non-pregnant controls. This phenomenon of 
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gestational liver growth was first reported in 1958 (Paschkis & Cantarow, 1958) and 
has been commented upon in a number of subsequent studies (Paschkis & Cantarow, 
1958; Schlede & Borowski, 1974; Cripps & Williams, 1975; Feingold et al., 1986; 
Hollister et al., 1987; Hapon et al., 2005; Dickmann et al., 2008). One early study 
demonstrated that the enlargement during pregnancy was reversible, and was 
associated with hepatocyte swelling without changes in total liver DNA content 
(Hollister et al., 1987). However, the mechanisms of pregnancy-induced liver growth 
have not been fully characterized and no effort has been made to identify the signals 
that drive the growth. Gestational liver enlargement is considered to be a response to 
increased hepatic metabolic demand. Given their role in recovery of liver mass 
following partial hepatectomy (Huang et al., 2006; Dai et al., 2008), it is possible 
that BAs and their receptors could drive gestational liver enlargement.  
 
Liver size in pregnant humans has not been investigated. In mice, the total mass of 
the fetal-placental unit at the end of gestation is approximately 30% of the total 
maternal weight. In humans, the fetal-placental unit comprises a significantly smaller 
proportion of total body weight so the metabolic demands on maternal organs are 
expected to be less marked in human, than in rodent, pregnancy. As such, pregnancy 
effects on maternal liver weight are expected to be less marked in humans than in 
rodents. Furthermore, because of large interindividual differences in maternal body 
weight, accurate correction of liver size to maternal body weight and measurement of 
liver size when non-pregnant and when pregnant is required in order to determine 
whether gestational liver growth occurs in humans as well as in rodents.   
 
1.5.4 Nuclear receptor expression and function during 
pregnancy 
 
Few papers have investigated the role of NRs in mediating adaptive maternal 
metabolism during pregnancy. To date, there are only two reports on hepatic NR 
expression during gestation (Sweeney et al., 2006; He et al., 2007). One of these 
papers performed hepatic microarray experiments in late pregnant rats (He et al., 
2007) and the other targeted their analysis to specific NRs in late pregnant mice 
(Sweeney et al., 2006).  
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Sweeney et al (2006) report decreased hepatic NR expression during pregnancy. At 
the mRNA level, the expression of Rxr, Ppar, Lxr and Fxr isoforms were all 
significantly reduced in the liver of late pregnant mice compared to controls. 
Furthermore, the expression of Tr, Lrh-1, Oxr, Pgc1α/β, Srebp isoforms and Shp 
were also significantly reduced. These alterations in NR expression are discussed in 
relation to changes in serum triglyceride and cholesterol levels during pregnancy. 
However, functional consequences of these gene expression effects are not 
presented. In addition, the potential functional significance of reduced expression of 
a broad range of functionally distinct NRs have not been discussed. 
 
Using hepatic microarrays, He et al (2007) investigated the effects of pregnancy on 
gene expression in the rat, with a focus on cytochrome P450 and NR gene 
expression. Consistent with the work of Sweeney et al, decreased hepatic expression 
of Shp and Fxr was reported in the pregnant rat. However, the expression of Pxr and 
Car were also reportedly decreased in these studies. Subsequently, the expression of 
18 cytochrome P450 genes were found to be repressed during pregnancy, while only 
three were induced. Data on a functional effect of these gene expression changes 
were not presented.    
 
Together, these reports demonstrate that pregnancy causes reduced expression of 
NRs and some cytochrome p450 enzymes in both mouse and rat liver. In particular 
Fxr and Shp were consistently repressed in both species (Sweeney et al., 2006; He et 
al., 2007). Neither the mechanism of repression nor the functional consequences of 
the gene expression effects of pregnancy are known.   
 
1.5.5 Bile acid homeostasis during pregnancy 
 
There is evidence that BA homeostasis is disrupted during pregnancy in humans and 
in rodents. In humans, the total BA pool is significantly larger in pregnant 
individuals than in non-pregnant controls (Kern et al., 1981). Furthermore, 
pregnancy was associated with an apparent (but non-significant) increase in the rate 
of BA biosynthesis and a significant reduction in the number of daily entero-hepatic 
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cycles of BAs (Kern et al., 1981). In addition, serum cholylglycine levels rise two-
fold during pregnancy in humans (Heikkinen et al., 1981) and measurement of total 
serum BAs by capillary electrophoresis also demonstrates that pregnant individuals 
have higher BAs than non-pregnant controls (Castano et al., 2006). Importantly, up 
to 40% of individuals develop biochemical cholestasis during pregnancy (serum BAs 
above 11µM) without developing clinical cholestasis (Pascual et al., 2002; Castano 
et al., 2006). Together, these data suggest that normal pregnancy in humans is a state 
of impaired BA homeostasis.  
 
Serum BA concentrations have not been reported in pregnant rodents. However, the 
gene expression of a number of hepatic BA-regulated genes have been assessed 
during gestation. As discussed above, there are reports of reduced hepatic expression 
of Fxr and Shp during pregnancy in both rats and mice (Sweeney et al., 2006; He et 
al., 2007). Furthermore, levels of Ntcp, Oatp2, Mrp2 and Mrp3 are also reported to 
be lower in the liver of pregnant rodents than non-pregnant controls (Cao et al., 
2001; Cao et al., 2002; Arrese et al., 2003). Despite apparently reduced trans-hepatic 
transport capacity during pregnancy in rodents (Reyes & Kern, 1979; Auansakul & 
Vore, 1982; Brock & Vore, 1984; Liu et al., 1992), the expression of the principal 
bile salt export pump (Bsep) is unaffected by pregnancy (Arrese et al., 2003).  
 
There are conflicting reports on the effect of pregnancy on BA biosynthesis. Late-
pregnant rats apparently have reduced function (as measured in liver microsomes) of 
the rate-limiting enzyme in BA biosynthesis, Cyp7a1 (Smith et al., 1998). However, 
He et al (2007) did not report changes in the expression of Cyp7a1 in late-pregnant 
rats and the expression of this gene was enhanced during mid gestation (13-days post 
conception) (He et al., 2007). Furthermore, the rate of BA biosynthesis in humans is 
apparently slightly increased during pregnancy (Kern et al., 1981).     
 
1.6 Intrahepatic cholestasis of pregnancy 
 
Intrahepatic cholestasis of pregnancy (ICP) affects approximately 0.7% of Caucasian 
pregnancies and is therefore the most common pregnancy-specific liver disease 
(Beuers & Pusl, 2006). ICP is a reversible form of cholestasis that usually manifests 
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in the third trimester (Heikkinen et al., 1981). ICP patients present with maternal itch 
and liver impairment and have significantly raised maternal and fetal serum BAs 
(Laatikainen & Ikonen, 1977). Maternally, ICP is relatively benign, although the 
puritus can be traumatic. ICP can result in fetal distress, spontaneous pre-term 
delivery and intrauterine death (Fisk & Storey, 1988). Affected individuals are at risk 
of subsequently developing gallstones.  
 
ICP has a complex aetiology with genetic, endocrine and environmental components. 
However, the primary events that first expose susceptible individuals to developing 
gestational cholestasis are not known.   
 
1.6.1 Bile acid profiles in ICP 
 
ICP is associated with raised maternal and fetal serum BAs. However, as discussed 
above, normal pregnancy also appears to be a state of mild biochemical cholestasis 
(Kern et al., 1981; Pascual et al., 2002; Castano et al., 2006). Indeed, a large 
proportion of healthy individuals surpass the upper normal limit of 11µM total serum 
BAs during pregnancy (Castano et al., 2006). ICP is therefore diagnosed based on 
serum BAs above the normal limit in association with either maternal puritus or 
elevated serum alanine aminotransferase (ALT) levels. A recent study has 
demonstrated increased fetal risk in ICP patients with serum BAs above 40µM 
(Glantz et al., 2005).  
 
Improvements in analytical methodologies have allowed the study of changes in the 
serum BA profile associated with ICP and have identified specific changes that could 
aid the diagnosis and management of treatment of the disease (Heikkinen et al., 
1981; Meng et al., 1997a; Castano et al., 2006; Lucangioli et al., 2009). Using 
capillary electrophoresis, chenodeoxycholic acid (CDCA), deoxycholic acid (DCA) 
and cholic acid (CA) were found to be modestly increased in ICP patients compared 
to controls (Castano et al., 2006). The levels of the toxic secondary BA LCA were 
increased 40-fold in individuals with ICP (Castano et al., 2006). The same study 
demonstrated that the rise in serum BAs in normal pregnancy was due mainly to 
increases in levels of ursodeoxycholic acid (UDCA), although LCA levels also 
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increased 2-6 fold in normal pregnant women (Castano et al., 2006). Therefore, LCA 
has been proposed as a biomarker for ICP and for response to treatment of the 
disease with ursodeoxycholic acid (Lucangioli et al., 2009).  
 
1.6.2 Genetics of ICP 
 
Evidence for a genetic aetiology for ICP comes from the demonstration that siblings 
have a 17-fold increased risk of developing the condition (Eloranta et al., 2001) and 
an increased prevalence in specific ethnic groups (Abedin et al., 1999). Many studies 
have investigated the genetic aetiology of ICP in several populations (for review 
(Dixon et al., 2008)). 
 
Our group and others, have identified genetic variation in the principal BA sensor 
FXR (Van Mil et al., 2007) and the hepatobiliary transporters BSEP (Eloranta et al., 
2003; Dixon et al., 2008), MDR3 (Jacquemin et al., 1999; Dixon et al., 2000), MRP2 
(Sookoian et al., 2008) and FIC1 (Mullenbach et al., 2005; Painter et al., 2005) that 
are associated with ICP. Some of these variants segregate within pedigrees 
(Mullenbach et al. 2003) or have a functional effects (Dixon et al., 2000; Van Mil et 
al., 2007). However, genetic variation in these genes accounts for only a small 
proportion of cases and many individuals develop ICP without harbouring known 
genetic susceptibility. Furthermore, most of these variants were identified in 
population-based studies and so represent risk factors for developing ICP, rather than 
disease causing mutations. Also, many individuals carrying variation in these genes 
do not develop ICP and most individuals that develop ICP are asymptomatic outside 
of pregnancy, demonstrating that gestation unmasks cholestasis in predisposed 
individuals. The primary events that expose individuals to risk of developing 
pregnancy-induced cholestasis are not known.  
 
1.6.3 Reproductive hormones implicated in ICP 
 
There is evidence for a hormonal aspect to the aetiology of ICP. Patients with a 
previous history of the disease can develop cyclical itching outside of pregnancy 
(Lammert et al., 2000). Cholestatic symptoms occur in some women following 
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administration of oral contraceptives and exogenous estrogens (Holzbach, 1976; 
Reyes & Simon, 1993; Crocenzi et al., 2003; Williamson et al., 2004). Furthermore, 
cholestasis occurs in the third trimester when reproductive hormones are at their 
highest and individuals with twin pregnancies are at higher risk of developing the 
disease (Gonzalez et al., 1989).    
 
The evidence that reproductive hormones play a role in ICP has lead to the 
publication of several reports of the effects of administration of high doses of 
reproductive hormones on the rodent liver. Injections of the stable, synthetic estrogen 
17α-ethinylestradiol (EE) (as a single injection or as multiple injections for up to 5 
days) reduces the expression of Bsep, Mrp2 and Ntcp at the mRNA and protein level 
(Arrese et al., 1995; Simon et al., 1996; Trauner et al., 1997; Green et al., 2000; 
Micheline et al., 2002; Mottino et al., 2002; Arrese et al., 2003; Geier et al., 2003; 
Crocenzi et al., 2005; Mottino et al., 2007). Furthermore, estrogens affect plasma 
membrane fluidity and osmotic membrane permeability through actions on AQP8 
protein, both potential mechanisms that alter bile flow (Lehmann et al., 2008).  
 
Administration of progesterone during early pregnancy could increase the risk of 
developing ICP later in gestation. The levels of progesterone metabolites in urine are 
significantly higher in ICP patients than controls and these parameters normalize 
following treatment (Meng et al., 1997a; Meng et al., 1997b, c; Reyes & Sjovall, 
2000; Glantz et al., 2008). Some progesterone metabolites inhibit BSEP function in 
vitro (Stieger et al., 2000; Vallejo et al., 2006).  
 
These reports have concluded that the increased levels of circulating reproductive 
hormones during pregnancy have the potential to interrupt the entero-hepatic 
circulation of BAs, causing cholestasis. However, the conclusions of these studies 
are based on administration of high doses of reproductive hormones by 
intraperitoneal injection. Indeed, in some cases, hepatotoxicity and hepatomegaly 
was induced by the hormone treatment (Ochs et al., 1986; Yamamoto et al., 2006). It 
remains possible that the pro-cholestatic actions of reproductive hormones are a 
secondary effect of the high doses administered.  
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The effect of physiological concentrations of non-synthetic estrogens (alone or in 
combination with progesterone) on bile homeostasis have not been studied over a 
time course similar to that of gestation. This project address this using pregnant mice 
and animals treated with silastic implants to deliver reproductive hormones over long 
periods. This system has been used to investigate the minimum progesterone 
requirement to maintain pregnancy in post-mating ovariectomised animals (Cohen & 
Milligan, 1993; Milligan & Cohen, 1994; Milligan et al., 1995; Milligan & Finn, 
1997). The models of Milligan et al are physiologically relevant because they release 
pregnancy-levels of reproductive hormones. This system could be useful in 
investigating the effects of reproductive hormones at pregnancy concentrations on 
genes implicated in cholestasis.   
 
1.6.4 Pharmacological treatment of ICP 
 
The drug most commonly used to treat ICP is ursodeoxycholic acid (UDCA). In a 
randomized, controlled trial, UDCA administration improved maternal puritus, 
reduced serum ALT and serum BA levels in ICP patients and improved fetal 
outcome (Glantz et al., 2005). UDCA is a hydrophilic BA that apparently has no 
adverse effects in the mother or the offspring (Kondrackiene et al., 2005). The 
mechanism by which UDCA ameliorates maternal symptoms and improves 
biochemistry in ICP patients is not fully understood. However, a number of 
mechanisms have been proposed. First and most simply, UDCA has been proposed 
to change the composition of the BA pool to be more hydrophilic and hence less 
hepatotoxic composition (Lucangioli et al., 2009). Secondly, UDCA is a ligand for 
PXR (Karpen & Crawford, 1999) and there is some in vivo evidence that it can also 
activate Fxr, thus elevating the hepatic response to raised serum BAs (Zollner et al., 
2003). In experimental models of cholestasis, UDCA targets the insertion of BSEP 
and MRP2 into the canalicular membrane, this is predicted to increase the flux of BA 
out of the hepatocyte (Serrano et al., 1998; Paumgartner & Beuers, 2002; Beuers, 
2006). 
 
The glucocorticoid dexamethasone has been used to treat ICP (Glantz et al., 2005). 
While the mode of action of dexamethasone is not known, it also activates PXR at a 
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low level (Goodwin et al., 2003). A recent randomized control trial demonstrated 
that dexamethasone treatment did not alleviate maternal puritus or reduce serum 
ALT levels (Glantz et al., 2005). While dexamethasone did reduce serum BA levels 
in patients with ICP, it was less effective than UDCA (Glantz et al., 2005).   
 
Rifampicin has been used to treat severe forms of ICP that are unresponsive to 
UDCA. There is little direct evidence for the mode of action of rifampicin in treating 
ICP. However, rifampicin is a potent activator of PXR and it is likely that PXR-
induced detoxification machinery mediate the principal protective mechanism 
(Bertilsson et al., 1998).  
 
1.6.5 Future perspectives in ICP 
 
To date, only a small proportion of ICP cases can be attributed to identified genetic 
variation. It is likely that the success of these genetic investigations has been 
hampered by the heterogeneity and size of the ICP cohort studied. As discussed 
previously, ICP must be distinguished from asymptomatic hypercholanaemia of 
pregnancy (AHP) and it has been suggested that individuals with AHP be 
distinguished form “normal” pregnancy in order to improve the power of genetic 
susceptibility studies. In order to fully understand the genetic contribution to ICP, a 
genome wide association study performed on a large cohort of well-defined ICP 
cases and controls will be necessary.  
 
Reproductive hormones have been implicated in unmasking cholestasis in 
genetically predisposed individuals during pregnancy. While data in model 
organisms suggests that this could be the case, physiologically relevant reproductive 
hormone experiments have not yet been conducted.  
 
Pregnancy is associated with marked alterations in food intake (Johnstone & 
Higuchi, 2001) and sleep patterns (Pien & Schwab, 2004). Many BA responsive 
genes (Galman et al., 2005) and NRs (Yang et al., 2006) are expressed in strict 
diurnal patters and alterations in the volume of food consumed, the composition of 
the diet as well as the time of eating and awaking hours during pregnancy are likely 
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to disrupt the circadian control of the entero-hepatic circulation. The potential for 
causing cholestasis by inducing shifts in feeding behaviour are currently being 
conducted by other groups, it remains to be determined whether these studies will 
have implications during gestation and influence the environmental aspect of the 
aetiology of ICP. 
   
Hepatic biopsies are not clinically indicated in ICP so there are no data on the effect 
of normal or cholestatic pregnancy on the expression of hepatic BA responsive 
genes. Non-invasive serum assays for the BA intermediate C4 and the intestinal 
signalling hormone FGF19 would, however, provide insight into the effects of 
normal and cholestatic pregnancy on the regulation of BA biosynthesis. 
 
1.7 Aims 
 
This thesis aims to investigate novel aspects on the role of PXR in mediating 
hepatoprotection against cholestatic injury. Furthermore, rodent models will be used 
to investigate the physiological adaptations of the maternal liver to the demands of 
pregnancy with a focus on NR-mediated bile acid homeostasis and intrahepatic 
cholestasis of pregnancy.  
 
1.8 Hypotheses 
 
1) Pregnancy-induced liver growth in mice is driven by nuclear receptor-
dependant bile acid signalling.  
2) Functional polymorphisms in PXR (NR1I2) contribute to the genetic 
aetiology of intrahepatic cholestasis of pregnancy. 
3) Gestational factors perturb hepatic bile acid homeostasis by acting on nuclear 
hormone receptors.  
4) Elevated basal expression of hepatic drug metabolising enzymes influences 
the phenotype of Pxr-/- mice treated with lithocholic acid.  
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2 Materials and Methods 
 
2.1  Materials 
 
Analytical grade chemicals and solvents were obtained from Abbott Labs 
(Queensborough, UK), Abcam (Cambridge, UK), Abgent (San Diego, USA), 
Affymetrix (Santa Clara, USA), Ambion (Abingdon, UK), Amersham 
Biosciences/GE Healthcare (Amersham UK), Applied Biosystems (Cheshire, UK), 
Bio-Rad (Hemel Hempstead, UK) Calbiochem (Nottingham, UK), Cambrex (Iowa, 
USA), Cell Signalling Technology (Danvers, USA), Chemicon (Harrow, UK), 
Corning (New York, USA), DAKO (Glostrup, Denmark), Dharmacon (Louisiana, 
USA), Fisher Scientific (Loughborough, UK), Infometrics (Washington, USA), 
Ingenuity Systems (Mountain View, USA), Invitrogen (Paisley, UK), LUX 
Biotechnology (Edinburgh, UK), National Diagnostics (Georgia, USA), New 
England Biolabs (Hitchin, UK), Perkin Elmer (Massachusetts, USA), Pierce (Illinois, 
USA), Promega (Southampton, UK), Qiagen (Crawley, UK), Raymond A Lamb 
(Eastbourne, UK), Roche (Lewes, UK), Rosetta Inpharmatics (Seattle, USA), Santa 
Cruz Biotechnology (Santa Cruz, USA), Sentinel Diagnostics (Milan, Italy), Special 
Diet service (SDS) (UK), Sigma-Aldrich (Pool, UK), Stratagene (Texas, USA), 
Thermo (Fife, UK), Vector (Peterborough, UK), VWR (Lutterworth, UK) and 
Zymed (San Francisco, USA).  
 
2.1.1 Chemicals, Reagents and Solvents  
 
0.5% Cholic Acid Supplemented ERD Diet: SDS 
0.5% Lithocholic Acid Supplemented ERD Diet: SDS 
1Kb DNA Ladder: Invitrogen 
17β-Estradiol: Sigma-Aldrich 
17α-Estradiol: Sigma-Aldrich 
20% Sodium Dodecyl Sulfate (SDS) Solution: National Diagnostics 
30% Acrylamide: Bio-Rad 
30% Hydrogen peroxide (H2O2): VWR 
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37% HCL: VWR 
Acetic Acid: VWR 
Agarose: Cambrex 
Ammonium Persulphate: Sigma-Aldrich 
Ampicillin: Sigma-Aldrich 
β-Mercaptoethanol: Sigma-Aldrich 
Big-Dye Terminator 3.0: Sigma-Aldrich 
Bovine Serum Albumin (BSA): Sigma-Aldrich 
Chloroform: Sigma-Aldrich 
Cholic Acid (CA): Sigma-Aldrich 
Coelenterazine: LUX Biotechnology 
Complete Protease Inhibitors: Roche 
Corn Oil: Sigma-Aldrich 
DAB Reagent: Zymed 
DPEC-treated H20: Ambion 
Deoxynucleotide triphosphate (dNTP): Sigma-Aldrich 
Dexamethasone: Sigma-Aldrich 
Dimethyl Sulfoxide (DMSO): Sigma-Aldrich 
Dithiothreitol (DTT): Bio-Rad 
ECL Plus Western Blotting Detection System: GE Healthcare 
Eosin: Raymond A Lamb 
ERD Diet: SDS 
Ethanol: Fisher Scientific 
Ethidium Bromide: Bio-Rad 
Ethyl Chloride: Roche 
Ethylenediaminetetraacetic Acid (EDTA): Sigma 
Fugene 6 Transfection Reagent: Roche 
Full-Range Rainbow Molecular Weight Markers: GE Healthcare 
Haematoxylin: VWR 
HEPS: Sigma-Aldrich 
HistoClear Reagent: National Diagnostics 
Hoechst 33342: Invitrogen 
Isofluorane: Abbott Labs 
Isopropanol: Fisher Scientific 
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KCl: Sigma Aldrich 
Lithocholic Acid (LCA): Sigma-Aldrich 
Methanol: Fisher Scientific  
MgCl2: Sigma-Aldrich 
NaAc 3M pH5.5: Sigma-Aldrich 
NaCl: Sigma-Aldrich 
NaOH: Sigma-Aldrich 
Oligonucleotides: Invitrogen 
Paraffin Wax: Raymond A Lamb 
Progesterone: Sigma-Aldrich 
Propridium Iodide: Sigma-Aldrich 
Protease Inhibitor Cocktail: Sigma-Aldrich 
Rifampicin: Sigma-Aldrich 
See-Blue Molecular Weight Marker: Invitrogen 
Skimmed Milk Powder: Premier Foods 
S.O.C. media: Invitrogen 
TEMED: Sigma-Aldrich 
Tris Base: Sigma-Aldrich 
Tris HCl: Sigma-Aldrich 
Triton X-100: Sigma-Aldrich 
Trizol Reagent: Invitrogen 
Tween 20: Sigma 
Ursodeoxycholic Acid (UDCA): Sigma-Aldrich 
 
2.1.2 Antibodies 
 
β-catenin (H-102): sc-7199 (Rabbit): Santa Cruz 
Cyclin-D1 (M-20): sc-718 (Rabbit): Santa Cruz 
CYP3A (L-14) (Goat): Santa Cruz 
GAPDH (ab-9485) (Rabbit): Abcam 
Ki-67: (TEC-3) (Rat): DAKO 
p16 (M-156): sc1207 (Rabbit): Santa Cruz 
p21 (C-19) (Rabbit): Santa Cruz 
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p27 (C-19): sc52A (Rabbit): Santa Cruz 
p53 (FL-393) (Rabbit): Santa Cruz 
Phospho Histone H3 Ser 10 (9701) (Rabbit): Cell Signalling Technology 
PXR (N-16) (Goat): Santa Cruz 
SULT2A (C-term) (Rabbit): Abgent 
Anti-Goat HRP: DAKO 
Anti-Rabbit HRP: DAKO 
Anti Rat HRP: DAKO 
 
2.1.3 Enzymes 
 
Taq Polymerase: Invitrogen 
Proteinase K: Qiagen  
DNase 1: Invitrogen 
Superscript II: Invitrogen 
 
2.1.4 Plasmids 
 
pGL3: Stratagene. 
pGL3-CYP3A4-Luciferase: Materials Transfer Agreement with GlaxoSmithKline 
(Goodwin et al., 1999). 
pSG5: Stratagene. 
pSG5-hPXR: Materials Transfer Agreement with GlaxoSmithKline (Staudinger et 
al., 2001b). 
pSG5-hRXR (Van Mil et al., 2007). 
Thymidine Kinase Promoter-Renilla Luciferase (pRL-TK): Promega 
 
2.1.5 Assay Kits 
 
ALT: Thermo 
BCA Protein Assay Kit: Pierce 
Bile Acids: Sentinel Diagnostics 
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Cholesterol: Thermo 
TUNEL assay: Promega 
Gene-Chip Cleanup Module: Affymetrix 
HiSpeed Plasmid Maxi Kit: Qiagen 
LucLite Reporter Assay Kit: Perkin Elmer 
One-Cycle cDNA Synthesis Kit: Affymetrix  
One-Cycle Target Labelling Reagents: Affymetrix 
QIAprep Spin Miniprep Kit: Qiagen 
QuickChange Site Directed Mutagenesis Kit: Stratagene 
RNeasy MiniElute Cleanup Kit: Qiagen 
SuperScript II First Strand Synthesis System For RT PCR: Invitrogen 
SYBR Green Master Mix: Qiagen 
Vectastain ABC Kits: Vector 
 
2.1.6 Cell Lines  
 
Human Hepatocellular Liver Carcinoma Cells (HepG2) 
 
2.1.7 Cell Culture Materials 
 
Dulbecco’s Modified Eagle Medium (DMEM): Sigma-Aldrich 
Phenol Red Free DMEM: Sigma-Aldrich 
Fetal bovine serum (FBS): Invitrogen 
L-Glutamine: Sigma-Aldrich 
Optimem: Invitrogen 
Penicillin (100U/mL): Sigma-Aldrich 
Streptomycin (50µg/mL): Sigma-Aldrich 
Trypsin: Sigma-Aldrich 
 
2.1.8 Buffers, Solutions and Gels  
 
DNA annealing buffer 
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400mM NaCl 
20mM Tris pH7.5 
2nM EDTA pH8.0 
 
10X DNA loading buffer 
 
0.1% Orange G 
40% Glycerol 
100mM EDTA pH8.0 
 
10X TBE 
 
900mM Tris Borate 
20mM EDTA pH8.0 
 
TE Buffer 
 
100mM Tris HCl pH8.0 
1mM EDTA pH8.0 
 
Immunostaining Blocking Buffer 
 
140mM NaCl 
2.5mM KCl 
1.5mM KH2PO4 pH 7.2 
10mM Na2HPO4 pH7.2 
1% (w/v) BSA 
 
Immunostaining permeabilising buffer 
 
140mM NaCl 
2.5mM KCl 
1.5mM KH2PO4 pH7.2 
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10mM Na2HPO4 pH7.2 
0.1% (v/v) Triton X-100 
 
RIPA lysis buffer 
 
150mM NaC 
1% NP-40 
0.5% Deoxycholic acid 
0.1% SDS 
50mM Tris pH 8.0 
Protease inhibitor cocktail (50µL/10ml)  
 
2x lammeli buffer 
 
4% (w/v) SDS 
20% (v/v) Glycerol 
10% (v/v) β-mercaptoethanol 
0.005% (w/v) Bromophenol Blue 
125mM Tris HCl pH6.8 
 
Polyacrylamide resolving gel 
 
375mM Tris Hcl pH8.8 
10-15% (w/v) Acrylamide/Bis 
0.1% (w/v) SDS 
0.1% (w/v) Ammonium Persulfate 
0.04% (v/v) TEMED 
 
Polyacrylamide stacking gels 
 
125mM Tris HCl pH6.8 
5% (w/v) Acrylamide/Bis 
1% (w/v) SDS 
1% (w/v) Ammonium persulfate  
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0.1% (v/v) TEMED 
 
SDS Running buffer 
 
0.1% (w/v) SDS 
 
Milk solution 
 
5% (w/v) skimmed milk powder 
140mM NaCl 
2.5mM KCl 
1.5mM KH2PO4 pH 7.2 
10mM Na2HPO4 pH7.2 
0.1% (v/v) Tween-20 
 
PBS-Tween 
 
140mM NaCl 
2.5mM KCl 
1.5mM KH2PO4 pH 7.2 
10mM Na2HPO4 pH7.2 
0.1% (v/v) Tween-20 
 
Transfer Buffer 
 
25mM Tris Base 
190mM Glycine 
20% (v/v) Methanol 
 
PBS 
 
140mM NaCl 
2.5mM KCl 
1.5mM KH2PO4 pH 7.2 
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10mM Na2HPO4 pH7.2 
 
Renilla buffer 
 
500mM HEPES pH7.8 
40mM EDTA 
10µg/mL Coelenterazine 
 
2.1.9 Software packages 
 
Rosetta Resolver: Rosetta Inpharmatics 
Ingenuity Pathway Analysis (IPA): Ingenuity Systems 
Microsoft Office Software Suite  
Pirouette v4.0: Infometrics  
Adobe suite 
CellProfiler cell image analysis software 
KnowItAll® Informatics System v7.8  
CodonCode aligner 
 
2.2 Human studies 
 
This study conforms with guidelines outlined in the 1975 Declaration of Helsinki and 
permission obtained from the Ethics Committee of the Hammersmith Hospitals NHS 
Trust, London (97/5197). Caucasian ICP cases were diagnosed on the basis of 
clinical symptoms in combination with routine laboratory investigations, as 
described previously (Mullenbach et al., 2003). Subjects were recruited and DNA 
samples collected by other members of the ICP research group. 
 
2.2.1 PCR amplification of human genomic DNA 
 
DNA was extracted from blood, and quantified by other members of the ICP 
research group. Target DNA was amplified using standard PCR protocols. PCR 
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primer sequences are shown in Appendix A and Appendix B. Reactions were 
typically 10µl or 25µl. Reactions contained 250µM dNTPs, 0.5µM forward and 
reverse primer, 10% (v/v) 10x PCR buffer, 20-100ng of DNA template and 1-5U 
Taq DNA Polymerase. Typical cycling conditions were denaturisation at 95oC for 4 
minutes followed by 34 cycles of 95oC for 45 seconds, 55-60oC for 45 seconds and 
68oC for 30 seconds. A final extension was conducted at 68oC for 10 minutes.  
 
2.2.2 Agarose gel electrophoresis  
 
1% (w/v) gels were cast by dissolving agarose in TBE buffer and adding 3µl 
0.2µg/mL ethidium bromide per 50mL of gel. Gels were loaded with sample in 10x 
DNA loading buffer and submerged in TBE in the electrophoresis tank. 
Electrophoresis was conducted at 120V and the DNA visualized using a 
transiluminator.  
 
2.2.3 DNA sequencing and analysis  
 
DNA (genomic PCR products or plasmid) was sequenced using standard protocols. 
0.1 volumes of 3M NaoH and 0.7 volumes isopropanol were added to PCR products 
to precipitate the DNA. PCR products were then centrifuged at 4,000rpm for 40 
minutes and the dried pellet re-suspended 10µl H2O. 4µl of PCR product or 1µg of 
miniprep DNA was subjected to DNA sequencing. DNA was combined with 8µl 
Big-Dye Terminator 3.0, 3.5pmol of the appropriate primer in a final volume of 
20µl. Samples were initially de-natured at 90oC, then 26 cycles of 96oC for 10 
seconds, 55oC for 5 seconds and 60oC for 4 minutes. Samples were then precipitated 
with 40µl 75% isopropanol, centrifuged at 4,000rpm for 40 minutes and the pellet 
washed with 70% ethanol. Samples were processed by the DNA Sequencing Service 
at the Institute of Reproductive and Developmental Biology. CodonCode software 
was used to align and inspect sequences.  
 
2.2.4 Site directed mutagenesis 
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Nonsense mutations were introduced into expression plasmids using the 
QuickChange Site Directed Mutagenesis Kit and according to the manufacturers 
guidelines. Olignonucleotide primers containing the desired mutation are designed 
complementary to opposite strands of the expression vector and extended by PCR 
using PfuTurbo DNA polymerase. This generates a mutated plasmid with staggered 
nicks. Dpn 1 endonuclease is specific for methylated DNA and digests the parental 
DNA template. Mutation-containing plasmids are transformed in to XL1-Blue 
supercompetent cells. Transformed cells were isolated and screened for the presence 
of the mutation.  
 
Mutagenesis primers were designed according to the manufacturers instructions, 
sequences are provided in Appendix C. Sample reactions contained 5µl 10x Reaction 
buffer, 50ng plasmid template, 125ng primer 1, 125ng primer 2, 1µl dNTP mix and 
1µl PfuTurbo polymerase (2.5U/µl). Samples were de-natured at 95oC for 30 
seconds then 12 cycles of 95oC for 30 seconds, 55oC for 1 minute and 68oC for 2.5 
minutes. Subsequently, 1µl of Dpn 1 (10U/µl) was added and the samples incubated 
for 1-hour at 37oC. 1µl of reaction mix was the added to 25µl of XL1-Blue 
Supercompetent Cells and incubated on ice for 30 minutes. The transformation 
reactions were heat-pulsed for exactly 45 seconds at 42oC then placed on ice. 0.5ml 
of warm S.O.C media was added and the reactions incubated at 37oC for 1-hour with 
shacking. 250µl was spread on LB-ampicillin plates and incubated overnight at 37oC. 
Five colonies were selected and subjected to small-scale plasmid DNA preparation 
followed by DNA sequencing reactions of the entire insert to validate the presence of 
the mutation within the normal vector. Selected transformants were then grown for 
large scale preparation of plasmid DNA for transfection and use in reporter assays.  
 
2.2.5 Small-scale plasmid DNA preparation 
 
Small-scale plasmid DNA preparations from transformed bacterial cells were 
routinely conducted using the QIAprep Miniprep Spin Kit. Briefly, colonies were 
selected from plates and inoculated into 5mL selective LB-broth and incubated at 
37oC overnight. The cell suspension was centrifugation at 4,000rpm for 15 minutes 
and the resultant pellet re-suspended in 250µl Buffer P1 and transferred to a 
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microcentrifuge tube. 250µl buffer P2 and 350µl buffer N3 were added, the solution 
was mixed and centrifuged at 13,000rpm for 10 minutes. The supernatant was 
applied to the QIAprep spin column and centrifuged for 15 seconds. The column was 
washed with Buffer PE and dried by centrifugation. DNA was eluted off the column 
by adding 50µl H2O and centrifuging for 1 minute. Typically, 10-15µg of DNA was 
obtained.     
 
2.2.6 Large-scale plasmid DNA preparation 
 
For larger scale Plasmid DNA preparations, the QIAprep Maxiprep Kit was used. 
Transformed cells were grown in 200ml selective LB-broth overnight at 37oC with 
shaking. The cell suspension was centrifuged at 4,000rpm for 15 minutes at 4oC. The 
bacterial pellet was re-suspended in 10ml Buffer P1 and 10ml Buffer P2 was added. 
Following a 5-minute incubation at room temperature, 10ml of Buffer P3 was added 
and the lysate incubated for 10 minutes in a QIAfilter cartridge. The lysate was 
passed through the cartridge into an equilibrated HiSpeed Maxi Tip. The lysate 
entered the resin and was then washed with 60ml Buffer QC. The DNA was eluted 
from the tip with 15ml Buffer QF and precipitated by adding 10.5ml isopropanol. 
The elute/isopropanol mixture was passed through a QIAprecipitator, which binds 
the DNA and was then dried by flushing with air. Finally, the DNA was eluted in to 
a microcentrifuge tube by passing 1.5ml Buffer TE through the QIAprecipitator. 
Typically, 0.5-1mg of plasmid DNA was obtained.  
 
2.2.7 Cell culture 
 
HepG2 cells were routinely cultured in DMEM supplemented with 10% (v/v) FBS, 
1% (v/v) penicillin (100U/ml), 1% (v/v) streptomycin (50µg/ml) and 1% (v/v) L-
glutamine.  
 
2.2.8 Plasmid Transfection 
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Fugene-6 reagent was used according to the manufacturers instructions to transfect 
plasmid DNA into cell lines. Transfections were carried out in 96-well cell culture 
plates containing immortalized cells at approximately 60% confluence in 5% FBS 
supplemented DMEM. Transfection reagent and Optimem were combined at the 
ratio specified by the manufacturers. The Fugene/Optimem solution was added to the 
plasmid DNA mixes at the appropriate solution:DNA ratio and incubated at room 
temperature for 15 minutes to allow the DNA to complex with the transfection 
reagent. The transfection solution was then added to the cells and incubated for 24h 
before cell harvesting or chemical treatment.  
 
2.2.9 Reporter assays 
 
Luciferase reporter assays are routinely used for the in vitro assessment of nuclear 
receptor function. Plasmids that constitutively express the full-length receptor of 
interest and its heterodimer partner RXR (expression plasmids) are transfected. A 
“reporter” plasmid is also transfected which contains the Luciferase gene under the 
control of a natural or synthetic promoter known to be responsive to the receptor of 
interest. Also transfected is a plasmid that constitutively expresses the Renilla gene, 
which serves as an internal control for transfection efficiency. Chemiluminescence 
can then be used to measure the production of Luciferase and Renilla. When 
normalised to Renilla, production of Luciferase is proportional to the activity of the 
receptor. This system can be used to assess ligand dependant activation of the 
receptor and the effects of genetic variation on receptor function.   
 
100ng CYP3A4-Luciferase reporter construct, 50ng pRL-CMV Renilla reporter 
construct, 6.25ng pSG5-hPXR expression plasmid and 6.25ng pSG5-hRXRα 
expression plasmid were transfected. In control experiments, the empty vector pSG5 
replaced the hPXR expression vector. 24h after transfection, cells were washed and 
ligands added as a 1000x stock solution in DMSO (Rifampicin) or 100% ethanol 
(LCA, UDCA and dexamethasone). Control transfections received vehicle alone. 
Firefly Luciferase activities were determined using the Luminescence Reporter gene 
Assay System. Following aspiration of the media, 50µl of 2x LucLite reagent was 
added to wells and incubated in the dark for 15 minutes. Cell lysate as transferred to 
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white plates and the luminescence read on a Victor 2 Multilabel Counter (Perkin 
Elmer, Boston, USA). Renilla buffer was then added to each well and incubated in 
the dark for 30 minutes before reading. Values are expressed as relative to internal 
control Renilla and corrected to induction observed with vehicle.  
 
2.3 Animal studies 
 
Procedures were conducted in accordance with the United Kingdom Home Office 
“Animals (Scientific Procedures) Act 1986”.  
 
Mice were C57Bl/J6 strain. Wild-type animals were purchased from Harlan 
laboratories (UK). Pxr-/- mice (Staudinger et al., 2001b) were provided under a 
materials transfer agreement with GlaxoSmithKline. Fxr-/- mice were generated and 
validated (Appendix D) in the laboratory of Prof Johan Auwerx and Dr Kristina 
Schoonjans and provided under a materials transfer agreement with the Ecole 
Polytechnique Federale de Lausanne, Switzerland. 
 
Animals were housed under standard conditions with free access to food (ERD diet, 
Special Diet Service) and water. Groups of at least 5 age, weight and sex matched 
animals were used for all procedures. Tissue collection was conducted between 1pm 
and 2pm, following 4-hours of fasting. Humane killing was performed by CO2 
asphyxiation, followed by dislocation of the neck. Blood was collected for serum 
analysis by cardiac puncture. Tissues were immersed in formalin solution for 
subsequent histological analysis, placed in PBS for hepatocyte isolation or snap 
frozen in liquid nitrogen and stored at -80oC. 
 
2.3.1 Pregnancy experiments 
 
Because circulating reproductive hormones are thought to have a significant effect 
on liver metabolism, non-pregnant animals were killed on the day of mating, which 
adequately controls for the stage of the menstrual cycle. Gestation in mice lasts 
between 19.5 and 21 days. Pregnant animals were therefore sacrificed on the 18th day 
of gestation to avoid the collection of tissues from animals already in labour. Under 
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our housing conditions wild-type mice have on average 7.2 pups per litter. Tissues 
were only collected from mice with 6, 7 or 8 fetuses. For dietary modification 
experiments, both pregnant and non-pregnant animals received the modified diet for 
a total of 30±2 days.  
   
2.3.2 Reproductive hormone treatment 
 
Delivery of reproductive hormones to female mice by silastic implants was 
conducted essentially as described (Cohen & Milligan, 1993; Milligan & Cohen, 
1994; Milligan et al., 1995; Milligan & Finn, 1997).  
 
Preparation of implants: Silastic tubing (2cm in length) was filled with solution. 
0.5cm plastic bungs sealed each end of the implant as described (Cohen & Milligan, 
1993).  
 
Ovariectomy: Animals were anaesthetised under Isofluorane. Ovaries were located 
and removed through a single dorsal incision, which was closed using Vicryl 
absorbable sutures. Animals were allowed to recover for 14-days prior to hormone 
treatment.  
 
Silastic implants: Animals were anaesthetised under Isofluorane. The incision made 
for ovariectomy was re-opened and silastic implants inserted subcutaneously. The 
wound was closed using absorbable sutures.   
 
2.3.3 Injections 
 
Animals received intraperitoneal injections twice daily at 9am and 5pm. Compounds 
were suspended in corn oil and 100µL volume was delivered per injection.   
 
2.3.4 Histological examination of tissues 
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Freshly harvested tissue was placed in 5% neutral buffered formalin overnight. 
Tissues were dehydrated in 75% ethanol for 48-hours then 100% ethanol for 2-hours. 
Samples were “cleared” in HistoClear reagent for 4-hours, which dissolved tissue 
lipids, then placed in melted paraffin wax for 2-hours before embedding. A 
microtome (Leica) was used to cut 5µm sections, which were mounted on Polysene 
coated slides and incubated at 37oC overnight.  
 
Haematoxylin and eosin (H&E) staining was conducted according to standard 
protocols. Slides were de-waxed in HistoClear and re-hydrated through 100%, 90% 
and 70% ethanol into H2O. Slides were then stained with Haematoxylin for 5 
minutes, then Eosin for 5 minutes. Slides were dehydrated through ethanol and 
placed in HistoClear. Cover-slips mounted and samples examined microscopically. 
 
Quantitative assessment of histological liver damage was performed on 
Haematoxylin & Eosin stained sections by a single pathologist (Dr Peter Clements, 
GlaxoSmithKline) who was blinded to the treatment and genotype of the sample. 
Histopathologic changes were assessed according to the following morphologic 
criteria: Lesion Score – estimation of the proportion of the liver affected by the 
individual changes described below, relative to the total area of liver section 
presented. Scored on an ordinal scale of 1-10.  
 
• Multifocal hepatocellular necrosis– coagulative necrosis of hepatocytes, 
which was multifocal to coalescing at moderate grade or above, originating 
adjacent to the portal tract and extending to midzonal and centrilobular 
regions; associated with variable congestion/haemorrhage.  
• Biliary proliferation– increased numbers of variably basophilic bile ducts and 
epithelial cells. Severity grading: minimal, just discernable; mild, present in 
the majority of portal tracts in affected areas, possible bridging of low 
numbers of tracts; moderate, significant bridging of adjacent portal tracts.  
• Neutrophilic inflammation– infiltration of inflammatory cells rich in 
neutrophil polymorphonuclear cells, associated with foci of hepatocellular 
necrosis and/or adjacent portal tracts. 
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2.3.5 Assessment of apoptosis 
 
The DeadEnd Colorimetric TUNEL System was used to assess apoptosis in 
histological tissue sections. The system end-labels fragmented DNA, which is feature 
of apoptotic cells. The Terminal Deoxynucleotidyl Transferase (rTdT) enzyme 
incorporates a biotynylated nucleotide at the 3’-OH end of the fragmented DNA. The 
biotynylated nucleotides are then bound by streptavidin labelled with horseradish 
peroxidase (Streptavidin HRP). End-labelled DNA fragments are then detected by 
the peroxidase substrate, hydrogen peroxide and diaminobenzidine (DAB).  
 
5µm histological tissue sections were mounted on Polysyne-coated slides, de-waxed 
in HistoClear and re-hydrated. The tissue was fixed by immersion in 10% neutral 
buffered formalin solution for 15 minutes. Slides were washed in PBS and immersed 
in 20µg/mL Proteinase K solution for 20 minutes to permeabilise the tissue. Slides 
were washed in PBS and re-fixed in 10% formalin. A positive control was treated 
with 5U/mL DNase 1. Slides were washed in PBS and immersed in Equilibration 
Buffer for 10 minutes. Tissues were covered with rTdT reaction mix (98% (v/v) 
Equilibration Buffer, 1% (v/v) Biotynylated Nucleotide Mix and 1% (v/v) rTdT 
Enzyme) and incubated at 37oC for 1-hour. Samples were covered in 2xSSC for 15 
minutes, washed in PBS and incubated in 0.3% hydrogen peroxide for 5 minutes to 
block endogenous peroxidases. Samples were washed in PBS and incubated with 
HRP solution for 5 minutes. DAB solution was prepared by combining 50µl of DAB 
Substrate Buffer with 950µL H2O then adding 50µL DAB 20x Chromogen and 50µL 
Hydrogen Peroxide 20x. Samples were immersed in DAB solution until the tissue 
turned brown (typically 15 minutes). Slides were mounted with glycerol and 
examined microscopically. 
 
2.3.6 Quantification of nuclear DNA content  
 
Hoechst method: Hoechst 33342 is a fluorescent stain that binds stoichiometrically to 
DNA. In the absence of fresh tissue from which to isolate cells for FACS analysis, 
the staining of histological tissue sections with Hoechst 33342, followed by 
quantitative fluorescence microscopy, is an accepted method of assessing nuclear 
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DNA content (Toyoda et al., 2005). 5µM tissue sections were mounted on Polysene-
coated slides, de-waxed in HistoClear and re-hydrated in H2O. Slides were immersed 
in Hoechst 33342 solution (1.62nM) for 20 minutes then washed three times in H2O. 
Cover-slides were mounted with glycerol and samples protected from the light. A 
Zeiss Axiovert 35 (Carl Zeiss, Gottingen, Germany) inverted microscope with Zeiss 
Plan Neafluar 40x objective was used to image the tissue sections. Images were 
captured in grey-scale using a charged couple camera (KAF 1400-G2, Arizona, 
USA). Analysis was performed in 12 bits using CellProfiler software (Carpenter et 
al., 2006). The programme selected hepatocyte nuclei for analysis and excluded cell 
debris, other cell types and overlapping nuclei. Proximity measurements identified 
bi-nucleate hepatocytes, these were counted but excluded from DNA content 
analysis. Every software-processed image was inspected manually. The nuclear 
DNA content of each nucleus (integrated intensity) is defined as the sum for the 
fluorescence of each pixel within the identified nucleus. At least 200 nuclei were 
assessed per tissue, these were taken from at least five images, which were selected 
for imaging at random but contained the same proportion of periportal, centrolobular, 
and mediolobular areas.   
 
Propridium iodide method: In order to confirm the results of the Hoechst staining 
method, propridium iodide staining followed by FACS analysis was performed, 
where possible, on freshly isolated tissue. A small piece of liver tissue was gently 
mashed in PBS solution and the resultant homogenate passed through a fine mash to 
separate individual cells. The cell suspension was fixed overnight in cold 75% 
ethanol, centrifuged at 2000rpm and the pellet re-suspended in PBS. The suspension 
was again centrifuged at 2000rpm and the pellet re-suspended in propridium iodide 
(50µg/ml) and subjected to FACS analysis. Histograms of fluorescence intensity 
were generated.  
 
2.3.7 Immunohistochemistry 
 
Immunohistochemistry was performed on 5µm tissue sections mounted on polysene-
coated slides (VWR). Slides were de-waxed in HistoClear and re-hydrated through 
100%, 90% and 70% ethanol into H2O. Antigen retrieval was performed by boiling 
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the slides in permeabilising buffer for 20 minutes. Samples were cooled and washed 
with PBS. Endogenous peroxidases were blocked by incubating for 20 minutes in 
methanol containing 3% H2O2 followed by washing in PBS. Samples were blocked 
for 30 minutes in normal serum, from the species in which the secondary antibody 
was raised, diluted 1:5 with PBS and supplemented with 4% (w/v) BSA. Primary 
antibodies were diluted in blocking solution (typically 1:100) and incubated with the 
sample at 4oC overnight. Slides were washed in PBS and secondary antibody (1:200 
dilution) applied for 1-hour. Samples were washed in PBS and the third antibody 
(ABC Kit (2 drops of solution A in 5mL PBS followed by 2 drops of solution B)) 
applied for 30 minutes. Samples were washed with PBS and stained with DAB 
premix solution for 15 minutes.  Finally, slides were washed with H2O, 
counterstained in Haematoxylin for 10 minutes, dehydrated in ethanol and mounted 
out of HistoClear.  
 
2.3.8 Protein extraction 
 
Proteins were extracted in RIPA buffer. 1ml of RIPA buffer was added to frozen 
tissue (50µg) or freshly harvested cells. Samples were homogenised (Ultra-Turax 
T25 Power Homogeniser), transferred to a microcentrifuge tube and centrifuged at 
13,000rpm for 15 minutes at 4oC. The supernatant was transferred to a clean tube and 
stored at -80oC.  
 
2.3.9 Determining protein concentration 
 
The BCA Protein Assay Kit was used to determine protein concentrations. Peptide 
bonds reduce Cu2+ from cupric sulphate to Cu1+, this product cholates with two 
molecules of bicinchoninic acid forming a purple solution. BSA protein standards 
were prepared and samples diluted with RIPA buffer to fall within the range of the 
standards. Reactions were performed in triplicate in 96-well plates. 100µl of working 
BAC reagent (50 parts Reagent A and 1 part reagent B) was added to 12.5µl of 
standard/sample was added. Absorbance was measured at 592nm following a 30 
minute incubation at 37oC.  
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2.3.10 SDS-PAGE 
 
The liquid resolving gel solution was pipetted between glass plates and overlaid with 
10% isopropanol to level the surface. Once set, the staking gel was poured over the 
resolving gel and a comb inserted. Samples were mixed with Lammeli sample buffer 
and heated at 95oC for 5 minutes. Typically, 50-100µg of protein was loaded in a 
volume not exceeding 25µL. See Blue Molecular Weight Marker was run alongside 
samples. Electrophoresis was conducted at 120V.  
 
2.3.11 Western blotting 
 
The Mini-trans Blot System (Bio-Rad) was used to transfer proteins from the 
resolving gel to nitrocellulose membranes. In transfer buffer, sponge pads and filter 
paper were placed above and below the gel/membrane and these and assembled into 
a transfer cassette. Electroblotting was performed at 120V for 1-hour. Membranes 
were incubated for 1-hour in milk solution. Primary antibodies were diluted (1:500-
1:2000) in milk solution before incubating, with shaking, with the membrane 
overnight at 4oC. Membranes were washed, three times, with PBS-tween for 10 
minutes. Membranes were incubated with secondary, HRP-conjugated, antibodies 
diluted (1:5000) in PBS-tween for 1-hour at room temperature. Membranes were 
washed, three times, with PBS-tween for 10 minutes and secondary antibodies 
detected ECL Plus reagent. 
 
2.3.12 RNA extraction  
 
Extraction of RNA from tissues was performed using Trizol reagent and according to 
the manufacturers instructions. 1mL of Trizol was added to 50-70mg of frozen 
tissue. The tissue was allowed to thaw and then homogenised (Ultra-Turax T25 
Power Homogeniser). The homogenate was transferred to 1.5mL microcentrifuge 
tubes. 0.2mL of ice-cold chloroform was added and the mixture was shaken for 10 
seconds. Samples were centrifuged (13,000rpm) at 4oC for 15 minutes. The aqueous 
phase was carefully removed and transferred to a clean microcentrifuge tube. 0.5mL 
ice-cold isopropanol was added to each sample, mixed and incubated at -20oC for 20 
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minutes to precipitate the RNA. Samples were centrifuged (13,000rpm) at 4oC for 15 
minutes and the supernatant was discarded. The RNA pellet was washed with 1mL 
ice-cold 75% ethanol, centrifuged (13,000rpm) at 4oC for 15 minutes and the 
supernatant discarded. Samples were air-dried and the RNA was re-suspended in 
20µL DEPC-treated H2O. RNA was quantified by measuring absorbance at 260nm 
and stored at -80oC.   
 
2.3.13 cDNA synthesis  
 
cDNA was synthesised using the SuperScript II First Strand Synthesis System For 
RT PCR (Invitrogen) and according to the manufacturers instructions. To digest 
contaminating DNA, 2µg of RNA, 1µL 10x DNase I reaction buffer and 1U DNase I 
were adjusted to a total reaction volume of 10µl with DEPC-treated H2O. Following 
incubation for 15 minutes at room temperature, the reaction was terminated by 
adding 1µL 25mM EDTA and heating for 10 minutes at 65oC. 2µL 10mM dNTPs, 
6µL Random Hexomers (50ng/µL) and 5µl DEPC-treated H20 were pre-mixed and 
added to each sample. The mixture was incubated at 65oC for 10 minutes. Half of the 
sample volume (6µL) was transferred to a clean tube and as a pre-mix containing, 
4µL 5x First Strand Buffer, 2µL 100mM DTT, 1µL RNase inhibitor and 1µL 
Superscript II was added. The other 6µL was similarly treated but DEPC-treated H20 
replaced the Superscript II, these samples serve as controls during gene expression 
analysis. A thermo-cycler was used to incubate samples at 25oC for 10 minutes, at 
42oC for 50 minutes and at 72oC for 10 minutes. Samples were diluted 2x with 
DEPC-treated H2O and stored at -20oC.    
 
2.3.14 Gene expression analysis 
 
Q-RTPCR was used to analyze gene expression. SYBR-Green fluoresces when 
intercalated into DNA synthesised from the target cDNA template. The fluorescent 
signal is proportional to the amount of the target cDNA present. The fluorescent 
signal is detected following each cycle of the PCR reaction. A cycle threshold (Ct) 
value is determined for each sample, which corresponds to the number of PCR cycles 
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required to generate a defined fluorescent signal of a magnitude set within the linear 
phase of the reaction. The fluorescent signal threshold is therefore a constant for the 
assessment of a single gene expression between multiple samples. Gene expression is 
then calculated relative to that of a “housekeeper” gene, which controls, primarily, 
for differences in cDNA amplification efficiency. Fold change can then be calculated 
from the relative gene expression of control and treated samples.  
 
Q-RTPCR was conducted in duplicate using SYBR-Green Master Mix and according 
to the manufacturers instructions. Q-RTPCR primer sequences are listed in Appendix 
E. Each 25µl reaction mix comprised 0.8µM primers, 1µl cDNA template and 12.5µl 
SYBR Green. PCR quantification was performed using a DNA Engine Opticon-2 
Real Time PCR Detection System (MJ Research). Typical cycling conditions were 
an initial denaturing step at 95oC for 2 minutes followed by 40 cycles of 95oC for 15 
second, 60oC for 30 seconds and 72oC for 30 seconds. The plate was read at the end 
of each cycle. Cyclophilin was used as a housekeeping gene.  
 
Gene expression (ΔCt) was determined by normalizing to values obtained for 
Cyclophilin. This calculation is performed for each sample by subtracting the mean 
of the duplicate Ct value for Cyclophilin from the mean of the duplicate Ct value of 
the gene of interest. ΔΔCt was calculated by subtracting the ΔCt of each sample from 
a single chosen cDNA ΔCt. Relative expression ±standard error of the mean (SEM) 
was then calculated based on the mean ΔΔCt values of each sample of a treatment 
group relative to mean ΔΔCt of control group.  
 
2.3.15 Expression microarrays and data analysis 
 
Preparation of samples for microarray analysis was conduced according the 
guidelines of the Medical Research Council Microarray Centre at Hammersmith 
Hospital and Affymerix.  
 
2.3.15.1 RNA extraction and purification 
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RNA was extracted from tissue using the Trizol method as described above. An 
RNA-cleanup procedure was conducted using the RNeasy MiniElute Cleanup Kit. 
Briefly, guanidine-thiocyanate-containing lysis buffer and ethanol are added the 
sample, this facilitates the precipitation and binding of the RNA to the silica gel 
membrane of the spin column. The column is then washed to remove contaminants 
and RNAs smaller than 200 nucleotides and the RNA eluted in water. RNA sample 
volume was adjusted to 200µl with H2O and 700µl buffer RLT added. 500µl 100% 
ethanol was then added and the sample centrifuged in the spin columns at 13,000rpm 
for 30 seconds. The column was washed by first adding 500µl buffer RPE and 
centrifuging, then adding 500µ 80% ethanol and centrifuging. The column was dried 
by centrifugation with the lid open for 5 minutes, the RNA was then eluted by adding 
14µl H2O and centrifuging at 13,000rpm for 2 minutes.   
 
RNA integrity was assessed by Bioanalyzer (2100 Bioanalyzer, Agilent 
Technologies) at the Medical Research Council Microarray Centre at Hammersmith 
Hospital. RNA integrity numbers (RIN) were assigned to all samples and each 
spectrum was also visually inspected. Only samples with a RIN greater than 8.2 were 
used for cRNA synthesis.  
 
2.3.15.2 cRNA synthesis 
 
RNA was processed using the One-Cycle cDNA Synthesis Kit and One-Cycle Target 
Labelling Reagents according to the manufacturers instructions (Affymetrix). 
Briefly, the first cDNA strand is synthesised from total RNA using the T7-Oligo(dT) 
priming method. Subsequently, DNA polymerase I is used to synthesise double 
stranded cDNA, which is used as a template to synthesise cRNA using labelled 
dNTPs. The reaction is initially spiked with a mixture of Poly-A+ controls, which 
serve as internal controls for reaction efficiency. All incubations were performed in a 
thermal cycler with a heated lid. For first strand cDNA synthesis, 10µg of total RNA, 
2µl T7-Oligo(dT) primers (50µM) and 1µl Poly-A+ controls are combined in a final 
volume of 11µl. The mixture is heated at 70oC for 2 minutes and cooled on ice. As a 
pre-mix, 4µl First Strand Buffer, 2µl DTT (0.1M) and 1µl dNTPs (10mM) were 
added and incubated at 42oC for 2 minutes. 2µl Superscript II is added and samples 
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incubated at 42oC for 1 hour. For second strand cDNA synthesis, the following 
reagents were added as a pre mix 91µl dH2O, 30µl Second Strand Buffer, 3µl dNTPs 
(10mM), 1µl DNA Ligase, 4µl DNA polymerase and 1µl RNase H and incubated at 
16oC for 2 hours. Clean-up of the double stranded cDNA was performed with the 
Gene-Chip Cleanup Module. 600µl of cDNA binding buffer was added and the 
samples transferred to a spin column and centrifuged at 13,000rpm for 1 minute. 
750µl of cDNA wash buffer was added to the column and centrifuged at 13,000rpm 
for 1 minute. The column was dried by spinning at 13,000rpm with the lid open and 
the sample eluted by adding 15µl cDNA Elution Buffer, incubating for 1 minute and 
centrifuging at 13,000rpm for 1 minute. Synthesis of labelled cRNA was conducted 
using One-Cycle Target Labelling Reagents. The following reagents were added to 
6µl of eluted double stranded cDNA, 14µl H2O, 4µl IVT Labelling Buffer, 12µl 
labelled NTP mix and 4µl IVT labelling enzyme mix. The samples were incubated at 
16oC for 16 hours. 60µl H2O, 350µl cRNA Binding Buffer and 250µl 100% ethanol 
was added to the sample and centrifuged at 13,000rpm through an IVT cRNA 
Cleanup Spin Column. 500µl IVT cRNA Wash Buffer followed by 500µl 80% Wash 
Buffer was then passed through the column by centrifugation. The column was dried 
by centrifugation with the cap open and the cRNA eluted by adding 11µl of H2O and 
centrifuging at 13,000rpm for 2 minutes. cRNA quantity and quality was determined 
by Nanodrop. The 260:280nm absorbance ratio was between 1.9 and 2.1. The cRNA 
was also run on the 2100 Bioanalyzer, a broad hump between 800 and 1500 
nucleotides demonstrated that the cRNA synthesis reaction was successful.  
 
2.3.15.3 Scanning and hybridization 
  
cRNA hybridisation to Affymerix Mouse Genome 430 2.0 arrays and subsequent 
scanning was performed by the Medical Research Council Microarray Centre at 
Hammersmith Hospital. Technical quality control was also performed by the 
Microarray Centre. There were no artefacts detected. The Poly-A+ controls, spiked 
into the reaction prior to cDNA synthesis, provided a linear fluorescent signal based 
on their starting concentration. Reporter sets designed within either the 3’ or 5’ end 
of housekeeping genes gave ratios of close to 1:1, demonstrating that acceptable 
 85 
lengths of cRNA had been amplified. Raw fluorescent intensities were also within 
acceptable limits.  
 
2.3.15.4 Data analysis 
 
The majority of the microarray data analysis was performed using the Rosetta 
Resolver software package, the algorithms for data analysis are published 
(Vardhanabhuti et al., 2006). Raw “.cel” files were uploaded into the Resolver 
system by the Microarray Centre. Experiment Definitions were “built” and 
individual “.cel” files were assigned to treatment group. The summed raw intensities 
of each array were “scaled” to allow direct comparison between individual probe sets 
on different arrays. Unsupervised principal component analysis was conducted on 
the entire dataset. It is acceptable to perform data reduction techniques in order to 
perform analysis only on genes that are considered to be expressed at a level above a 
certain threshold (Schnoes et al., 2008). While there is no consensus on the threshold 
that should be applied, following discussion with collaborators at GlaxoSmithKline, 
probe sets with a mean, scaled intensity of less than 30U in both groups of a two-way 
comparison were excluded from further analyses. cDNA synthesis from 1µg of total 
RNA followed by Q-RTPCR produced a Ct value of 32 cycles for a gene (Pparγ) 
with a mean, normalized fluorescence intensity of 30U. Rosetta Resolver software 
was used to create lists of fold-change, p-value, 2D hierarchal clustering, Venn-
diagrams and canonical pathway analysis. Ingenuity Pathway Analysis was also used 
to examine disease-related pathways and networks of interacting genes.     
  
2.3.16 Serum ALT 
 
High serum concentrations of the liver enzyme alanine aminotransferase (ALT) is a 
marker of abnormal liver function in mice and in humans. ALT was measured in 
serum using the Infinity ALT Liquid Stable Reagent and according to the 
manufacturers instructions. In the reaction, ALT catalyzes the conversion L-alanine 
and 2-oxoglutarate to pyruvate and L-glutamine. Subsequently, pyruvate and NADH 
is converted by LDH in the reaction to form L-lactate and NAD. The oxidation of 
NADH decreases the absorbance of the sample at 340nm and the rate of decrease is 
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proportional to the ALT content of the sample. Reactions were carried out in 96-well 
plates in duplicate. 10µl of sample was combined with 100µl of working reagent and 
read at 340nm every 10 seconds for 5 minutes. ALT activity (U/L) is proportional to 
the change in absorbance per minute during the linear phase of the reaction.   
 
2.3.17 Bile acid extraction and measurement 
 
Bile acids were determined in serum directly. Faecal and tissue bile acids were first 
extracted by homogenisation in 20x (w/v) 75% ethanol followed by shaking for two 
hours at 55oC. The homogenate was centrifuged at 13,000rpm and the supernatant 
assayed. Bile acids were extracted from tissue and faeces in triplicate (three pieces of 
tissue per organ). Urinary bile acids were first extracted using Bond Elute Solid 
Phase Extraction Columns (Varian, Palo Alto, USA) and corrected to total urinary 
proteins. All samples were diluted or concentrated by evaporation to fall within the 
linear range of the assay.  
 
Bile acids were measured using a kit and according to the manufacturers instructions. 
The 3α hydroxysteroid dehydrogenase converts bile acids into 3-keto bile acids in 
the presence of NAD. The reaction forms NADH, which reacts with nitrotetrazolium 
blue (NBT), the colour intensity is proportional to the bile acid concentration of the 
sample. Reagent 1 is prepared by reconstituting one vial of Reagent 1a with one vial 
of Reagent 1b. In duplicate, 20µl of sample or standard is combined with 40µl 
Reagent 1 and incubated with at room temperature for 10 minutes. 10µl of Reagent 2 
is added to one of the wells of the duplicate (“test”) and 10µl H2O added to the other 
well of the duplicate (“blank”). Reactions were incubated at 37oC for 20 minutes and 
measured at 546nm. Bile acid concentrations were calculated based on the standards, 
following subtraction of blank values. 
 
2.3.18 Lipid extraction 
  
Lipids were measured in serum directly. With slight modifications, the Folch method 
(Folch et al., 1957) was used to extract lipids from tissue. Weighed tissue was 
homogenized in 20x volume chloroform/methanol (2:1) solution and incubated with 
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shaking at room temperature for 20 minutes. The homogenate was centrifuged at 
13,000rpm for 20 minutes and the liquid phase recovered. The supernatant was then 
washed by adding 0.2 volume 0.9% NaCl and shaking. The solution was centrifuged 
at 2000rpm for 15 minutes, the upper phase was removed and discarded and the 
lower, lipid-containing phase evaporated under N2. The lipid residue was then re-
suspended in an appropriate volume of PBS Triton X-100. Extractions were 
conducted in triplicate (three pieces of tissue per organ).  
 
2.3.19 Cholesterol assay 
 
Cholesterol was measured in serum or tissue extracts using the Infinity Cholesterol 
Liquid Stable Reagent according to the manufacturers guidelines. Cholesterol esters 
in the sample are first hydrolyzed to free cholesterol. The free cholesterol in the 
sample is oxidised by cholesterol oxidase and hydrogen peroxide is a product of the 
reaction. The hydrogen peroxide then combines with hydroxybenzoic acid and 4-
aminoantipyrine to form a quinoneimine dye that is quantified at 550nm. Samples 
were assayed in triplicate in 96-well plates. 10µl of sample or calibrator was 
combined with 100µl of reagent and incubated at 37oC for 15 minutes before reading 
the plate at 550nm. Cholesterol concentrations were then calculated based on the 
absorbance of the calibrator.  
 
2.3.20 Magnetic resonance spectroscopy and data analysis 
 
Metabolomic profiling of intact tissue by magic angle spinning (MAS) 1H magnetic 
resonance spectroscopy (MRS) was performed in collaboration with The 
Translational MR Spectroscopy Grouping, Division of Clinical Sciences, Imperial 
College London. Sample preparation, data acquisition and data analysis was 
performed essentially as described (Cobbold et al., 2008). Under the guidance of Dr 
Jane Cox, freshly thawed tissue was spun (4000Hz) at 4oC in sealing cells (Doty 
Scientific Inc., Columbia, South Carolina, USA) using a MAS probe (Doty Scientific 
Inc.) interfaced with a JEOL Eclipse 500+ spectrometer (JEOL (UK) Ltd, Welwyn 
Garden City, UK) and an 11.75T superconducting magnet (Oxford Instruments, 
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Oxford UK). A pulse and collect sequence was used, water and macromolecular 
signals were repressed to emphasize lower molecular weight metabolite signals.  
 
Raw data analysis was performed by Dr Jeremy Cobbold. KnowItAll® Informatics 
System v7.8 (Bio-Rad, Philadelphia, USA) was used to process the spectra, as 
described (Cobbold et al., 2008). Relative quantitative analysis of metabolites 
between samples was possible by scaling the spectra to the sum of the total spectral 
integral. Partial least squares discriminant analysis (PLS-DA) with orthogonal signal 
correction was used to determine factors associated with class membership using 
Pirouette v4.0 software package (Infometrics, Washington, USA). A leave-one-out 
algorithm was used to determine the predictive power of the model and the Q2 value 
indicates the validity of the discrimination, with values >0.05 considered significant. 
Examination of individual spectral resonances and assignment of peaks was also 
performed by Dr Jeremy Cobbold, as described (Cobbold et al., 2008). 
  
2.4 Statistics 
 
Typically, values are presented as mean ±SD for technical replicates or mean ±SEM 
for biological replicates. Where appropriate, data are presented as histograms. 
Rosetta Resolver, Ingenuity Pathway Analysis and KnowItAll software have 
specialist statistical algorithms for calculating statistical significance. Microsoft 
Office Excel software was used to perform t-tests, one-way and two-way ANOVA 
for determination of statistically significant differences in mean. In all cases, p<0.05 
is considered statistically significant. 
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3 Adaptive Mechanisms of Gestational Liver Growth 
in the Absence of Nuclear Receptor Signalling 
 
3.1  Introduction  
 
The hepatocytes of the liver maintain the ability to grow and proliferate in response 
to increased metabolic demand or physical injury. In mice, 70% hepatic resection 
initiates hepatocyte proliferation that restores liver mass within just 10-days of 
surgery (Dai et al., 2008). Bile acids and their nuclear receptor sensors Fxr, Pxr and 
Car, are required for the normal progression of liver regeneration in mice (Huang et 
al., 2006; Dai et al., 2008).  
 
Pregnancy is a period that requires a significant increase in the metabolic capacity of 
the maternal liver. Maternal liver enlargement during pregnancy was first reported in 
mice in 1958 (Paschkis & Cantarow, 1958) but little is known regarding the cellular 
or molecular mechanisms by which the growth is achieved or the stimuli that drive 
the enlargement.  
 
Serum bile acids and reproductive hormones are raised during pregnancy in humans 
and cause liver growth in some animal models (Huang et al., 2006; Yamamoto et al., 
2006). Bile acids or reproductive hormones may drive gestational liver enlargement 
in mice. Pregnancy induced liver growth in mice will be characterized and insight 
into the mechanisms and signals driving the enlargement will be provided.  
 
This chapter will focus on data from wild-type and Pxr-/- mice. Alexandra Milona 
was responsible for the maintenance, experiments and data analysis conducted on 
Fxr-/- mice.  
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3.2 Results 
 
3.2.1 Unlike bile acids, pregnancy levels of reproductive 
hormones are not sufficient to drive liver growth 
 
In order to investigate the potential involvement of reproductive hormones and bile 
acids in driving gestational liver enlargement, liver weight and total serum bile acids 
were initially measured in pregnant mice, in long-term cholate-fed mice and in mice 
treated with pregnancy-levels of reproductive hormones.  
 
Liver weight was 66% (p<0.01) greater in pregnant mice than in non-pregnant 
controls (Fig. 3.1A). The increase in liver weight in pregnant mice was associated 
with a 7-fold (p<0.05) increase in total serum bile acids (Fig.3.1B). As expected, 
long-term cholate-feeding (30-days) of female mice resulted in a significant increase 
in liver weight (63% (p<0.01)) and total serum bile acid levels (14-fold, p<0.01) 
(Fig. 3.1A and B). Therefore, pregnancy and cholate feeding cause liver growth 
associated with raised serum bile acids.   
 
Pregnancy-levels of reproductive hormones were administered to ovariectomised 
mice via silastic implants over a time course similar to that of pregnancy (18-days). 
The reproductive hormones caused significant uterine swelling compared to vehicle 
treated mice, demonstrating that the treatment was effective. The reproductive 
hormones had no significant effect on liver weight or total serum bile acid levels 
(Fig. 3.1A and B).    
 
These data demonstrate that physiological doses of reproductive hormones alone are 
not sufficient to drive liver enlargement, they are therefore unlikely to be the primary 
signal driving gestational hepatomegaly. In contrast, serum bile acid levels 
comparable to those in pregnant mice are associated with hepatomegaly in cholate-
fed animals. Therefore bile acids plausibly contribute to pregnancy-induced liver 
growth in mice.    
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3.2.2 Gestational liver growth in mice is a result of hepatocyte 
hypertrophy 
 
Pregnancy-induced liver enlargement was first reported in mice in 1958 but the 
mechanisms by which the growth is achieved have been incompletely investigated 
(Hollister et al., 1987). Therefore, pregnancy-induced liver growth was characterized 
in normal mice.  
 
Preliminary investigations revealed that normal liver architecture is maintained in 
pregnant animals. No evidence of fibrosis, necrosis or infiltration of non-hepatic 
cells was found, suggesting that pregnancy-induced liver growth in mice is a result of 
hepatocyte hyperplasia (cell proliferation) or hypertrophy (cell swelling).  
 
Total liver protein per gram of tissue was unaffected by pregnancy (p=0.89 
compared to non-pregnant), indicating that the change in mass is likely to be 
functional and not simply a result of increased cellular water content.  
 
Preliminary microscopic investigation of H&E stained liver sections revealed an 
apparent increase in hepatocyte size (cross-sectional surface area) in pregnant 
animals compared to non-pregnant controls. In order to quantify the increase in cell 
size, the number of hepatocytes per microscope field were counted. However, under 
normal conditions, a significant proportion of hepatocytes are bi-nucleate, which 
makes identification of individual cells difficult. β-catenin immunostaining was 
performed in order to enable clear identification of hepatocyte cell membrane (Fig. 
3.2A) and accurate counting of the number of hepatocytes per microscope field. 
Hepatocytes were counted in 10 high power (x40 magnification) microscope fields 
per animal (n=6). The number of hepatocytes per microscope field was reduced by 
19% (p<0.01) in pregnant mice compared to non-pregnant controls (Fig. 3.2B). A 
reduction in the number of hepatocytes per field is indicative of increased hepatocyte 
cross-sectional surface area in pregnant mice compared to non-pregnant controls.  
 
While hepatocyte hypertrophy appears to account for the bulk of the pregnancy-
induced increase in liver size, the potential role of hepatocyte proliferation in  
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achieving the growth was also assessed. The Ki-67 protein is expressed at all stages 
of the cell-cycle except G0. Therefore, while Ki-67 immunostaining is often used as 
a marker of proliferation, it is better described as a marker of cell cycle 
entry/progression. Ki-67 immunostaining was used as a marker of cell cycle 
progression and phospho-histone-H3 immunostained mitotic figures as a highly 
specific marker of cell division (mitosis). Pregnancy caused a 10-fold (p<0.01) 
increase in the proportion of Ki-67+ hepatocytes (Fig. 3.2C) without affecting the 
proportion of hepatocytes undergoing cell division (Fig. 3.2D). This finding 
demonstrates that pregnancy causes hepatocyte cell-cycle entry without causing 
mitosis. Finally, by performing TUNEL staining on histological liver sections, it was 
demonstrated that pregnancy had no significant affect on the proportion of apoptotic 
hepatocytes (Fig. 3.8). Together, these findings demonstrate that pregnancy causes 
hepatocyte growth associated with cell cycle entry/progression that is uncoupled 
from both mitosis and apoptosis.  
 
Polyploidy is a known adaptive response to hepatic metabolic stress. It was therefore 
determined whether pregnancy causes an increase in hepatocyte nuclear DNA 
content. Two methods were used to assess nuclear DNA content, quantitative 
fluorescence microscopy and FACS analysis. Quantitative fluorescent imaging of 
histological sections stained with Hoechst is a published method for the 
quantification of nuclear DNA content (Toyoda et al., 2005). 5µm liver sections 
(n=6) were stained with Hoechst 33342 and imaged in greyscale. Cell Profiler 
software, with manual screening, was used to identify hepatocyte nuclei and sum the 
fluorescent intensity of each pixel within the nucleus as a measure of the DNA 
content of that nucleus. Because the histological sections intersect individual nuclei, 
counting of a large number of cells is required to generate histograms for data 
interpretation. The Cell Profiler also identified bi-nucleate hepatocytes. The 
proportion of bi-nucleate hepatocytes was unaffected by pregnancy. Bi-nucleate 
hepatocytes and cells with overlapping nuclei were excluded from the analysis due to 
artefacts in fluorescent intensity. Figure 3.3A shows that pregnancy causes the 
emergence of a population of hepatocytes that contain twice the nuclear DNA 
content of controls. In order to confirm this finding using a more conventional 
technique, the pregnancy experiment was repeated and hepatocytes were isolated 
from tissue prior to freezing. Briefly, a small piece of liver tissue was gently crushed  
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in PBS solution and filtered through a fine mesh in order to achieve a suspension of 
single hepatocytes. The hepatocytes were then stained with propridium iodide (PI) 
and subjected to FACS analysis. FACS analysis of propridium iodide stained crude 
cell isolates revealed a statistically significant shift towards higher nuclear DNA 
content in the hepatocytes of pregnant mice compared to non-pregnant controls 
(p<0.01). In summary, two independent assays were used to demonstrate that 
hepatocyte nuclear DNA content is increased in pregnant animals compared to non-
pregnant controls. Pregnancy in mice therefore causes a significant proportion of 
hepatocytes to enter the cell cycle, grow, progress through DNA synthesis and arrest 
prior to mitosis.     
 
It has been demonstrated here that pregnancy has a significant effect on the 
hepatocyte cell cycle. Next, the effect of pregnancy on the protein expression of a 
number of cell cycle regulators was assessed. Western blots were conducted using 
pooled total liver protein extracts for six non-pregnant and six pregnant mice. 
Hepatic GAPDH levels were unaffected by pregnancy and demonstrated that a 
roughly equal amount of protein was subjected to western blotting in both groups 
(Fig. 3.4). Pregnancy increased the hepatic expression of the tumour suppressor p53 
approximately two fold over the level observed in non-pregnant controls (Fig. 3.4). 
Degradation of p27 is known to be required for cyclin D1 mediated cell cycle 
progression and while pregnancy caused markedly reduced expression of p27, the 
expression of cyclin D1 was also reduced by pregnancy (Fig. 3.4). The expression of 
p21, which inhibits cell cycle progression and is partly controlled by p53, was 
unaffected by pregnancy (Fig. 3.4). Together, these data demonstrate that pregnancy 
has complex effects on the hepatocyte cell cycle with apparently progressive (down-
regulation of p27) and inhibitory (up-regulation of p53 and down-regulation of 
cyclin D1) changes in the expression of cell cycle regulators.  
 
In conclusion, pregnancy-induced liver growth in mice was characterized. Pregnancy 
alters the protein expression of cell-cycle regulators, causes hepatocytes to enter the 
cell-cycle, grow and progress through DNA synthesis before arresting prior to 
mitosis. Therefore, pregnancy-induced liver growth is primarily a result of 
hepatocyte hypertrophy. 
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3.2.3 Cholic acid feeding causes liver growth by hepatocyte 
proliferation 
 
Bile acids are potentially implicated in driving pregnancy induced liver growth (see 
Fig. 3.1A and B) and the basic cellular mechanisms that achieve gestational 
hepatomegaly have been characterized. Next, the mechanisms of cholate-induced 
liver growth will be determined in order to compare and contrast these mechanisms 
with those of pregnant animals.  
 
In an initial time-course of 0.5% cholate feeding, liver growth (here measured as a 
proportion of body weight) occurred in female mice between three and seven days of 
feeding (Fig. 5.5A). Continuation of the feeding regimen did not significantly affect 
liver/body weight ratio between seven and 30-days (Fig. 3.5A). This observation 
demonstrates that bile acids cause rapid, but limited, liver growth in mice.  
 
In pregnant mice, liver enlargement was achieved primarily by hepatocyte 
hypertrophy (Fig 3.2B). In cholate-fed mice however, despite the bulk of liver 
growth being achieved by the seventh day of cholate feeding, hepatocyte size was 
not significantly different to chow-fed animals (Fig 3.5B). Therefore, unlike 
pregnancy, hepatocyte hypertrophy does not contribute to cholate-induced 
hepatomegaly. Assessment of cell cycle progression and mitosis was again 
performed by Ki-67 and phospho-histone-H3 immunostaining. The proportion of Ki-
67+ hepatocytes increased from background level to almost 30% (p<0.001) between 
three and seven days of feeding (Fig. 3.5C). The proportion of Ki-67+ hepatocytes 
decreased between seven and 30-days of feeding, which is in line with the lack of 
change in liver size between these time points, but remained significantly higher than 
background levels (Fig. 3.5C). The proportion of phospho-histone-H3 positive 
mitotic figures also increased significantly between three and seven days of feeding 
(Fig 3.5D). Notably, the increase in mitotic figures was not as dramatic as that of Ki-
67+ cells and suggest that the major mitotic events occurred before the seventh day 
of feeding but after the third day of feeding. These data demonstrate that in contrast  
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to pregnancy, cholate feeding causes hepatomegaly not by hepatocyte hypertrophy 
but rather by hepatocyte hyperplasia.   
 
The quantitative fluorescent imaging approach to estimate DNA content was 
employed to determine whether, as was the case during pregnancy, cholate feeding 
caused an increase in hepatocyte nuclear DNA content. Indeed, average hepatocyte 
nuclear DNA content was increased in mice fed the cholate-supplemented diet (Fig. 
3.6A).  
 
The temporal changes in expression of cell cycle regulators over the time-course of 
cholate feeding were assessed by western blot (Fig 3.6 B). On the whole, the pattern 
of expression was for cell-cycle promoting changes to occur first which then became 
more growth inhibiting towards the end of the time course. The expression of the 
tumour suppressor p53 was unaffected after one-day of feeding and was then 
markedly decreased by day-three. Despite some increase in expression between day 
seven and day 30, the expression of p53 remained lower than in control mice. The 
expression of the cell-cycle promoter Cyclin D1 increased on day three and remained 
at this level until the end of the study. The growth inhibitor P27 was significantly 
reduced after just one-day of cholate feeding but its expression recovered to control 
levels following 30-days. Finally, the expression of the cell cycle inhibitor, P21, 
started to increase after three days of cholate feeding and following seven and thirty 
days, its expression was markedly higher than in control mice. These data 
demonstrate that cholate-feeding significantly affects the expression of cell cycle 
regulators. Short-term cholate-feeding caused pro-proliferative protein expression 
effects while long-term feeding induces growth-arrest pathways that are likely to 
prevent continuation of liver enlargement beyond that observed following seven days 
(Fig. 3.5A).  
 
These data demonstrate that while cholate-feeding and pregnancy achieve liver 
growth by different mechanisms (hyperplasia and hypertrophy respectively), cell 
cycle progression and polyploidy are common features. While it is difficult to make 
conclusions on the general affects of pregnancy and cholate feeding on cell cycle 
regulators, their expression is dynamic and affected by signals of pregnancy and 
cholate feeding.  
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3.2.4 Neither raised serum bile acids nor Pxr are required for 
gestational liver growth 
 
Cell cycle progression and polyploidy were common to the hepatocytes of pregnant 
and cholate-fed mice. Therefore, the potential role of bile acids in gestational liver 
growth was investigated by conducting pregnancy experiments in long-term cholate-
fed mice, and in mice deficient of the bile acid responsive nuclear receptors Pxr and 
Fxr.  
 
To assess pregnancy in long-term cholate-fed mice, animals received the modified 
diet and were mated following 12-days (pregnant group) or 29-days (non-pregnant 
group) of dietary supplementation. In this way, non-pregnant (1-day post conception) 
and pregnant (18-days post conception) mice received the dietary modification for a 
total of 30-days. Pregnancy was maintained in long-term cholate-fed animals with no 
effect on fetal number or weight. Importantly, serum bile acids and liver weight are 
further increased by pregnancy in long-term cholate-fed mice and the magnitude of 
change was comparable to that in chow-fed animals (Fig 3.7A and B). Pregnancy can 
therefore induce a second wave of liver enlargement, and a further increase in serum 
bile acids in mice that have already undergone the effects of bile acid feeding.  
 
Mice lacking the bile acid sensors Pxr or Fxr did not develop raised serum bile acids 
during pregnancy (Fig. 3.7A) but the proportional increase in gestational liver 
enlargement was similar to that in control mice (Fig. 3.7B). While it is of interest that 
serum bile acids are not raised in Pxr-/- and Fxr-/- mice, the data demonstrate that 
neither raised serum bile acids nor Pxr/Fxr-mediated signalling is required for 
pregnancy-induced liver growth.   
 
3.2.5 Pxr-/- mice undergo gestational hepatomegaly by 
essentially the same mechanisms as wild-type mice.  
 
While the normal mechanisms of liver regeneration following partial hepatectomy 
are not maintained in Fxr-/- and Pxr-/- mice, the phenotype is relatively subtle and  
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compensatory/redundant pathways clearly exist to ensure that liver re-growth occurs 
(Huang et al., 2006; Dai et al., 2008). For these reasons, despite the magnitude of 
hepatomegaly being unaffected compared to control animals, the mechanisms of 
gestational liver growth in the long-term cholate-fed and Pxr/Fxr-/- mice was 
assessed.  
 
In long-term cholate-fed mice, pregnancy caused hepatocyte enlargement in line with 
that of chow-fed mice (Fig. 3.8A). Pregnancy increased the proportion of Ki-67+ 
hepatocytes in cholate-fed mice but the magnitude of effect was slightly blunted 
compared with pregnancy in control-fed mice (Fig. 3.8B). As was the case in chow-
fed animals, pregnancy had no effect on the proportion of phospho-histone-H3 
positive mitotic figures or TUNEL positive hepatocytes (Fig. 3.8C and D). Cholate 
feeding increased nuclear DNA content but unlike in chow-fed mice, pregnancy had 
no further effect on hepatocyte DNA content in these mice (Fig 3.9A). These data 
demonstrate that the normal mechanisms of gestational liver enlargement, by 
hepatocyte hypertrophy, are broadly maintained in long-term cholate-fed animals but 
that the hepatocytes do not progress through S-phase of the cell cycle. In control-fed 
mice, pregnancy significantly affected the protein expression of a number of cell-
cycle regulators but, with the exception of a slight increase in p53, these effects were 
not maintained in the long-term cholate-fed animals (Fig 3.9B). It is therefore 
possible that the effects of pregnancy on cell-cycle regulators observed in wild-type 
mice control hepatocyte progression through S-phase and arrest the cells prior to 
mitosis.    
 
The hepatocytes of Pxr-/- mice display a perturbed proliferative response to partial 
hepatectomy (Dai et al., 2008). As indicated by a reduced number of cells per field, 
the hepatocytes of non-pregnant female mice were significantly larger than those of 
wild-type mice (Fig. 3.8A). In addition, the proportion of Ki-67+ and phospho-
histone-H3 positive hepatocytes (Fig. 3.8B and C) was also significantly reduced in 
non-pregnant Pxr-/- mice compared to wild-type animals, while nuclear DNA content 
(Fig. 3.9A) and the proportion of apoptotic cells (Fig. 3.8C) was unaffected. Despite 
these basal differences between wild-type and Pxr-/- mice, the basic mechanisms of 
gestational liver enlargement were maintained in the absence of Pxr. Pregnancy 
increased hepatocyte size to a similar extent in wild-type and Pxr-/- mice (Fig. 3.8A).  
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The proportion on Ki-67+ hepatocytes was also increased by pregnancy in Pxr-/- 
mice but the fold-increase in Ki-67+ cells was larger than that in wild-type mice (Fig 
3.8B). Pregnancy did not affect the proportion of mitotic or apoptotic cells in Pxr-/- 
mice (Fig. 3.8 C an D). In summary, the data demonstrate that while there are subtle 
changes in the mechanisms that achieve gestational liver growth in wild-type and 
Pxr-/- mice, there is maintenance of the basic mechanism of cell-cycle entry and 
growth that is uncoupled from mitosis and apoptosis. Pxr-/- mice express similar 
levels of hepatic p53 and cyclin D1 protein to wild-type mice but they express 
slightly higher basal levels of p27 and p21 (Fig. 3.9B). The effect of pregnancy on 
the expression of these cell-cycle regulators was similar in wild-type and Pxr-/- mice 
(Fig. 3.9B), which is consistent with the phenotypic characterization of these mice 
(Fig 3.8 and Fig. 3.9A).   
 
Mice lacking the principal bile acid sensor Fxr underwent gestational liver 
enlargement by mechanisms that differed from those in wild-type mice. Pregnancy-
induced hepatocyte enlargement was blunted in Fxr-/- mice (Fig. 3.8A). Pregnancy 
caused cell cycle entry as measured by increased proportion of Ki-67+ hepatocytes in 
Fxr-/- mice (Fig. 3.8B). Unlike in wild-type animals, nuclear DNA content was not 
increased by pregnancy in Fxr-/- mice (Fig. 3.9A) and cell proliferation, as measured 
by a significant increase in the proportion of mitotic hepatocytes, appears to 
contribute to the change in liver size (Fig. 3.8C). Despite these differing 
mechanisms, of the four cell cycle regulators that were assessed, only p27 was 
differentially affected by pregnancy in wild-type and Fxr-/- mice (Fig. 3.9B). Hepatic 
p27 was down-regulated by pregnancy in wild-type mice and up-regulated in mice 
lacking Fxr (Fig. 3.9B).   
 
3.2.6 Gestational liver growth is likely to be driven by a 
placental lactogen 
 
Principal bile acid sensor Fxr is required to maintain the normal mechanisms of 
gestational liver growth in mice. However, raised serum bile acids are not necessary 
to drive liver growth during pregnancy and reproductive hormones are not sufficient 
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to drive the hepatomegaly. Next, it was investigated whether a signal of fetal or 
placental origin is likely to drive gestational liver enlargement.  
 
In total, 18 pregnant wild-type animals were sacrificed for the studies presented in 
this thesis. There was significant variation in fetal number (between 5 and 12 fetuses) 
between pregnant mice. A significant correlation, R2=0.56, between fetal number and 
liver weight in pregnant mice (Fig 3.10A). This finding indicates that the signal 
driving gestational liver enlargement is plausibly of fetal or placental origin.   
 
While pregnancy increases wet liver weight (see Fig. 3.1A), the liver/body weight 
ratio was similar in non-pregnant and pregnant (18-days post conception) animals 
(Fig. 3.10B). It could therefore be argued that the maternal liver is simply sensing 
and responding to changes in maternal body weight. However, on the 12th day of 
gestation, liver weight is disproportionately large relative to maternal body weight 
(Fig. 3.10B). This important finding suggests the presence of a gestational signal that 
drives liver growth prior to increases in maternal body weight.  
 
In mice, the bulk of placental development precedes that of the fetus such that 
placental mass does not increase between day 14 and parturition while on day 14, 
fetal mass is less than 10% of that at parturition. The finding that liver growth 
precedes changes in fetal growth is suggestive that a placental signal initiates at least 
the early stages of gestational hepatomegaly. Liver/body weight ratio increases 
further during lactation in mice, as measured on the 16th day of lactation (Fig. 
3.10B). From early in pregnancy the placenta produces lactogens and growth 
hormones, and during weaning lactogens are produced by the pituitary. Growth 
hormone and placental lactogen treatment are known to cause organ enlargement and 
these compounds are therefore potential signals driving, and then maintaining, 
hepatomegaly in wild-type mice.  
 
Finally, the mRNA expression of hepatic growth hormone receptor (Ghr) and 
prolactin receptor (Prlr) were measured using Q-RTPCR in non-pregnant and 
pregnant mice. Pregnant mice expressed 9-fold higher levels of Ghr and 5-fold 
higher expression of the Prlr than non-pregnant controls (Fig. 3.11). The expression 
of Ghr and Prlr was 2-fold lower in long-term cholate-fed mice than in chow fed  
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animals but the fold induction in response to pregnancy was of a similar magnitude 
to that of wild-type animals (Fig. 3.11). Basally, Pxr-/- mice express lower levels of 
the Ghr than wild-type mice but similar levels of Prlr (Fig. 3.11). As was the case in 
long-term cholate-fed animals and control mice, pregnancy caused a significant up-
regulation of the hepatic Ghr and Prlr in mice lacking Pxr (Fig. 3.11). Fxr-/- mice 
also express lower basal levels of Ghr and Prlr than wild-type mice but both genes 
were induced to a similar extent by pregnancy in these animals as was the case in 
wild-type mice (Fig. 3.11). Therefore, control, long-term cholate fed, Pxr-/- and Fxr-/- 
mice undergo gestational liver growth to the same extent and their hepatic expression 
of Ghr and Prlr are also increased during pregnancy to a similar extent. The 
mechanism of pregnancy induced liver growth is altered in Fxr-/- mice so our 
suggestion that the hepatomegaly is mediated through Ghr and/or the Prlr implies 
that Fxr is involved in transducing the signal from these receptors but that redundant 
mechanisms exist to drive the growth in its absence.  
3.3 Discussion and conclusions 
 
Gestational liver enlargement was first reported in mice in 1958 (Paschkis & 
Cantarow, 1958). Despite being observed or commented upon in a number of 
subsequent reports, little progress has been made in the characterization of 
gestational liver growth or the signals that initiate and maintain it (Paschkis & 
Cantarow, 1958; Schlede & Borowski, 1974; Cripps & Williams, 1975; Feingold et 
al., 1986; Hollister et al., 1987; Hapon et al., 2005; Dickmann et al., 2008). In this 
chapter, it was found that pregnancy causes maternal liver growth by inducing 
hepatocyte hypertrophy in association with cell cycle progression and DNA synthesis 
that is uncoupled from mitosis. While pregnancy-induced and cholate-induced 
hepatomegaly share some common features, namely cell cycle progression and 
polyploidy, the basic mechanisms are different because cholate feeding causes liver 
enlargement by potentially mitogenic hepatocyte hyperplasia. The bile acid receptors 
Fxr and Pxr are not required to drive pregnancy-induced liver growth. However, Fxr 
is required to maintain the normal mechanisms of this process because in Fxr-/- mice, 
gestational liver enlargement occurs as a result of potentially mitogenic hyperplasia. 
Importantly, maternal liver growth precedes fetal and maternal body weight gain, is 
proportional to fetal number but does not precede placental development. These 
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findings, together with growth hormone and prolactin receptor expression data, 
suggest that placental lactogens may be the signals that drive pregnancy-induced 
liver growth. 
 
Because reproductive hormone levels rise dramatically during pregnancy and can 
cause hepatomegaly and hepatotoxicity in rodent models (Ochs et al., 1986; 
Yamamoto et al., 2006), the potential for gestational levels of E2 and Pn in causing 
maternal liver enlargement was assessed. The E2+Pn treatments had no effect on 
liver size so reproductive hormones alone are not sufficient to explain pregnancy-
induced liver growth. Furthermore, the hepatomegaly reported to be associated with 
reproductive hormones is likely to be a result of the supraphysiological 
concentrations administered to these mice.  
 
Serum bile acid levels are increased in human pregnancy (Castano et al., 2006) and 
BA-feeding causes liver growth in mice (Huang et al., 2006). This work 
demonstrates that total serum bile acids are increased in pregnant mice and that the 
liver growth induced by pregnancy and cholate-feeding are of a similar magnitude. 
Using independent assays, CA-feeding was confirmed to cause liver growth by 
hepatocyte hyperplasia associated with polyploidy (Huang et al., 2006). While 
Hollister et al, report that gestation does not affect total liver DNA content (Hollister 
et al., 1987), it was clearly shown here using two independent assays on biological 
replicates, that hepatocyte nuclear DNA increases in pregnant mice.  
 
Pregnancy in mice causes controlled hepatocyte cell cycle entry and growth that is 
associated with altered expression of cell cycle regulators. These findings have 
implications in the understanding of the physiological regulation of the hepatocyte 
cell cycle. Transiently increasing liver function in the absence of potentially 
mitogenic hepatocyte proliferation is of clinical relevance. The hypertrophic effects 
of pregnancy are likely to be physiologically preferable to potentially harmful 
hepatocyte proliferation.  
 
Pxr-/- mice underwent gestational liver growth by similar mechanisms to wild type 
mice. However, the hepatocytes of non-pregnant Pxr-/- mice were larger than those in 
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wild type animals. This finding suggests that Pxr may play a role in hepatocyte 
development.  
 
Because mice lacking Fxr undergo gestational liver enlargement primarily by 
hepatocyte hyperplasia, our data demonstrate redundancy in the normal mechanisms 
of pregnancy-induced liver growth. Fxr-/- mice spontaneously develop hepatocellular 
carcinoma in older life (Kim et al., 2007; Yang et al., 2007), it is possible that the 
hepatocyte proliferation during pregnancy could increase the risk of the later 
development of hepatocellular carcinoma. This is potentially clinically relevant 
because individuals with functional variants of FXR are at increased risk of 
developing gestational cholestasis, which may also affect the hepatocyte cell-cycle.  
 
An important observation presented in this chapter is that maternal liver weight is 
disproportional to maternal body weight during mid gestation. This finding 
demonstrates that the maternal liver does not respond to changes in maternal mass 
during pregnancy. Therefore, a specific liver growth-promoting signal is likely to 
exist and be present in the maternal circulation during mid gestation. The finding that 
maternal liver weight increases as a linear function of fetal number suggests that the 
growth-promoting signal is of fetal or placental origin. Because fetal weight 
increases linearly from day 14 until parturition and placental weight increases from 
day 6 to day 14 (Iguchi et al., 1993) the signal driving maternal liver growth, 
observed at day 12, is likely to be placental in origin.  
 
mRNA expression data suggest that stimuli acting through the maternal liver Ghr and 
Prlr are plausible signals driving pregnancy-induced liver growth. It is known that 
from the 8th day of gestation in mice, placental lactogens I and II (PL-I and PL-II) 
replace pituitary growth hormone and prolactin (Ogren & Talamantes, 1988). 
Furthermore, placental lactogens increase the metabolic capacity of the pancreas 
during mid pregnancy by stimulating islet cell growth and proliferation (Vasavada et 
al., 2000; Gupta et al., 2007; Karnik et al., 2007). These findings, together with the 
temporal increase in liver weight suggest that placental growth factors, in particular 
PL-I (Ogren & Talamantes, 1988) may drive the early phase of pregnancy-induced 
liver growth in mice. Furthermore, a second phase of liver enlargement during 
lactation suggests that lactogens are capable of driving hepatomegaly. Other growth 
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factors and transduction pathways such as the hepatocyte growth factor (HGF) and 
IGF-I signalling may also be involved in regulating pregnancy-induce liver growth.  
 
Compared to the situation in humans, pregnancy in rodents can be considered more 
metabolically demanding because the utero-placental mass can approach 50% of the 
maternal pre-pregnant body weight. Therefore pregnancy-induced liver growth in 
humans is unlikely to result in liver enlargement to the extent seen in rodents. 
However, the human liver is known to respond to metabolic stress by growth and 
detailed measurement of human liver during pregnancy may therefore reveal that 
gestational liver enlargement also occurs in humans. Experiments to measure liver 
size in pregnant humans should be conducted, ideally including individuals with 
multiple pregnancies where the utero-placental mass is larger than in individuals 
with singleton pregnancies.  
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4 hPXR (NR1I2) and SULT2A1 Variants in 
Intrahepatic Cholestasis of Pregnancy 
 
4.1  Introduction 
 
The evidence for a genetic component to ICP is compelling and comes from familial 
clustering of the disease and reports of a higher incidence in mothers and sisters of 
patients with ICP. Heterozygous mutations have been reported in NR1H4 (FXR), 
ABCB11 (BSEP), ABCB4 (MDR3) and ATP8B1 (FIC-1) in a small number of ICP 
cases (Jacquemin et al., 1999; Dixon et al., 2000; Eloranta et al., 2003; Mullenbach 
et al., 2005; Painter et al., 2005; Van Mil et al., 2007; Dixon et al., 2008; Sookoian 
et al., 2008). Several of these variants are risk factors for the disease and for some; a 
functional effect has been demonstrated (Van Mil et al., 2007) or implied (Dixon et 
al., 2008). However, genetic variation in these bile acid responsive genes accounts 
for only a small number of ICP cases.   
 
Serum concentrations of the hepatotoxic secondary bile acid lithocholic acid (LCA) 
are 27-fold higher in ICP patients than in normal pregnant women (Castano et al., 
2006). LCA activates hPXR resulting in induction of hepatic detoxification 
machinery (Staudinger et al., 2001b). The sulfotransferase, SULT2A1, is a hPXR 
target gene induced by LCA and is considered to be a key enzyme in the protection 
of the liver against LCA-mediated injury (Staudinger et al., 2001b). Because LCA is 
implicated in the pathogenesis of ICP (Castano et al., 2006; Lucangioli et al., 2009), 
Functional genetic variation in hPXR (NR1I2) and/or SULT2A1 could increase risk of 
developing the disease and hence contribute to the aetiology of ICP. 
 
Three drugs that have been used to treat ICP, rifampicin, dexamethasone and 
ursodeoxycholic (UDCA) (Williamson, 2001; Glantz et al., 2005) acid are activators 
of hPXR. The mechanism of action of these drugs are not fully understood but 
activation of hPXR could contribute to their protective effect. There are considerable 
inter-individual differences in response to treating ICP (Glantz et al., 2005). 
Functional genetic variation in hPXR (NR1I2) could contribute to the differential 
response to treatment of ICP with hPXR-ligands.   
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4.2 Results 
 
4.2.1 Sequencing of SULT2A1 in a Caucasian ICP cohort  
 
In order to identify potential genetic variation that could contribute to the aetiology 
of ICP, the entire coding region of the SULT2A1 gene (six exons) was sequenced in a 
cohort of 96 ICP patients. There was no coding variation in the SULT2A1 gene in 
this Caucasian ICP cohort. Therefore, coding genetic variation in SULT2A1 is not a 
major contributor to the aetiology of ICP in this Caucasian population. However, a 
single coding SNP predicted to result in an alanine to threonine change at amino acid 
position 261 was detected in exon-6 of an individual of mixed race (Caucasian and 
Afro-Caribbean). The published database frequencies demonstrate that this is a 
common variant within Afro-Caribbean populations (minor allele frequency (MAF) 
0.20).  
 
4.2.2 Sequencing of hPXR (NR1I2) in a Caucasian ICP cohort.  
 
In preliminary analysis, the entire coding region of hPXR (NR1I2) was sequenced in 
a cohort of 121 Caucasian ICP patients. Seven individuals were found to be 
heterozygous for a non-synonymous change of G to A at position 106. This 
polymorphism is located in exon 2 and the predicted amino acid change is glycine to 
argenine at position 36 (G36R).  
 
Subsequently, hPXR (NR1I2) exon two was sequenced in an additional 226 subjects 
in order to determine the frequency of G36R within the Caucasian ICP population. In 
total, sequencing of 347 ICP patients identified 12 individuals heterozygous for 
G36R. This additional screening of exon two also identified two individuals that 
were heterozygous for another non-synonymous single nucleotide polymorphism, C 
to T at position 79. The predicted amino acid change for this variant is proline to 
serine at position 27 (P27S). In this population of 347 ICP patients, the MAF for 
C79T and G106A are 0.006 and 0.035, respectively.  
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The MAF for G36R is consistent with that reported in healthy populations. This is 
the first report of P27S in a Caucasian population but the MAF is consistent with that 
reported in a healthy African population. Therefore, coding genetic variation in 
hPXR (NR1I2) is unlikely to contribute to the aetiology of ICP in this Caucasian 
cohort.  
 
4.2.3 Functional assessment of hPXR variants in response to 
ligands of interest to ICP. 
 
In vitro reporter gene assays are commonly used to screen for nuclear receptor 
ligands and have also been used to assess the functional affect of genetic variation 
within these receptors. A comprehensive analysis of the function of all known hPXR 
(NR1I2) variants in a single standardized assay will be condiucted. The function of 
the variants identified in the ICP population will be tested over a range of 
concentrations of ligands of interest to ICP.  
 
Site directed mutagenesis was conducted on the wild-type pSG5-hPXRΔATG (for 
efficient in vitro translation, the first codon of PXR (CTG) was changed to ATG 
(Staudinger et al., 2001b) expression plasmid  in order to create the variant hPXR 
expression plasmids. In all cases, the entire insert was sequenced to confirm the 
presence of the mutation.  
 
In a preliminary experiment, the protein expression of wild-type and variant hPXR 
was assessed in an immortalized human liver cell line, HepG2 cells. 30µg of wild-
type or variant hPXR expression plasmid was transfected into HepG2 cells using 
Fugene6 transfection reagent in six-well cell culture plates. 24-hours after 
transfection, total cellular proteins were extracted in RIPA buffer. 100µg of total 
cellular proteins was subjected to SDS-PAGE and western blot. In vitro synthesised 
wild-type hPXR was included as a positive control. Membranes were probed with 
anti human PXR antibody. For unknown reasons, variant E18K shows a small shift, a 
finding that has been observed by others. Approximately equal amounts of hPXR 
protein are synthesized from the wild-type and variant pSG5-hPXRΔATG expression 
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plasmid (Figure 4.1). Cells transfected with the empty vector, pSG5, had low levels 
of hPXR protein expression (Figure 4.1).  
 
Reporter assays were conducted in 96 well cell culture plates using HepG2 cells. The 
cells were transfected with plasmids expressing full-length wild-type or variant 
pSG5-hPXRΔATG expression plasmids (6.25ng/well). In addition, plasmids 
(6.25ng/well) constitutively expressing full length RXR and Renilla were also 
transfected. RXR is the obligate heterodimer partner of PXR. The expression of 
Renilla was assayed and serves as an internal control for transfection efficiency. The 
reporter plasmid (2.25ng/well) contained the Luciferase gene under the control of a 
synthetic promoter consisting of two known hPXR recognition sites cloned from 
upstream regions of the CYP3A4 gene and known to be required for its PXR-
mediated transcription (Goodwin et al., 1999). 24-hours after transfection, cells were 
treated with ligand or vehicle. Luciferase activity was measured 24-hours after 
treatment with ligand, values were corrected to those obtained for Renilla and 
expressed as relative Luciferase units (RLU) corrected to vehicle. Representative 
data from experiments conducted three times are presented.  
 
Initially, three drugs used to treat ICP, rifampicin, ursodeoxycholic acid (UDCA) and 
dexamethasone, were confirmed to activate hPXR in vitro (Figure 4.2). Furthermore, 
LCA, which is implicated in the pathogenesis of ICP also activates hPXR in vitro 
(Figure 4.2). Rifampicin was by far the most potent activator of PXR. Under the 
conditions reported here, 10µM rifampicin was found to activate PXR to a greater 
extent than LCA, dexamethasone or UDCA when administered at 100µM 
concentrations (Figure 4.2). At this concentration (100µM), LCA induced hPXR 
activity more strongly than UDCA, and dexamethasone was the least potent hPXR 
ligand (Figure 4.2).  
 
The ability of all known hPXR variants to activate transcription of the CYP3A4 
promoter in the presence of ligands implicated in the pathogenesis or treatment of 
ICP was assessed (Figure 4.2). Compared to wild-type hPXR, three variants R98C, 
Q158K and R381W significantly reduced the transactivation of the CYP3A4 
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promoter in the presence of rifampicin, LCA, UDCA and dexamethasone (Figure 
4.2). Variant I403V also reduced hPXR function in response to rifampicin, LCA and 
UDCA but its effect in the presence of dexamethasone did not reach statistical 
significance compared to wild-type protein (Figure 4.2). While R98C and Q158K 
effectively abolished hPXR function, the effect of R381W and I403V was modest 
(Figure 4.2). Neither P27S nor G36R, which were detected in the ICP cohort, 
affected hPXR activity in response to any of the ligands tested (Figure 4.2).  
 
In order to confirm that neither P27S nor G36R affected hPXR function in response 
to ligands of interest to ICP, the variants ability to activate the CYP3A4 promoter 
over a range of concentrations of LCA, UDCA and dexamethasone were tested. Both 
P27S and G36R have been tested over a range of concentrations of rifampicin and 
found not to alter PXR function. LCA was tested over a concentration range of 10-
150µM and UDCA and dexamethasone were tested over a concentration range of 10-
250µM. As expected, LCA caused a marked toxicity-related reduction in RLU at 
concentrations above 100µM (Figure 4.3). However, P27S and G36R performed as 
wild-type protein in response to the three ligands and at all concentrations tested 
(Figure 4.3). Therefore, it is unlikely that individuals harbouring P27S or G36R are 
at increased risk of LCA-mediated hepatotoxicity or a perturbed response to 
treatment of ICP with rifampicin, UDCA or dexamethasone.    
  
4.3 Discussion and conclusions 
 
The entire coding region of hPXR (NR1I2) and SULT2A1 was sequenced in a cohort 
of 121 and 96 ICP patients respectively. No novel non-synonymous variants were 
detected in hPXR (NR1I2) or SULT2A1. Subsequent sequencing of exon two of 
hPXR (NR1I2) in additional ICP patients revealed that two known coding variants 
were present in the ICP cohort at frequencies similar to those reported in healthy 
populations (Hustert et al., 2001; Zhang et al., 2001; Koyano et al., 2002; Lim et al., 
2005; Bosch et al., 2006).  
 
SULT2A1 is a PXR target-gene responsible for sulphating bile acids and targeting 
them for excretion in the urine or faeces. As such, SULT2A1 is key component of
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the bodies defence against cholestatic injury (Staudinger et al., 2001b). While coding 
variation in SULT2A1 could contribute to the genetic aetiology of ICP, this was 
found not to be the case. It remains possible that genetic variation in other bile acid 
detoxification enzymes could contribute to ICP.  
 
PXR plays a role in co-ordinating the hepatic detoxification of the toxic bile acid 
LCA which is implicated in the pathogenesis of ICP (Staudinger et al., 2001b; Xie et 
al., 2001). Furthermore, three drugs that have been used to treat ICP, rifampicin 
UDCA and dexamethasone are PXR ligands. hPXR (NR1I2)  is therefore a plausible 
candidate gene for ICP and genetic variation in hPXR (NR1I2) could contribute to 
the inter-individual variation in response to treatment. The hPXR (NR1I2) gene has 
been sequenced in a number of populations. To date, 13 non-synonymous 
polymorphisms have been identified (Hustert et al., 2001; Zhang et al., 2001; 
Koyano et al., 2002; Lim et al., 2005; Bosch et al., 2006).  
 
Of the 13 identified coding SNPs in the hPXR (NR1I2) gene, three (G36R, R98C and 
R122Q) are located in the predicted DBD and seven (R148Q, Q158K, D163G, 
A370T, C379G, R381W and I403V) are in the resolved LBD. Most of these variants 
have been tested in reporter assays for their ability to activate transcription of the 
CYP3A4 promoter in the presence of ligand (Hustert et al., 2001; Zhang et al., 2001; 
Koyano et al., 2002; Lim et al., 2005; Bosch et al., 2006). Little is known regarding 
the mechanism by with variants in PXR affect the function of the receptor. In the 
case of Q158K, loss of interaction with the steroid receptor co-activator-1 in the 
presence of ligand has been demonstrated and is a likely mechanism (Lim & Huang, 
2007). Inter laboratory variation in methodology makes comparison of these results 
difficult and can mask or unveil functional effects. For example, despite no change in 
protein expression, hPXR function is significantly affected by variant Q158K in 
HepG2, but not LS174T cells (Lim et al., 2005). In addition to the cell line, it is also 
likely that the reporter constructs, ligand concentrations and incubation times will 
affect the outcome of reporter assays designed to assess the functional affect of 
genetic variation within nuclear hormone receptor.  
 
Reporter assays demonstrated that the function of the hPXR protein was not affected 
by the predicted amino acid changes P27S or G36R in response to a range of 
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concentrations of ligands implicated in the pathogenesis of ICP or used to treat the 
disease. Therefore, genetic variation in hPXR (NR1I2) is unlikely to contribute to the 
pathogenesis or treatment response of ICP in this Caucasian population.  
 
In conducting the standardized reporter assay, this is the fist assessment of all known 
hPXR (NR1I2) variants. Variants R98C, R122Q, Q158K, R381W and I403V have 
previously been reported to reduce hPXR function in reporter assays (Hustert et al., 
2001; Zhang et al., 2001; Koyano et al., 2002; Lim et al., 2005; Bosch et al., 2006). 
Variants R98C, Q158K, R381W and I403V were confirmed to reduce hPXR 
function in response to ligand. A reduction in the function of R122Q was not 
observed however. The reported effect of R122Q was reported to be modest and the 
assay was reported in a different cell line, COS-7 cells (Zhang et al., 2001). 
Furthermore, in LS174T cells, variant D163G enhanced PXR-mediated activation of 
the CYP3A4 promoter in the presence of rifampicin (Hustert et al., 2001). This 
finding was not replicated here in HepG2 cells. This is the first functional analysis of 
the variant C379G, reported in a Dutch population (Bosch et al., 2006). C379G did 
not alter hPXR function in response to any of the ligands tested here.  
 
This report, and those of others (Koyano et al., 2004; Lim et al., 2005) have found 
that two variants, R98C and Q158K abolished hPXR function in response to ligands, 
including the endogenous hepatotoxic bile acid LCA. While all of the functional 
coding SNPs in hPXR (NR1I2) are rare, individuals harbouring function altering 
genetic variation in hPXR (NR1I2) are not reported to be abnormal. This could be 
because there are no reports of individuals homozygous for a functional SNP in the 
hPXR (NR1I2) gene. Furthermore, there are no disease associated functional 
polymorphisms in the NR1I2 locus.   
 
Studies into the genetic aetiology of ICP have been hampered by the heterogeneity 
and size of the ICP cohort studied. Genome-wide associations studies are 
increasingly being used to identify genetic contributions to complex diseases. A 
genome-wide association study would provide a comprehensive assessment of the 
role of genetic variants in the risk on developing ICP. However, such a study would 
require a cohort of cases and controls far larger than any published to date.  
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In this chapter, the contribution of coding genetic variation in the hPXR (NR1I2) 
gene to the aetiology of ICP in a Caucasian population was assessed. No evidence 
was found that that coding genetic variation in hPXR (NR1I2) contributes to the 
aetiology of ICP. Furthermore, a comprehensive analysis of all known hPXR 
(NR1I2) variants in a single standardized assay was conducted. The hPXR (NR1I2) 
variants identified in the ICP cohort are unlikely to predict treatment response 
because they do not alter hPXR function in response to drugs used to treat ICP. 
Finally, while subtle changes in experimental design can mask or unveil a function 
affect of genetic variation, these are not maintained in a standardized assay. 
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5 Hepatic Bile Acids May Accumulate During 
Pregnancy as a Result of Reduced Farnesoid-x-
receptor (Fxr) Function 
 
5.1  Introduction 
 
Intrahepatic cholestasis of pregnancy is the most common gestational liver disease 
(Abedin et al., 1999; Heinonen & Kirkinen, 1999). ICP usually develops in the third 
trimester and is diagnosed based on raised serum bile acids together with abnormal 
liver function tests and/or puritus. The aetiology of ICP is complex and poorly 
understood. There is compelling evidence for a genetic component to the aetiology 
of ICP. Our group and others have identified genetic variation in the central bile acid 
sensor FXR and its target genes, the hepatic transporters BSEP, MDR3 and FIC1 that 
influence susceptibility to ICP (Van Mil et al., 2007) (Eloranta et al., 2003; Dixon et 
al., 2008) (Jacquemin et al., 1999; Dixon et al., 2000) (Sookoian et al., 2008) 
(Mullenbach et al., 2005; Painter et al., 2005). However, genetic variation in these 
genes accounts for only a small proportion of cases.   
 
Evidence that reproductive hormones contribute to the aetiology of ICP comes from 
findings that the disease is more common amongst twin pregnancies, in which 
reproductive hormones are higher than in singleton pregnancies (Lammert et al., 
2000). Furthermore, women that develop ICP commonly develop cyclical cholestasis 
when they are not pregnant (Holzbach, 1976; Reyes & Simon, 1993; Crocenzi et al., 
2003; Williamson et al., 2004). There is also limited evidence that high levels of 
reproductive hormones can cause cholestasis in rodents, although the doses 
administered are supraphysiological (Yamamoto et al., 2006). 
 
Total serum bile acids rise during pregnancy in humans (Castano et al., 2006) and 
this also occurs in mice (see Fig. 3.1). In humans, pregnancy causes up to 40% of 
normal individuals to surpass the threshold of clinical cholestasis (11µM) without 
developing disease (Castano et al., 2006). Pregnancy has therefore been suggested as 
a period of bile acid stress during which individuals with function-altering genetic 
variation in bile acid protective genes or experiencing unrelated biliary events are at 
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risk of developing cholestatic disease (Van Mil et al., 2007). It is not known how or 
why pregnancy causes an apparent loss of bile acid homeostasis. It is also not known 
whether the regulators of the entero-hepatic circulation, including PXR and FXR, 
respond to this condition or contribute to causing it.   
 
To date, understanding of the molecular pathology of ICP has focused on the results 
of genetic susceptibility data or supraphysiological reproductive hormone treatment 
experiments. These data fail to address the primary events that expose individuals to 
risk of developing ICP. Some of these problems will be addressed in this chapter by 
using pregnant mice and physiologically relevant models of reproductive hormone 
challenge and gestational cholestasis.    
 
5.2 Results  
 
5.2.1 Raised hepatic bile acids in pregnant mice. 
 
Serum bile acid concentrations are raised during pregnancy in humans (Castano et 
al., 2006) and this was also the case in mice (see Fig. 3.1). However, raised serum 
bile acids could result from efficient mechanisms of protection against the hepatic 
accumulation of bile acids. In order to determine whether hepatic bile acids are also 
raised during gestation in mice, hepatic bile acid concentrations in non-pregnant and 
pregnant mice were compared. Furthermore, hepatic bile acid concentrations were 
also determined in a model of bile acid overload (long-term cholate-fed animals), in 
a genetic model of cholestasis (Fxr-/- mice) and in mice lacking Pxr.   
 
Previous studies have found that bile acids accumulate in the liver of cholate-fed and 
Fxr-/- mice (Huang et al., 2006; Yang et al., 2007). These findings were replicated 
here as both our long-term cholate-fed and Fxr-/- mice had significantly higher 
hepatic bile acids than control mice (Fig. 5.1A). Also as expected, hepatic bile acids 
in Pxr-/- mice were not statistically different to those of controls (Fig. 5.1A). 
Interestingly, pregnant mice had (7-fold, p<0.05) higher hepatic bile acids than non-
pregnant controls (Fig. 5.1A). Indeed, the level of hepatic bile acids in the pregnant  
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mice were comparable with those in the cholate fed and Fxr-/- animals (Fig. 5.1A). 
Therefore, pregnancy causes raised hepatic bile acids in mice.  
 
Alanine aminotransferase (ALT) is a liver enzyme that is released into the circulation 
during hepatic damage. Serum ALT levels are routinely used to monitor liver injury 
in humans and mice. The three groups of mice with raised hepatic bile acids 
(cholate-fed, Fxr-/- and pregnant animals) also had significantly raised serum ALT 
levels (Fig. 5.1B). This finding suggests that pregnant mice exhibit liver dysfunction 
but the level of ALT remained within the reported normal range (<40U/L) in all 
groups.  
 
Therefore, normal pregnant animals have a hepatic bile acid and serum ALT 
phenotype that is similar to those in cholate-fed and Fxr-/- mice.  
 
5.2.2 Hepatic metabolic profiling of pregnant, cholate-fed and 
Fxr-/- mice. 
 
Magic angle spinning 1H nuclear magnetic resonance (NMR) was conducted on 
intact liver tissue to compare the effects of pregnancy to those caused by cholate-
feeding or the absence of Fxr on the metabolic profile of the liver. Tissue from Pxr-/- 
mice were not analyzed because these animals had normal hepatic bile acid 
concentrations and their metabolite profile would therefore be uninformative for 
understanding the effects of raised bile acids on liver metabolism. These experiments 
were conducted in collaboration with Drs Jane Cox and Jeremy Cobbold. Partial 
least squares discriminant analysis (PLS-DA) was conducted on the entire data set. 
PLS-DA separated each model-group from control-group with 100% accuracy on 
cross-validation with a statistically significant predictive ability (Table 5.1). These 
unbiased analyses demonstrated that the metabolic composition of the liver is 
significantly affected by pregnancy, following cholate-feeding and in mice lacking 
Fxr. 
 
In subsequent analyses conducted by Dr Jeremy Cobbold, the spectral regions 
contributing most to each model were identified and the primary and major  
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Table 5.1. Partial least squares discriminant analysis (PLS-DA) of model vs 
control mice with list of metabolites contributing to the discrimination between 
groups. 
Model Leave-
one-out 
accuracy 
Q2 Major discriminators 
Pregnant 100% 0.95 CH=CHCH2CH2; CH=CH; CH2CH2CO; (CH2)n; 
CH3CH2; CH=CHCH2CH=CH; glucose, glycogen; 
CH2CH2CO  
Cholate-
fed 
100% 0.99 CH3CH2; CH=CHCH2CH2; PtC; CH2CH2CO; 
(CH2)n; CH=CHCH2CH=CH; CH2CH2CO; 
CH=CH  
FXR-/- 100% 0.77 CH=CH; CH=CHCH2CH2; CH3CH2; 
CH2CH2CO; (CH2)n; CH=CHCH2CH=CH; 
glycogen; glyceryl of lipid; PtC 
All analyses used 1 factor and 2 orthogonal signal corrections. Metabolites are listed in order of 
decreasing influence on the model. Lipid CH3CH2 (methyl); lipid (CH2)n (methylene); lipid 
CH2CH2CO (methylene to a-methylene to carboxyl); lipid CH=CHCH2CH2 (allylic); lipid CH2CH2CO 
(a-methylene to carboxyl); lipid CH=CHCH2CH=CH (diallylic- “PUFA”); lipid CH=CH (n-ene 
group); tCho, total choline; Cho, choline; PC, phosphocholine; GPC, glycerophosphocholine; PtC, 
phosphatidylcholine.Those listed in bold were correlated with all three model states. These data were 
analysed by Dr Jeremy Cobbold.  
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discriminators were assigned. Six of these discriminators contributed to all of the 
models (Table 5.1).  In collaboration with Dr Cobbold, it was determined whether 
these six discriminators were positively or negatively correlated with each model 
state. It was found that for all six discriminators, the correlation was the same in the 
pregnant and Fxr-/- models, while this was not the case in the cholate-fed model (Fig. 
5.2). These findings indicated that pregnancy and Fxr-deficiency have a similar 
effect on a sub-set of resonances while cholate feeding has distinct effects.  
 
Finally, the NMR data were used to assess the relative and absolute levels of a 
number of parameters that have been associated with hepatic disease or altered 
metabolic state. For example, increased total lipid-to-water ratio, decreased 
polyunsaturation indices and decreased total choline have been demonstrated to be 
associated with non-alcoholic fatty liver disease (Cobbold et al., 2008). These 
analyses were performed by Dr Jeremy Cobbold. The total lipid, PUI, tcho:lipid ratio 
and the PC+GPC/tCho ratio were significantly affected by the cholate-feeding (Fig. 
5.3). However, in pregnant or Fxr-/- mice, despite also having raised hepatic bile 
acids (Fig. 5.1), these parameters were not significantly affected (Fig. 5.3).  
 
Therefore, unbiased and supervised analyses of metabolomic data generated from 
intact tissue NMR experiments demonstrated that pregnancy had a similar effect on a 
sub set of resonances as were caused by absence of Fxr. In contrast, pregnancy had 
distinct effects when compared to cholate-feeding.  
 
5.2.3 Hepatic microarray analysis.    
 
Cholate-feeding is a state of bile acid overload and, as such, the transcriptional 
profile of the liver is likely to be a response to the bile acid challenge. In contrast, the 
transcriptional events in the Fxr-/- mice are the primary cause, not a consequence, of 
the raised serum and hepatic bile acids in these animals. Therefore, the 
transcriptional effects of pregnancy were compared to those that occur in response to 
cholate-feeding and in mice lacking Fxr. These comparisons will suggest whether the 
hepatic gene expression events of pregnancy are likely to contribute to their bile acid 
phenotype or are a response to it.  
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Hepatic Affymerix gene expression microarray experiments were performed on six 
non-pregnant, pregnant, cholate-fed, Fxr-/- and Pxr-/- animals. Technical quality 
control criteria were met in all cases and the raw scan data were processed using the 
Rosetta Resolver software package for microarray data analysis. Unsupervised 
principal component analysis (PCA) was conducted using the entire data set of each 
sample. There was clear separation between the test and control group in all cases, 
without outliers. These unsupervised data demonstrate that each condition had a 
greater effect on liver transcription than the inter-individual variability between 
mice.  
 
Of the 15,601 liver expressed probe sets (see Methods), almost half (7,225) were 
significantly (p<0.05) affected during pregnancy. A Bonferoni adjusted p-value is a 
highly stringent form of multiple test correction that minimises false positive results. 
Using this highly stringent multiple test correction, pregnancy was found to 
significantly (p<0.0000032) affect the expression of 982 probe-sets, demonstrating 
that pregnancy has a major effect on hepatic transcription. 506 genes were affected 
over 2-fold (p<0.01) in the liver of pregnant mice compared to non-pregnant 
controls; 49% of these were up-regulated and 51% were down regulated 
(Supplementary compact disk).  
 
Pregnancy and cholate feeding affected 508 and 266 genes respectively (2-fold, 
p<0.01). Venn diagrams were constructed to assess the similarities in the genes 
affected by pregnancy and by cholate-feeding. Of the 734 genes affected by either 
pregnancy or cholate feeding, only 53 were commonly affected by both conditions 
(Fig. 5.4A). While this proportion of commonly affected genes is low, chance alone 
would predict only 9 genes in common between these two datasets. Therefore, 
pregnancy and cholate-feeding affect more genes in common than would be expected 
by chance alone. 2-dimensional (2D) hierarchal clustering on the 53 genes 
commonly affected by pregnancy and cholate-feeding was conducted to determine 
the proportion of these genes that are similarly affected under both conditions (Fig. 
5.4B). As expected, individual samples from control, pregnant and cholate-fed mice 
clustered according to experimental group. The hierarchal cluster reveals that almost 
exactly half of the commonly affected genes are similarly affected by pregnancy and  
 135 
 
 
 136 
cholate-feeding while half are differently affected by both conditions (Fig. 5.4B). 
Therefore, more genes are commonly affected by pregnancy and by cholate-feeding 
than expected by chance alone but the responses of these genes to each condition are 
not similar.  
 
Next, hepatic microarray data from Fxr-/- and pregnant mice were compared. 144 
genes were differentially expressed (2-fold, p<0.01) in the Fxr-/- mice compared to 
the wild-type controls (Fig. 5.5A). Of these, only 27 genes were also affected by 
pregnancy in wild-type animals (Fig. 5.5A). As was the case in the cholate-fed 
animals however, this proportion of genes is greater than expected by chance alone 
and suggests some similarity in the genes affected during pregnancy and in the 
absence of Fxr. 2D clustering on these 27 genes demonstrated that 80% were 
similarly affected in Fxr-/- mice and in pregnant mice. This finding suggests that the 
effects of pregnancy and Fxr deficiency are similar (Fig. 5.5B).  
 
Hepatic microarrays were also conducted on Pxr-/- mice. A number of known 
alterations in gene expression compared to wild type mice were confirmed. These 
included upregulation of hepatic Cyp2c55 (+7-fold, p<0.01) and repression of 
hepatic CD36 (-2-fold, p<0.01). Hepatic genes significantly altered in Pxr-/- mice are 
presented with this thesis on a supplementary compact disk. However, because Pxr-/- 
mice have normal hepatic and serum bile acids, either Pxr does not play a role in the 
basal maintenance of hepatic bile acids or adaptive mechanisms exist such that Pxr is 
not required to maintain these processes. Therefore, the focus of this section of the 
chapter will be the comparison of pregnant, cholate-fed and Fxr-/- mice.   
 
Unsupervised and unbiased microarray analysis demonstrated that pregnancy has a 
major effect on maternal hepatic transcription. Furthermore, the effects of pregnancy 
were compared to those of two other models of bile acid challenge, cholate-feeding 
and Fxr deficiency. Using Venn diagrams identified sub-sets of genes affected by 
both pregnancy and cholate feeding/Fxr deficiency. 2D hierarchal clustering 
demonstrates that pregnancy has a similar effect on gene expression as in Fxr-/- but 
not cholate-fed mice.  
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5.2.4 Pathway analysis of microarray data 
 
Rosetta Resolver canonical pathway analysis was performed to determine whether 
gene expression effects are over-represented in specific metabolic pathways. A fold-
change threshold was not set for these analyses because several small, but 
significant, changes in a metabolic pathway could have a biologically relevant affect 
that would be overlooked by setting a high fold-change threshold. Therefore, bio-sets 
were generated for each 2-way comparison containing genes affected by the 
condition with a confidence threshold of p<0.01. Pathway analyses are performed by 
comparing a user-defined “query” bio-set to a “reference” bio-set for a particular 
metabolic pathway. A p-value for statistical significance is assigned based on the 
probability that the intersection of query and reference bio-set is greater than 
expected by chance alone, i.e. if the query was a random set of genes. Fig. 5.6 shows 
the five most significantly affected canonical pathways in the pregnant, cholate-fed 
and Fxr-/- mice. While the order of these pathways is different between groups, the 
pathways affected in each group are similar. Furthermore, ingenuity pathway 
analysis revealed similar results for disease-associated gene networks (Fig. 5.7) 
 
Cholesterol is the precursor to bile acids. Cholate-feeding is known to eliminate bile 
acid biosynthesis and result in the accumulation of hepatic cholesterol. As expected 
therefore, long-term feeding of the cholate diet resulted in a significant increase in 
liver cholesterol concentration (Fig. 5.8A). In contrast to the effects of cholate-
feeding, Fxr-/- mice have high serum bile acids as a result of enhanced bile acid 
biosynthesis. This is consistent with our finding that Fxr-/- animals have reduced 
hepatic cholesterol concentrations (Fig. 5.8A). Interestingly however, despite having 
raised serum and hepatic bile acids, hepatic cholesterol content in pregnant mice was 
not different to non-pregnant, control mice (Fig. 5.8A).  
 
The pathway of cholesterol biosynthesis (Fig. 5.6) forms part of “The biosynthesis of 
steroids”. Unlike the effects on the other significantly affected canonical pathways, 
the affected genes in cholesterol biosynthesis were down-regulated in the pregnant, 
cholate-fed but not Fxr-/- mice. Supervised analysis of the cholesterol biosynthesis  
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pathway with a confidence cut-off of 2-fold, p<0.05 demonstrated that pregnancy 
down-regulated the expression of 6 of the 19 genes involved in converting Acetyl-
CoA to cholesterol, including the rate-limiting enzyme Hmgcr (Fig. 5.8B). Cholate-
feeding down-regulated 13 out of the 19 genes of the cholesterol biosynthesis 
pathway (Fig. 5.8B). In most cases, the magnitude of gene repression caused by 
cholate feeding was greater than that caused by pregnancy.  In Fxr-/- mice, none of 
the genes in the cholesterol biosynthesis pathway were significantly affected (Fig. 
5.8B). Therefore, pregnant and cholate-fed mice have raised hepatic bile acids and 
reduced expression of cholesterol biosynthetic genes. As a consequence of impaired 
bile acid biosynthesis, cholesterol elimination in the bile is inhibited and hepatic 
cholesterol accumulates.  
 
The response of the hepatocyte to accumulation of cholesterol is to strongly repress 
its biosynthesis in cholate-fed mice. Fxr-/- mice have high hepatic bile acids as a 
result of elevated bile acid biosynthesis and impaired bile acid transport. As a 
consequence of their enhanced bile acid synthesis, Fxr-/- mice have reduced hepatic 
cholesterol levels. The situation in pregnant mice is interesting because they have 
high hepatic bile acids without any affect on hepatic cholesterol content. Sub sets of 
genes were found to be affected by pregnancy and by either cholate-feeding or Fxr-
deficiency and in the case of the Fxr-/- mice this sub set of genes was affected 
similarly to during pregnancy. Unsupervised pathway analysis demonstrated that 
pregnancy, cholate-feeding and Fxr-deficiency significantly affected similar 
canonical pathways and manual analysis of the pathway of cholesterol biosynthesis 
demonstrated that a high proportion of these genes are repressed in the pregnant 
mice. 
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5.2.5 Regulation of the entero-hepatic circulation during 
pregnancy, cholate-feeding and in the absence of Fxr.  
 
The array data were confirmed by Q-RTPCR to assess the expression of genes 
involved in the entero-hepatic circulation of bile acids. Importantly, the Q-RTPCR 
data correlated well with those from the microarray (Table 5.2).  
 
The effect of cholate feeding on the expression of genes involved in the entero-
hepatic circulation of bile acids is well established. Therefore, as expected, long-term 
cholate-fed mice have a marked reduction in the expression of the Cyp7a1, the rate-
limiting enzyme in bile acid biosynthesis (Table 5.2). This finding was associated 
with a 4.6-fold increase in the expression of the negative regulator of Cyp7a1, the 
Fxr target gene Shp (Table 5.2). Furthermore, the expression of Cyp8b1, which 
differentially synthesises cholic acid over chenodeoxycholic acid during the process 
of bile acid biosynthesis, was also markedly repressed by the cholate-diet. The 
expression of bile acid importers Ntcp, Oatp1 and Oatp4 were decreased 1.9, 4.9 and 
1.2 fold respectively (p<0.05) following long term cholate feeding. The expression of 
canalicular and alternative exporters Bsep, Mdr1a, Oatp2, Mrp3 and Mrp4 were 
increased 1.6, 5.1, 1.9, 1.7 and 2.2 fold respectively (p<0.05) upon cholate feeding 
(Table 5.2). Taken together, these gene expression data confirm the response of the 
liver to bile acid overload through decreasing bile acid biosynthesis and basolateral 
uptake and by increasing bile acid export, thus protecting the hepatocyte form the 
harmful affects of this bile acid. In the intestine, the cholate diet repressed the 
expression of the ileal bile acid importer Asbt, and increased the expression of the 
signalling hormone Fgf15 (7-fold, p<0.01), the intracellular bile acid binding protein 
Ibabp and the bile acid exporter couplet Osta/b. 
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Table 5.2: Hepatic bile acid-responsive gene expression in pregnant, 
CA-fed and Fxr-/- mice.  
 Pregnant CA-feeding Fxr-/- 
BA Synthesis 
Cyp7a1  1.6 (1.6) -41.3 (-57) 1.8 (2.5) 
Cyp8b1 1.6 (1.7) -84.4 3.4 (5.4) 
Cyp27a1 -1.4 -1.2 -1.3 
Portal BA Uptake  
Ntcp (Slc10a1) -1.7 (-1.6) -1.9 (-1.7) -1.2 (-1.9) 
Oatp1 (Slco1a1) NS -4.9 NS 
Oatp4 (Slco1b2) -1.8 -1.2 NS 
BA Hydroxylation 
Cyp3a11 -1.2 1.7 NS 
BA Sulphation 
Ugt2b4 NS NS NS 
Sult2a1 NS NS NS 
Biliary BA Export 
Bsep (Abcb11) -1.4 (-1.5) 1.6 (1.8) -2.0 (-2.0) 
Mdr1a (Abcb1a) -1.9 5.1 -2.1 
Mrp2 (Abcc2) NS NS NS 
Alternative BA Export 
Oatp2 (Slco1a4) -3.5 1.9 -1.4 
Mrp3 (Abcc3) -11.5 (-9.4) 1.7 (1.8) NS (NS) 
Mrp4 (Abcc4) NS 2.2 NS 
Ostα/β NS NS NS 
Nuclear Receptors/Cofactors  
Fxr (Nr1h4) -1.2 -1.3 NA 
Shp (Nr0b2) -2.6 (-3.0) 4.6 (4.2) -2.8 (-2.4) 
Pxr (Nr1i2) NS 1.8 -1.6 
Car (Nr1i3) NS -1.4 NS 
Pparα  NS -1.4 -1.2 
Hnf4α 
Lrh-1 (Nr5a2) 
1.3 
-1.3 
1.2 
-1.3 
NS 
1.4 
Pgc1a 
(Ppargc1a) 
-1.7 NS -1.8 
Fold changes are relative to control. Figures in brackets are results from Q-
RTPCR. All fold changes are significant (p<0.05). NS, not significantly 
affected. NA, not applicable.    
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The microarray data also confirmed many of the known gene expression differences 
between wild-type and Fxr-/- mice. As expected, the Fxr-/- animals have dysregulated 
bile acid biosynthesis with high basal expression of both Cyp7a1 and Cyp8b1 (1.8-
fold and 3.4-fold respectively, p<0.05) (Table 5.2). Furthermore, the Fxr-/- mice had 
reduced expression of the Fxr target-gene and negative regulator of Cyp7a1, Shp (-
2.8-fold) (Table 5.2). Finally, the expression of other Fxr target genes were found to 
be significantly decreased in the Fxr-/- mouse, Bsep (-2.0 fold), Mdr1a (Mdr3)(-2.1 
fold) and Oatp4 (-1.4 fold) (Table 5.2). Therefore, as expected, Fxr-/- mice display 
enhanced expression of bile acid biosynthetic genes and reduced expression of bile 
acid exporters. 
 
These findings have independently demonstrated known hepatic gene expression 
affects that are a response to bile acid overload (i.e. the effect of long-term cholate 
feeding) and identified gene expression effects that can result in bile acid overload 
(those in Fxr-/- mice). Next, the expression of hepatic bile acid responsive genes in 
pregnant mice, which have high serum and hepatic bile acids, were assessed. The 
interesting question is whether the gene expression effects of pregnancy are likely to 
be a response to bile acid overload or a cause of it. Pregnancy had relatively little 
affect on the expression of bile acid responsive genes in the terminal ileum. The 
expression of the apical bile acid transporter Asbt, the intracellular bile acid binding 
protein Ibabp, the signalling hormone Fgf15 and the basolateral transporter couplet 
Ostα/β were not significantly affected by pregnancy. However, a small increase in 
the expression of another intestinal basolateral transporter, Mrp3 (+1.2-fold, p<0.05) 
was detected in the pregnant animals. In the liver, pregnancy affected the expression 
of a number of bile aid responsive genes. The expression of bile acid biosynthesis 
enzymes Cyp7a1 and Cyp8b1 were increased (both 1.6-fold) in pregnant animals 
compared to non-pregnant controls (Table 5.2). In association with the increase in 
Cyp7a1 expression, its negative regulator Shp was decreased 2.6-fold in the livers of 
pregnant mice (Table 5.2). Furthermore, a decrease in expression of basolateral 
importers Ntcp (-1.7-fold), Oatp2 (-3.5-fold) and Oatp4 (-1.8-fold) and the biliary 
exporters Bsep (-1.4-fold) and Mdr3 (-1.9-fold) was measured in the pregnant mice 
(Table 5.2). Surprisingly, there was a 11.5-fold reduction in the expression of the 
alternative exporter Mrp3 in pregnant animals compared to non-pregnant controls 
(Table 5.2). Other hepatic transporters that are known to be responsive to bile acids, 
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Mrp4, Mrp2, Mdr1 and Ostα/β were not significantly affected by pregnancy (Table 
5.2).      
 
In summary to this section, the effects of pregnancy on the expression of bile acid 
responsive genes were compared to the effect of bile acid overload and a genetic 
model of cholestasis, Fxr deficiency. Despite having high serum and hepatic bile 
acids, the transcriptional profile in the pregnant mice is not one of response to bile 
acid overload. Rather, increased expression of bile acid biosynthesis enzymes and 
decreased expression of bile acid transporters were detected in the pregnant animals. 
This pattern of gene expression is similar to that observed in mice lacking Fxr and 
can therefore be considered pro-cholestatic. In the following sections, 
physiologically relevant reproductive hormone treatments are conducted and 
pregnancy experiments in long-term cholate fed and Fxr-/- mice in order to further 
investigate these findings.    
 
5.2.6 Reproductive hormones are not sufficient to drive the 
hepatic gene expression effects of pregnancy.  
 
Reproductive hormone treatments were conducted using silastic implants to deliver 
estrogen and progesterone to ovariectomised mice at serum concentrations 
equivalent to those in pregnant mice and over a time course similar to that of 
pregnancy, 18-days (Milligan & Cohen, 1994). Several experiments have shown that 
high concentrations of reproductive hormones can be cholestatic (Yamamoto et al., 
2006). The data presented here will determine whether physiologically relevant 
concentrations of these hormones can drive the pro-cholestatic gene expression 
affects that were observed during pregnancy in wild-type mice.  
 
Compared to vehicle-treated controls, the reproductive hormone treatments caused 
uterine swelling in all animals, demonstrating that the treatment was affecting a 
reproductive hormone-responsive organ. As described in Chapter 3, the reproductive 
hormone treatments had no effect on serum bile acids. The expression of Bsep was 
slightly but significantly decreased upon reproductive hormone treatment, a finding 
that is consistent with the effect of pregnancy. However, compared to pregnancy, the 
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reproductive hormone treatment differentially effected the expression of Mrp3, Shp 
and Cyp7a1. Furthermore, the reproductive hormones did not significantly affect the 
expression other genes that were affected by pregnancy e.g. Cyp8b1, Ntcp, Mdr3. 
Therefore, the reproductive hormone treatments were not sufficient to maintain the 
pro-cholestatic gene expression effects of pregnancy on the liver. It remains possible 
that the high circulating reproductive hormones contribute to the bile acid phenotype 
of pregnant mice.   
 
5.2.7 Repressed bile acid biosynthesis and induced hepatic 
transport prevents hepatic bile acid accumulation in 
pregnant cholate-fed mice.   
 
Next, it was investigated whether the pro-cholestatic effects of normal pregnancy are 
maintained in long-term cholate fed mice. For these analyses, both the non-pregnant 
and the pregnant groups were fed the modified diet for a total of 30±2 days.  
 
In contrast to the situation in control-fed mice, pregnancy had no effect on hepatic 
bile acids or serum ALT levels in long-term cholate fed mice (Fig. 5.9A and B). 
Consistent with the control fed mice, pregnancy did not effect on hepatic cholesterol 
content in the long-term cholate fed animals (Fig. 5.9C).  
 
In the control-fed mice, pregnancy increased hepatic bile acids without affecting 
hepatic cholesterol content. Pregnancy in these control mice significantly reduced the 
expression of 6 out of 19 genes in the pathway of cholesterol biosynthesis. In the 
long-term cholate-fed animals however, neither hepatic bile acids nor cholesterol 
were affected by pregnancy and none of the 19 genes in the cholesterol biosynthesis 
pathway were reduced by pregnancy (Fig. 5.9D). It is therefore possible that the high 
hepatic bile acids in the control-fed pregnant mice influence, or are influenced by, 
the observed changes in the pathway of cholesterol biosynthesis.  
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Because of the differences in hepatic bile acid phenotype in pregnant long-term 
cholate fed and control-fed mice, the expression of hepatic bile acid-responsive 
genes were analyzed using the microarray data and Q-RTPCR. A number of the pro-
cholestatic gene-expression effects of normal pregnancy were maintained in the 
pregnant long-term cholate-fed animals (Fig. 5.9E). For example the expression of 
Ntcp, Oatp4, Bsep, Oatp2, Mrp4 and Shp were all reduced by pregnancy in control-
fed and cholate-fed animals (Fig. 5.9E). However while Mrp3 was reduced 11.5-fold 
in control-fed mice, it was only repressed 2.2-fold in the long-term cholate fed mice 
(Fig. 5.9E). In the cholate-fed mice, pregnancy did not increase the expression of the 
bile acid biosynthesis enzymes Cyp7a1 and Cyp8b1, which is in contrast to the 
observed effects in the control fed mice (Fig. 5.9E). Because these genes are not de-
repressed in the pregnant cholate fed mice, it seems unlikely that they could account 
for the raised serum bile acids observed in these animals (Chapter 3, Figure 3.7A). 
The fact that hepatic bile acids do not change in these animals supports this 
suggestion and indicates that defects in bile acid transport contribute to the rise in 
serum bile acids in the pregnant cholate-fed mice compared to the non-pregnant 
cholate fed mice.     
 
Pregnancy experiments were conducted in long-term cholate-fed mice to determine 
whether the bile acid phenotypes of control-fed animals are maintained in these 
mice. The phenotypic and transcriptional data in these long-term cholate-fed mice 
are difficult to interpret, partly because of the significant basal-differences between 
non-pregnant control-fed and cholate-fed mice. However, it was found that 
pregnancy does not further increase hepatic bile acids in long-term cholate-fed 
animals. This phenotype was investigated by focusing gene expression analysis on 
the pathway of cholesterol biosynthesis and the entero-hepatic circulation. The liver 
responds to bile acid overload by reducing the expression of genes involved in the 
biosynthesis of cholesterol in order to prevent the accumulation of cholesterol 
resulting from its decreased conversion in to bile. Because pregnancy does not 
repress the expression of key enzymes in the pathway of bile acid biosynthesis, it is 
unlikely that cholesterol biosynthetic genes are repressed in order to prevent 
cholesterol accumulation in the livers of pregnant mice.  
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5.2.8 Pro-cholestatic gene expression and raised hepatic bile 
acids are not maintained in pregnant Fxr-/- mice.  
 
Non-pregnant Fxr-/- mice have elevated hepatic bile acids and reduced hepatic 
cholesterol compared to non-pregnant wild-type mice. During pregnancy in wild-
type animals, pro-cholestatic gene expression was observed that was similar those in 
mice lacking Fxr. For this reason, pregnancy could be a state of reduced Fxr 
function. In order to test this hypothesis, pregnancy experiments in Fxr-/- mice were 
conducted to determine whether pro-cholestatic gene expression occurs in the 
absence of Fxr.  
 
The array data were used to search for potentially pregnancy-regulated Fxr target 
genes. There were no known Fxr target-genes upregulated in the pregnant mice. 
Furthermore, there were no genes that were basally repressed in the Fxr-/- mice and 
induced solely in the wild-type animals (supplementary compact disk). Therefore, 
despite high hepatic bile acids in pregnant wild-type mice, no evidence of direct Fxr 
activation during pregnancy was found.   
 
Pregnancy had no effect on hepatic bile acids or cholesterol in mice lacking Fxr (Fig. 
5.10 A and B). Pregnancy increased serum ALT levels in both wild-type and Fxr-/- 
mice and while the magnitude of increase was similar in both groups, the absolute 
increase was significantly greater in mice lacking Fxr (Fig. 5.10C).  
 
The analysis was again focused the pathway of cholesterol biosynthesis and bile acid 
homeostasis. As was the case in the long-term cholate fed mice, pregnancy had little 
affect on the genes in the cholesterol biosynthesis pathway in Fxr-/- mice (Fig. 
5.10D). Therefore, in long term cholate fed and in Fxr-/- mice, pregnancy has no 
effect on hepatic bile acids or cholesterol and no repressive effect on the genes of the 
cholesterol biosynthesis pathway. These findings are in contrast to the situation in 
control mice, where pregnancy increases hepatic bile acids and represses cholesterol 
biosynthesis in order to maintain a stable hepatic cholesterol content (Fig. 5.10B and 
D).   
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The data indicate that pregnancy could be a state of reduced Fxr function that causes 
pro-cholestatic gene expression. The fact that Fxr-/- mice do not accumulate hepatic 
bile acids during pregnancy is consistent with this proposal. In wild-type mice, 
pregnancy repressed the expression of the direct Fxr-target genes Bsep, Ntcp, Oatp2 
and Shp and enhanced the expression of the indirect Fxr-target genes Cyp7a1 and 
Cyp8b1 (Fig. 4.10E). In Fxr-/- mice, neither Bsep, Oatp2 nor Shp were repressed and  
Cyp8b1 was not induced by pregnancy. However, the induction of Cyp7a1 in 
pregnant wild-type mice was also present in Fxr-/- animals, as was the repression of 
Ntcp (Fig. 4.10E). Finally, Mrp3 was repressed 11.5-fold by pregnancy in wild-type 
animals but only 2.0-fold in mice lacking Fxr (Fig. 4.10E). Therefore, it is plausible 
that Fxr-/- mice do not develop raised hepatic bile acids during pregnancy because the 
pro-cholestatic gene expression effects in these animals are less marked that those in 
wild-type mice, possibly because they are a result of reduced Fxr function.    
 
5.3 Summary and conclusions 
 
In this chapter physiologically relevant animal models were used to investigate the 
metabolic adaptations of the maternal liver to the demands of pregnancy with a focus 
on bile acid homeostasis.  
 
For unknown reasons, serum bile acids are raised during normal human pregnancy 
(Castano et al., 2006), this is also demonstrated here to be the case in mice. In 
humans, primary bile acids contribute most to the change in serum bile acids during 
pregnancy (Castano et al., 2006). These primary bile acids are ligands of the 
principal bile acid sensor Fxr and genetic variation in FXR and its target genes are 
implicated in the pathogenesis of ICP. In this section, hepatic bile acids are shown to 
be raised during pregnancy in mice, and found at a level comparable to those in 
cholate-fed and Fxr-/- mice. Subsequently, hepatic microarrays and targeted gene 
expression analysis were used with the objective of determining whether the liver is 
responding to bile acid overload during pregnancy or whether the gene expression 
effects are pro-cholestatic.    
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The gene expression effects of pregnancy on the maternal liver were pro-cholestatic 
and resembled a state of reduced Fxr function. Indeed, a number of direct Fxr-target 
genes (e.g. Bsep and Shp) were repressed during pregnancy while two genes 
indirectly repressed by Fxr (Cyp7a1 and Cyp8b1) were induced in the livers of 
pregnant mice. In mice where anti-cholestatic mechanisms were strongly induced 
(i.e. long-term cholate-fed animals), pregnancy did not cause the accumulation of 
hepatic bile acids. Similarly, hepatic bile acids were not raised during pregnancy in 
Fxr-/- mice. These findings therefore demonstrate that pregnancy causes perturbed 
hepatic bile acid homeostasis in mice and that this could be caused by a state of 
reduced Fxr-function. Several of the gene expression effects reported here are in 
keeping with those reported elsewhere. Notably, the effect of pregnancy on the 
expression of Shp has been demonstrated in two previous reports (Sweeney et al., 
2006; He et al., 2007). However, this is the first complete microarray analysis of 
hepatic gene expression in the late pregnant mouse and demonstrates many pro-
cholestatic hepatic gene expression effects. Interestingly, pregnancy had little effect 
on intestinal bile acid responsive genes, including the signalling hormone Fgf15.  
 
Pregnancy reduced (11-fold) the expression of the multiple drug resistance-
associated protein Mrp3. While the function of this protein is not fully understood, it 
has been implicated in the export of bile acids from hepatocytes (Zelcer et. al. 2003). 
Therefore, the dramatic repression in Mrp3 expression could make a major 
contribution to causing the raised hepatic bile acids in pregnant mice. The regulation 
of Mrp3 expression is poorly understood and experiments to determine the 
mechanism of its repression during pregnancy should be conducted.  
 
Additional experiments are required in order for firm conclusions on Fxr-function 
during pregnancy to be drawn. Treatment of pregnant mice with the specific Fxr 
agonist GW4064 would be expected to prevent the gestational accumulation of 
hepatic bile acids. Furthermore, the signal driving pro-cholestatic gene expression 
during pregnancy has not been identified in these studies. Physiologically relevant 
reproductive hormone experiments did not mimic the gene expression effects of 
pregnancy, suggesting that estradiol and progesterone are unlikely cause the raised 
hepatic bile acids found in pregnant mice. Identification of a pregnancy-specific pro-
cholestatic signal will prove challenging. Initial experiments using primary hepatic 
 154 
cells treated with serum from pregnant or non-pregnant animals and analysis of Fxr-
target gene expression would at least identify whether the pro-cholestatic signal is a 
circulating factor.  
 
Insulin and the secondary bile acid lithocholic acid (LCA) are potential signals that 
may inhibit Fxr-function during pregnancy. In order to maintain a steady supply of 
glucose for fetal development, gestation is a state of insulin resistance with raised 
circulating maternal insulin levels. However, there are conflicting reports on the 
effect of insulin on Fxr function. One study suggests that insulin can inhibit Fxr 
function (Zhang et al., 2004b). As such, the pro-cholestatic gene expression observed 
during pregnancy could be a secondary consequence of altered insulin signalling. In 
humans, the levels of LCA are raised significantly during gestation and LCA is a 
partial antagonist of FXR (Yu et al., 2002). Therefore, it is possible that increased 
levels of circulating insulin could inhibit hepatic Fxr function during gestation.  
 
Perturbed FXR function is in keeping with the normal rise in serum bile acids in 
humans (Castano et al., 2006). Furthermore, this mechanism is also in keeping with 
the genetic aetiology of ICP. As such, the cholestatic nature of normal pregnancy 
exposes individuals with functional variation in bile acid-protective genes, or 
experiencing unrelated biliary events, to an increased risk of developing gestational 
cholestatic disease. Furthermore, the finding that hepatic bile acids did not rise 
during pregnancy in cholate fed mice may explain, in part, the mode of action of 
UDCA, a bile acid commonly used to treat ICP (Williamson, 2001). UCDA is a 
weak FXR-ligand in vitro but can activate Fxr in vivo (Zollner et al., 2003). As such, 
the anti-cholestatic effects of UDCA on FXR could prevent, or reverse, the pro-
cholestatic effects of normal pregnancy.  
 
Surprisingly, pregnancy decreased the expression of 6 out of the 19 genes in the 
cholesterol biosynthesis pathway. As expected, cholate-feeding markedly decreased 
cholesterol biosynthetic genes in order to prevent the accumulation of hepatic 
cholesterol resulting from inhibited bile acid biosynthesis. The pregnant mice are not 
responding to bile acid overload and they do not have a marked decrease in apparent 
bile acid biosynthesis, which is the case in the cholate-fed animals. It is therefore 
possible that the reduced expression of cholesterol biosynthetic genes in the livers of 
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pregnant mice is a response to prevent the flux of metabolites through this pathway, 
thus preventing a further increase in bile acid biosynthesis. Furthermore, this finding 
also supports the findings of others that the majority of the cholesterol that is 
required for fetal development is produced within the fetal compartment (Calandra, 
1975; Innis, 1986; Belknap & Dietschy, 1988; Woollett, 1996; Smith et al., 1998).  
 
This chapter demonstrates that pregnancy has a major effect on maternal hepatic 
function. Pregnancy caused pro-cholestatic gene expression in the liver, which 
resulted in the accumulation of hepatic bile acids. These effects were not maintained 
in Fxr-/- mice or in a model of Fxr activation, suggesting that pregnancy could be a 
state of reduced hepatic Fxr function in mice.  
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6 Intestinal Lithocholic Acid Hydroxylation Affects 
Hepatic Pregnane-x-receptor Activation 
 
6.1  Introduction 
 
Lithocholic acid (LCA) is formed in the intestine by bacterial modification of the 
primary bile acids synthesized in the liver. LCA is considered the most hepatotoxic 
of all bile acids due to its detergent action and because it has antagonist-like effects 
on the function of the principal bile acid sensor Fxr (Yu et al., 2002). Unlike other 
bile acids, LCA reduces the expression of the hepatic bile salt export pump (Bsep) 
and can therefore be considered to be actively cholestatic (Yu et al., 2002).  
 
LCA is an endogenous ligand of both mouse and human PXR and initial reports 
suggested that PXR-activation was the primary mechanism of protection against 
LCA (Staudinger et al., 2001b; Xie et al., 2001). In vivo, LCA up-regulates the 
expression of hepatic Pxr target genes, including phase-I hydroxylation enzymes 
(Cyp3a11 and Cyp2b10), phase-II sulfation enzymes (Sult2a1) and phase-III 
exporters (Oatp2 and Mrp2) (Staudinger et al., 2001b; Xie et al., 2001; Zhang et al., 
2004a; Fickert et al., 2006). However, some studies have not replicated the effects 
LCA on hepatic Cyp3a11 expression (Kitada et al., 2003; Uppal et al., 2005; Beilke 
et al., 2009). Furthermore, Pxr is not required for intestinal induction of Cyp3a11 in 
response to LCA (Makishima et al., 2002) and the hepatic constitutive androsterone 
receptor (CAR) responds to LCA and shares an overlapping target gene profile with 
Pxr (Uppal et al., 2005). In addition, one strain of Pxr-/- mouse expresses elevated 
basal levels of a number of LCA-protective genes (Staudinger et al., 2001b; Teng & 
Piquette-Miller, 2007; van Waterschoot et al., 2008) whereas another does not (Xie 
et al., 2000) and there are also conflicting reports on the relative toxicity of LCA in 
wild-type and Pxr-/- mice (Staudinger et al., 2001b; Xie et al., 2001).  
 
This chapter will address novel aspects of the molecular pathology of LCA-mediated 
toxicity in wild-type and Pxr-/- mice. There is currently no consensus on the effects of 
LCA on hepatic cytochrome P450 enzyme expression, on the basal level of 
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expression of these enzymes in Pxr-/- mice or on the relative toxicity of LCA in wild-
type and Pxr-/- animals. These discrepancies will also be addressed in this chapter.  
 
6.2 Results  
 
6.2.1 Intestinal cytochrome P-450 enzymes respond to LCA and 
influence hepatic detoxification machinery 
 
LCA is formed in the gut and intestinal Cyp3a11 is reported to be induced by LCA-
feeding in a manner that is independent of Pxr (Makishima et al., 2002). However, 
the functional significance of intestinal cytochrome P450 induction on the systemic 
protection against LCA has not been assessed. Intraperitoneal injection of LCA 
bypasses first-pass gut transit and intestinal metabolism. The effects of feeding and 
injecting LCA on hepatic detoxification machinery were therefore compared.  
 
The expression of several hepatic and intestinal BA-responsive genes were assessed 
in response to both routes of LCA administration. In preliminary analyses it was 
confirmed that both LCA-feeding and injection significantly repress the hepatic 
expression of Cyp7a1, the rate-limiting enzyme in BA biosynthesis (13-fold and 5-
fold respectively, p<0.01). Furthermore, expression of the intestinal hormone Fgf15, 
which signals to the liver to repress bile acid biosynthesis, was, as expected, 
significantly up-regulated (6.3-fold, p<0.01) by LCA-feeding. Therefore, both the 
feeding and injection regimen were effective because they induced alterations in key 
bile acid-responsive genes in both the intestine and the liver.   
 
Next, the effects of LCA on the gene expression of hepatic transport proteins was 
assessed. Consistent with its pro-cholestatic effects, LCA feeding significantly 
(p<0.05) reduced the expression of hepatic exporters Bsep, Mrp2 and Oatp2 (Table 
6.1). The expression of the importers Ntcp, Oatp1 and exporters Mrp3, Mrp4 and 
Mdr3 were also decreased by the LCA-feeding but the effect did not reach statistical 
significance (Table 6.1). Intraperitoneal LCA-injection also repressed the expression 
of hepatic transporters. As such Ntcp, Oatp1, Oatp2, Bsep and Mrp2 were 
significantly reduced following LCA-injection and the expression of Mrp3, Mrp4  
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Hepatic genes Feeding Injection 
Ntcp 0.76 0.26* 
Oatp1 0.71 0.11* 
Oatp2 0.61* 0.12* 
Bsep 0.69* 0.42* 
Mrp2 0.63* 0.41* 
Mrp3 0.75 1.34 
Mrp4 0.95 0.96 
Mdr3 0.80 1.20 
Table 6.1. Effect of dietary and intraperitoneal administration of LCA on the 
hepatic transporter gene expression. Data are fold change compared to control diet 
or injection of vehicle. *p<0.05 compared to control. 
 
 Hepatic genes Relative expression in Pxr-/- mice 
Sult2a1 1.12 
Ntcp 1.17 
Oatp1 0.91 
Oatp2 1.15 
Bsep 0.88 
Mrp2 1.15 
Mrp3 1.34 
Mrp4 1.31 
Mdr3 1.23 
Table 6.2. Hepatic mRNA expression of Sult2a1 and hepatic transporters in 
Pxr-/- mice. Data are fold change compared to wild type *p<0.05 compared to wild 
type. 
 
Intestinal genes Relative expression in Pxr-/- mice 
Asbt 0.88 
Ibabp 0.90 
Osta 0.90 
Ostb 0.81 
Table 6.3. Intestinal mRNA expression of bile acid transporters and binding 
proteins in Pxr-/- mice relative to wild-type animals. *p<0.05 compared to wild-
type 
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 Wild type Pxr-/- 
Asbt 0.48* 0.83 
Ibabp 1.32 1.98* 
Fgf15 6.30* 6.27* 
Osta 0.78* 1 
Ostb 0.75 1 
Table 6.4. Effect of LCA-feeding on intestinal bile acid responsive gene 
expression in wild-type and Pxr-/- mice. Data are fold change relative to control 
diet. p<0.05 compared to chow-fed. 
 
 
 Wild-type Pxr-/- 
Cyp7a1 0.08* 0.30* 
Mrp2 0.63* 0.91 
Bsep 0.69* 0.89 
Ntcp 0.76 0.84 
Oatp1 0.71 0.66 
Oatp2 0.61* 0.74 
Mrp3 0.75 0.73 
Mrp4 0.95 0.79 
Mdr3 0.80 0.80 
Table 6.5. The effect of LCA-feeding on hepatic bile acid biosynthesis and 
transporter gene expression in wild type and Pxr-/- mice. Data are fold change 
relative to control diet *p<0.05 compared to chow-fed. 
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and Mdr3 were also reduced but the effect was not statistically significant (Table 
6.1). Hence, both LCA-feeding and LCA-injection repress the expression of hepatic 
transporters.  
 
The phase-I detoxification enzymes, Cyp3a11, Cyp2c55 and Cyp2b10 are reported to 
be target-genes of Pxr and induced in response to either LCA (Cyp3a11 and 
Cyp2b10) or dietary toxins (Cyp2c55) (Staudinger et al., 2001b; van Waterschoot et 
al., 2008). The phase-II sulfotransferase Sult2a1 is also induced by LCA via Pxr and 
its function in sulfating bile acids, prior to urinary excretion, requires the sulphur 
donor synthesis enzyme Papss2 (Staudinger et al., 2001b; Sonoda et al., 2002). 
Following intraperitoneal injection of LCA, total hepatic Cyp3a protein was induced 
(Fig. 6.1A). In contrast, LCA feeding did not induce hepatic Cyp3a protein and its 
level of expression was, in fact, slightly reduced following three days of LCA 
feeding (Fig. 6.1A). Intraperitoneal injection of LCA up-regulated the liver mRNA 
expression of Cyp3a11, Cyp2b10, Cyp2c55 (p=0.07) and Sult2a1 (Fig. 6.1B). In 
contrast, the feeding experiments significantly down-regulated the expression of 
hepatic Cyp3a11, Cyp2b10, Cyp2c55 and Sult2a1 (Fig. 6.1B). Therefore, LCA-
feeding and LCA-injection differentially affect the expression of this sub-set of 
hepatic phase-I and phase-II detoxification enzymes. Finally, both LCA-feeding and 
LCA-injection were found to decrease the expression of hepatic Papss2, and to a 
similar extent  (Fig. 6.1B).  
 
Next, intestinal and hepatic phase-I gene expression responses to LCA-feeding were 
compared. In the liver, LCA feeding repressed the expression of Cyp3a11, Cyp2b10 
and Cyp2c55 (Fig. 6.1A and B) while in the intestine, their expression was increased 
(Fig. 6.2). Therefore, LCA-feeding induces a sub-set of phase-I detoxification 
enzymes in the intestine and represses their expression in the liver. Neither Sult2a1 
nor Papss2 were detected by 40 cycles of Q-RTPCR amplification in the intestine.  
 
Together, these data suggest that the intestine is the primary site of induction of a 
sub-set of phase-I enzymes in response to LCA-feeding. Furthermore, the induction 
of hepatic phase-I enzymes following LCA-injection suggests that this is an adaptive 
response that occurs in the absence of intestinal detoxification.  
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6.2.2 Elevated hepatic, and reduced intestinal, expression of 
Cyp3a11 and Cyp2c55 in Pxr-/- mice 
 
A number of reports have demonstrated that mice lacking Pxr display altered 
expression of LCA-protective genes. The relative expression of a number of these 
genes in Pxr-/- mice were determined under our housing conditions. The basal 
expression levels of bile acid transporters in the liver (Table 6.2) and in the intestine 
(Table 6.3) of Pxr-/- mice were not significantly different to the level of expression in 
wild-type mice.   
 
Most (Staudinger et al., 2001b; Teng & Piquette-Miller, 2007; van Waterschoot et 
al., 2008), but not all (Xie et al., 2000) of the reports that assessed the hepatic 
expression of Cyp3a11 in mice lacking Pxr have found that its basal expression is 
higher in Pxr-/- mice than in controls. The level of Cyp2c55 is also reported to be 
higher in Pxr-/- mice than in controls (van Waterschoot et al., 2008). Under the 
conditions reported here, Pxr-/- mice do express significantly higher hepatic levels of 
Cyp3a11 and Cyp2c55 than wild-type mice (Fig. 6.3). Interestingly, the intestinal 
expression of both of these genes was reduced in Pxr-/- compared to wild-type mice 
(Fig. 6.3). Therefore, Pxr-/- mice express elevated hepatic and reduced intestinal 
levels of two genes that are implicated in hepatoprotection against LCA. The fact 
that both Cyp3a11 and Cyp2c55 are repressed in the intestine and induced in the liver 
of Pxr-/- mice (Fig. 6.3) is a novel finding and supports our suggestion that the 
intestine can influence hepatic detoxification machinery.  
 
Finally, Pxr-/- mice were found to express similar hepatic levels of Cyp2b10 as wild-
type animals but the intestinal expression of this gene was 4-fold higher than in wild-
type animals (Fig. 6.3).  
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6.2.3 Pxr-/- mice are protected against LCA-mediated 
hepatotoxicity 
 
Pxr-/- mice express elevated hepatic and reduced intestinal expression of a number of 
LCA-protective genes (see Fig. 6.3). Furthermore, sub-sets of hepatic drug 
metabolizing enzymes are differentially affected by LCA-feeding and LCA-injection 
(see Fig. 6.1). Because there are conflicting reports on the relative toxicity of LCA in 
wild-type and Pxr-/- mice (Xie et al., 2000; Staudinger et al., 2001b), it was 
investigated whether the route of LCA administration could account for these 
discrepancies. To this end, LCA was delivered to wild-type and Pxr-/- mice by 
dietary supplementation (0.5% w/w for 3 or 7-days) or by intraperitoneal injection 
(0.125mg/mouse twice daily). Control mice received standard chow or vehicle 
injection (corn oil).  
 
Surprisingly, feeding a 0.5% w/w LCA diet for 7-days caused significant weight loss 
in wild-type mice but not in Pxr-/- animals (Fig. 6.4A). This finding suggests that the 
diet is tolerated by Pxr-/- but not wild-type animals. Indeed, subsequent quantitative 
assessment of hepatotoxicity, performed on H&E stained sections by Dr Peter 
Clements (Director of Discovery and Regulatory Pathology, GlaxoSmilKline), 
revealed that the severity of liver damage caused by LCA-feeding was greater in 
wild-type mice than in Pxr-/- animals (Fig. 6.4B an C). Consistent with these 
observations, serum levels of a marker of liver damage, alanine aminotransferase 
(ALT), were significantly higher in wild-type mice than in Pxr-/- mice on the third 
day of LCA-feeding (Fig. 6.4D).  
 
In addition to being protected against LCA-feeding, Pxr-/- mice were also protected 
against intraperitoneal injection of LCA (Fig. 6.5). As was the case with LCA-
feeding, Pxr-/- mice suffered less severe histological liver damage (Fig. 6.5A) and 
had reduced serum ALT levels compared to wild-type mice (Fig. 6.5B).  
 
These data demonstrate that, under the conditions reported here, Pxr-/- mice are 
protected against hepatotoxicity caused by LCA. Furthermore, this phenotype was  
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observed in LCA-feeding and LCA-injection experiments demonstrating that it is 
independent of the route of LCA administration and that the mechanisms underlying 
the protection is likely to be hepatic, not intestinal, in origin.  
 
6.2.4 Increased urinary bile acids and decreased serum bile 
acids in LCA-fed Pxr-/- mice 
 
The mechanism protecting Pxr-/- mice against LCA-mediated hepatotoxicity was 
investigated.  
 
There are no studies that have investigated basal metabolic rate in Pxr-/- mice. It is 
therefore plausible that Pxr-/- animals consume less food than wild-type mice and 
hence, in the feeding experiment, their daily LCA intake would also be reduced. It 
was found that total food intake was unaffected by diet or genotype (p=0.93), 
therefore protection of the Pxr-/- mice against dietary LCA-mediated toxicity was not 
due to reduced ingestion of LCA. 
 
It is plausible that Pxr-/- mice are resistant to LCA-feeding because of reduced 
intestinal LCA-absorption. In order to test this hypothesis, bile acids in the faeces of 
LCA-fed wild-type and LCA-fed Pxr-/- mice were extracted and measured. Over a 
24h period, no difference in total faecal bile acid excretion in LCA-fed wild-type or 
Pxr-/- animals was found (p=0.86). Therefore, neither reduced intestinal absorption 
nor increased faecal excretion contribute to protecting Pxr-/- mice against 
hepatotoxicity caused by LCA-feeding.   
 
Total serum bile acids were measured in wild-type and Pxr-/- mice fed a control or 
LCA-supplemented diet. While LCA-feeding increased total serum bile acids in both 
wild-type and Pxr-/- mice, the magnitude of increase was significantly greater in the 
wild-type mice than in the Pxr-/- animals (Fig. 6.6A). Indeed, LCA-fed wild-type 
mice had 6-fold higher serum bile acids that LCA-fed Pxr-/- mice.  
 
Serum bile acids may be lower in LCA-fed Pxr-/- mice than in LCA-fed wild-type 
mice because of altered urinary bile acid excretion. Animals were housed in  
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metabolic cages for collection of individual urine samples and measurement of 
urinary flow rate. Urinary flow rate was unaffected by diet or genotype (p=0.79). 
Measurement of total urinary bile acids demonstrated that the LCA-supplemented 
diet significantly increased urinary bile acid concentrations in both wild-type and 
Pxr-/- mice (Fig. 6.6B). Importantly however, LCA-fed Pxr-/- animals had 2.5-fold 
higher urinary bile acids than LCA-fed wild-type mice (Fig. 6.6B). These data 
suggest that Pxr-/- mice are protected against LCA-mediated hepatotoxicity as a 
result of enhanced urinary bile acid excretion.  
 
6.2.5 Elevated basal expression of hepatic Papss2 protects Pxr-
/- mice against LCA-mediated hepatotoxicity.  
 
Under the conditions reported here, Pxr-/- mice are protected against dietary and 
intraperitoneal injection of LCA (see Fig. 6.4 and Fig. 6.5) and LCA-fed Pxr-/- 
animals have enhanced urinary bile acid excretion compared to wild-type mice (Fig. 
6.6). Potential molecular mechanisms protecting Pxr-/- mice against LCA were 
investigated next. The basal and LCA-responsive gene expression in the intestine and 
livers of control and LCA-treated (injection and feeding) wild-type and Pxr-/- mice 
were investigated. Elevated expression of hepatoprotective genes in LCA-injected 
and LCA-fed Pxr-/- mice could contribute to the mechanism protecting them against 
this bile acid.  
 
Pxr-/- mice were protected against intraperitoneal injection of LCA (Fig. 6.5), which 
bypasses first-pass gut metabolism. This suggests that the molecular mechanism of 
protection is likely to be hepatic, rather than intestinal, in origin. Indeed, there is no 
evidence from intestinal gene expression analysis for a mechanism that would 
plausibly afford protection of Pxr-/- mice against LCA-feeding. Fgf15 was induced in 
response to LCA-feeding in both wild-type (+6.3-fold) and Pxr-/- mice (+6.3-fold). 
Despite small differences in the magnitude of expression change, Asbt, Ibabp and 
Ostα/β were also similarly affected in both groups of mice (Table 6.4). Despite their 
basal levels being lower in Pxr-/- mice than in controls, Cyp3a11 and Cyp2c55 were 
induced in the intestine in response to LCA-feeding to a similar extent in both groups 
of mice (Fig. 6.7). Therefore, while Pxr is required for the basal maintenance of the  
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expression of these genes in the intestine, it is not required for their induction in 
response to LCA-feeding. The intestinal induction of Cyp2b10 in response to LCA-
feeding observed in wild-type mice did not occur in Pxr-/- animals (Fig. 6.7). This 
finding suggests that Pxr mediates the intestinal induction of Cyp2b10 in response to 
LCA. Investigating the role of Pxr in regulating the intestinal induction of Cyp2b10 
is beyond the scope of this project but is a significant finding and warrants further 
investigation. However, neither the basal nor LCA-responsive levels of expression of 
these LCA-protective genes are higher in Pxr-/- mice than in wild-type animals, 
suggesting that they are unlikely to contribute to the mechanisms protecting Pxr-/- 
mice against LCA-mediated toxicity.   
 
Hepatic gene expression was next analysed in LCA-fed and LCA-injected wild-type 
and Pxr-/- mice. LCA-feeding significantly reduced the expression of Cyp7a1 in both 
wild-type (-12.5-fold) and Pxr-/- mice (-3.3-fold). LCA feeding also decreased the 
expression of hepatic transporters in both wild-type and Pxr-/- mice but the 
magnitude of effect was less marked in Pxr-/- mice and these changes did not reach 
statistical significance (Table 6.5). It is likely that the apparently reduced effect of 
LCA on the expression of Cyp7a1 and hepatic transporters in Pxr-/- mice is a 
secondary affect resulting from the lower circulating bile acids in these animals.  
 
As described previously, in wild-type mice, LCA-feeding reduced the mRNA 
expression of hepatic Cyp3a11 and total Cyp3a protein whereas LCA-injection 
induced the hepatic expression of this gene and protein group (Fig. 6.1). Pxr-/- mice 
express high basal levels of Cyp3a11 and total Cyp3a protein (Fig. 6.3 and 6.8A). In 
Pxr-/- mice, LCA-feeding reduced the expression of Cyp3a11/Cyp3a to a similar 
extent as in wild-type mice but because of their high basal expression, their level 
remained higher in LCA-fed Pxr-/- animals than in LCA-fed wild-type mice (Fig 
6.8). Intraperitoneal injection of LCA up-regulated the expression of Cyp3a11/Cyp3a 
in wild-type but not Pxr-/- mice (Fig. 6.9). Indeed, the expression of hepatic Cyp3a11 
was significantly reduced by LCA-injection in Pxr-/- mice and total Cyp3a protein 
was also slightly reduced (Fig. 6.9). Despite not being induced by LCA-injection in 
Pxr-/- mice, the high basal expression of Cyp3a11/Cyp3a in these animals resulted in 
levels of expression that were comparable in LCA-injected wild-type and knockout  
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mice (Fig. 6.9). It is therefore unlikely that the basal or responsive hepatic expression 
level of these enzymes confer protection of Pxr-/- mice against LCA.  
 
Next, the expression of hepatic Cyp2b10 was assessed in response to LCA-feeding 
and injection in wild-type and Pxr-/- mice. LCA-feeding repressed Cyp2b10 in both 
wild-type and knockout mice (Fig. 6.8). The level of hepatic Cyp2b10 expression in 
Pxr-/- mice was therefore comparable to that in wild-type mice in both control and 
LCA-fed groups (Fig. 6.8). While intraperitoneal injection of LCA significantly 
induced the hepatic expression of Cyp2b10 in wild-type and Pxr-/- mice, the 
induction was markedly blunted in the knockout mice (Fig. 6.9). LCA-injected Pxr-/- 
mice therefore had significantly lower expression of hepatic Cyp2b10 than LCA-
injected wild-type animals (Fig. 6.9). Cyp2b10 does not therefore contribute towards 
the protection of Pxr-/- mice against LCA relative to wild-type mice.  
 
The response of Cyp2c55 to LCA-feeding in wild-type and Pxr-/- mice was similar to 
that of Cyp2b10 (Fig. 6.8). Despite the high basal levels in Pxr-/- animals, LCA-
feeding repressed hepatic Cyp2c55 expression in both groups of animals and resulted 
in a similar level of expression in LCA-fed wild-type and Pxr-/- mice (Fig. 6.8). The 
hepatic induction of Cyp2c55 in response to LCA-injection in wild-type mice did not 
reach statistical significance but its expression was significantly repressed in Pxr-/- 
mice (Fig. 6.9). This pattern of expression is similar to that observed for Cyp3a11 
(Fig. 6.8 and Fig. 6.9). The level of Cyp2c55 remained higher in LCA-injected Pxr-/- 
mice than in LCA-injected wild-type animals (Fig. 6.9).    
 
The expression of the bile acid sulfotransferase, Sult2a1, was reduced by LCA-
feeding in wild-type but not in Pxr-/- mice (Fig. 6.8). As a result, the level of Sult2a1 
expression was higher in LCA-fed Pxr-/- animals than in LCA-fed wild-type mice 
(Fig. 6.8). LCA-injections caused a marked up-regulation in Sult2al expression in 
wild-type mice but had no effect on its expression in mice lacking Pxr (Fig. 6.9). As 
a result, LCA-injected wild-type mice had significantly higher expression of Sult2a1 
than LCA-injected Pxr-/- animals (Fig. 6.9) suggesting that this gene is also unlikely 
to form part of the mechanism protecting Pxr-/- mice from LCA.  
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Finally, the hepatic expression of the sulfate donor synthesis enzyme Papss2 was 
assessed. LCA-feeding reduced the expression of Papss2 to a similar extent in both 
wild-type and Pxr-/- mice (Fig. 6.10). Intraperitoneal injection of LCA also repressed 
hepatic Papss2 in wild-type and in mice lacking Pxr. Importantly however, Pxr-/- 
mice express high basal expression of Papss2 and the level of expression remained 
higher in LCA-fed Pxr-/- mice and LCA-injected Pxr-/- mice than in wild-type 
animals (Fig. 6.10). Because sulfation increases bile acid water solubility and aids 
their urinary excretion, it is plausible that LCA-fed Pxr-/- mice excrete more bile 
acids in their urine than LCA-fed wild-type mice due to enhanced hepatic BA 
sulfation caused by elevated Papss2 expression.  
 
6.3  Discussion and conclusions 
 
This chapter has provided novel insights into the role of hepatic and intestinal Pxr in 
mediating gene and protein expression responses to LCA. In doing so, a phenotype 
of hepatoprotection against LCA-toxicity was discovered in mice lacking Pxr.   
 
LCA is formed in the intestine so intraperitoneal injection, which bypasses first-pass 
gut transit, is not a physiologically relevant route of administration. Using feeding 
experiments, an active role for the intestine in LCA hydroxylation (Makishima et al., 
2002) was confirmed. Furthermore, additional evidence was provided, with regard to 
LCA metabolism, that detoxifying systems in the intestine can influence those in the 
liver (van Waterschoot et al., 2008). Hepatic phase-I and phase-II enzymes were 
induced in response to LCA-injection but no evidence was found of their up-
regulation in response to LCA-feeding. These results partly explain why hepatic 
Cyp3a11 is reported to be unaffected (Kitada et al., 2003; Beilke et al., 2009), 
induced (Staudinger et al., 2001b; Xie et al., 2001; Zhang et al., 2004a; Fickert et al., 
2006) and even repressed (Uppal et al., 2005) by different LCA treatments. Further, 
Pxr-/- mice express high hepatic levels and low intestinal levels of Cyp3a11 and 
Cyp2c55, which is also consistent with a reciprocal relationship between intestinal 
and hepatic phase-I metabolising enzymes.  
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Findings here, and those of others (Staudinger et al., 2001b), have demonstrated that 
the induction of several hepatic genes following LCA injection is Pxr-dependent. 
However, LCA-feeding did not increase the hepatic expression of these genes and 
the induction of intestinal Cyp3a11 and Cyp2c55 occurred through mechanisms 
independent of Pxr. Furthermore, the only evidence found here for Pxr-mediated 
responses to a physiological route of LCA administration was the absence of 
intestinal Cyp2b10 up-regulation in Pxr-/- mice. However, double knockout mice for 
both Pxr and Car are more sensitive to LCA than either individual knockout animal 
(Uppal et al., 2005), which demonstrates that both receptors can mediate protection 
against LCA. Absence of Car and bypass of gut metabolism by intraperitoneal 
injection could be considered examples of failure of the normal mechanisms of 
protection against LCA. The feeding and injection experiments presented here 
suggest that Pxr-mediated gene induction in response to LCA is an adaptive, and not 
a primary, mechanism of protection against toxicity caused by this bile acid. This 
conclusion is drawn because Pxr is required to mediate liver metabolism following 
intraperitoneal LCA administration but not following, physiologically relevant, 
dietary administration of LCA.  
 
Pxr-/- mice were protected against LCA-mediated toxicity. This phenotype was found 
in association with enhanced urinary bile acid excretion. These results are not 
consistent with Xie et al who reported that Pxr-/- mice were more sensitive to LCA 
than wild-types (Xie et al., 2001). However, the route of LCA administration and the 
strain of mouse was different to that used here. In support of the findings presented 
here, Pxr-/- mice are resistant to cholic acid-induced toxicity, reportedly due to 
enhanced basal expression of Mrp3 (Teng & Piquette-Miller, 2007). The increased 
hepatic Mrp3 expression in the Pxr-/- mice did not reach statistical significance in the 
current study. Differences in the reported basal gene expression in Pxr-/- mice (Xie et 
al., 2000; Staudinger et al., 2001b; Teng & Piquette-Miller, 2007) have been difficult 
to reconcile. However, there is indirect evidence (van Waterschoot et al., 2008) that 
altered standard diet composition could explain these discrepancies. Enhanced 
urinary BA excretion in LCA-fed Pxr-/- mice has been observed before (Staudinger et 
al., 2001b) but their resistance to LCA-mediated toxicity was not reported, possibly 
due to masking of the phenotype by other factors, including the time-course of the 
study.  
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Analysis of relative cytochrome p450 expression levels revealed that they are 
unlikely to mediate the principal mechanism of protection of the Pxr-/- mice against 
LCA-toxicity. Increased urinary BA excretion is indicative of enhanced hepatic 
sulfation. However, expression of the key sulfotransferase, Sult2a1, is higher in 
LCA-injected wild-type than Pxr-/- animals and is therefore unlikely to contribute to 
the enhanced BA excretion in LCA-treated Pxr-/- mice. Papss2 is the sulfate donor 
synthesis enzyme required for BA sulfation and subsequent excretion in the urine 
(Xu et al., 2003). Pxr-/- mice were found to express consistently higher levels of 
Papss2 than wild-type mice following both LCA-feeding and injection. It is not 
known whether elevated cellular Papss2 is sufficient to increase LCA sulfation and 
excretion in the absence of up-regulated expression of the sulfotransferase enzymes. 
However, it is plausible that increased expression of Papss2 contributes to the 
enhanced urinary excretion of BAs in LCA-treated Pxr-/- mice. 
 
LCA is implicated in the pathogenesis of a number of cholestatic diseases and this 
work highlights the lack of knowledge of the molecular pathology of this actively 
cholestatic compound. The finding that intestinal hydroxylation influences liver 
metabolism has implications in the planning and interpretation of experiments 
designed to assess the molecular toxicity of BAs, dietary toxins and orally 
administered pharmaceuticals. Elevated expression of drug metabolizing enzymes 
limits the value of Pxr-/- mice as a model for studying the involvement of this 
receptor in responses to xenobiotic stress. However, the phenotype of the Pxr-/- 
mouse provides useful insights into mechanisms of protection against cholestatic 
compounds and this information could be used to target novel therapeutic agents.  
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7 Discussion 
 
7.1 Mechanisms of gestational liver enlargement in mice 
 
Pregnancy causes marked maternal liver growth in rodents. This phenomenon is 
assumed to be a physiological adaptation to the increased metabolic demand on this 
organ during gestation. Despite being first reported in 1958 (Paschkis & Cantarow, 
1958), the mechanism of gestational liver growth has been incompletely 
characterized and no effort has been made to identify the signals that initiate or 
maintain the growth.  
 
This thesis presents the most comprehensive characterisation of gestational liver 
enlargement in mice to date. It was found that the liver does not simply sense and 
respond to changes in maternal mass because during mid gestation the liver is 
disproportionately large compared to maternal body weight. Subsequently, increased 
hepatocyte cross-sectional surface area was identified in pregnant mice and this 
occurred in association with increased nuclear DNA content and cell cycle 
progression in the absence of mitosis. Increased hepatocyte size is in keeping with 
the only other report on the mechanism of gestational liver growth in mice (Hollister 
et al., 1987). However, Hollister et. al reported no change in total liver DNA content. 
While the total DNA content of the liver was not measured directly in this thesis, two 
independent assays, on biological replicates, were used to demonstrate that the DNA 
content of individual hepatocytes was increased in the livers of pregnant mice 
compared to non-pregnant controls. It is difficult to reconcile the data presented here 
on DNA content with those of Hollister et. al, partly because of the lack of detail in 
methodology described in the original publication (Hollister et al., 1987).   
 
Pregnancy caused significant changes in the hepatic protein expression of cell cycle 
regulators. This is one of the few reports that describes such marked alterations in the 
expression of these proteins during a normal physiological event, in a tissue normally 
comprised of quiescent cells. Pregnancy caused a combination of apparently cell-
cycle progressive and cell-cycle inhibitory changes in the expression of these 
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proteins. The pattern of expression is complex and difficult to interpret with 
certainty. However, the effects are likely to reflect the phenotypic observations that 
pregnancy causes cell cycle progression and DNA replication that is uncoupled from 
mitosis.  
 
Pregnancy was found to cause a significant rise in serum bile acids in mice. 
However, this finding is consistent with a number of reports demonstrating raised 
serum bile acids in pregnant humans (most recently, (Castano et al., 2006)). Because 
reproductive hormones and bile acids are raised during pregnancy and can cause 
liver growth in mice (Huang et al., 2006; Yamamoto et al., 2006), these compounds 
could drive gestational liver enlargement. In order to investigate the potential role for 
bile acids and reproductive hormones in driving pregnancy-induced liver growth, 
bile acid induced liver enlargement was characterized and physiologically relevant 
reproductive hormone experiments were performed. The model of Milligan and 
Cohen (Cohen & Milligan, 1993; Milligan & Cohen, 1994; Milligan & Finn, 1997) 
were used to deliver pregnancy-levels of reproductive hormones to ovariectomised 
mice over an 18-day period. In a preliminary experiment, serum levels of 
progesterone were found to be similar in pregnant and in hormone treated mice 
however, accurate measurement of serum estradiol concentration in pregnant and 
hormone treated mice was not possible because of the low circulating levels and 
technical difficulties resulting such as the hormone binding to laboratory plastics. 
However, the hormone treated mice all displayed significant uterine swelling 
compared to vehicle treated animals, demonstrating that the treatment was able to 
affect a known reproductive hormone-responsive tissue. Because the reproductive 
hormones had no effect on liver size, they are unlikely to be the primary mechanism 
of driving gestational hepatomegaly in mice, although it remains possible that they 
form a component of the signal. Furthermore, it is likely that the hepatomegaly and 
hepatotoxicity reported to be associated with reproductive hormone treatments of 
mice (Yamamoto et al., 2006) is likely due to the supra-physiological doses 
administered.  
 
Cholate-feeding is known to cause liver growth in mice and the mechanism by which 
this occurs is known to be primarily by hepatocyte proliferation in association with 
polyploidy (Huang et al., 2006). These findings were confirmed using independent 
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assays. The principal mechanisms of gestational and bile acid-induced liver growth 
are different but cell cycle entry and polyploidy are common features of both 
conditions. It is therefore possible that the raised serum bile acids in pregnant mice 
signal the hepatocyte cell-cycle entry in pregnant animals.  
 
To further investigate the role of bile acids in gestational liver enlargement, 
pregnancy experiments in long-term cholate-fed mice and in animals lacking the bile 
acid-responsive nuclear receptors Pxr and Fxr were conducted. It was found that 
raised serum bile acids are not required for pregnancy-induced hepatomegaly 
because liver growth occurred in Pxr-/- and Fxr-/- mice despite no change in bile acids 
in these animals. While there were significant basal differences in hepatocyte size 
and nuclear DNA content in non-pregnant Pxr-/- and cholate fed mice, the normal 
mechanisms of pregnancy-induced liver growth were broadly maintained in these 
mice. In contrast, gestational hepatomegaly was achieved in Fxr-/- mice by adaptive 
hepatocyte hyperplasia. This finding demonstrates that Fxr is required for the normal 
mechanisms of gestational liver growth in mice and in the absence of Fxr, the growth 
is achieved by a potentially mitogenic mechanism that has features in common with 
cholate-fed animals. Long term cholate-feeding causes hepatocellular carcinoma in 
mice, as does absence of Fxr, both as a result of uncontrolled hepatocyte hyperplasia 
(Kim et al., 2007). It is likely that the hypertrophic effects of pregnancy are 
physiologically preferable to potentially mitogenic hepatocyte hyperplasia and that 
the mechanism of gestational liver growth in mice lacking Fxr are likely to put these 
animals at even higher risk of subsequently developing hepatocellular carcinoma. 
Indeed future experiments investigating the incidence of hepatocellular carcinoma in 
Fxr-/- mice that have, and have-not, been pregnant could confirm a role for this 
nuclear receptor in hepatoprotection during pregnancy.  
 
The principal signal driving gestational liver growth was not identified here. 
However, circumstantial evidence is provided that this signal is of placental origin. 
This evidence comes from our finding that maternal liver weight correlates with fetal 
number. Furthermore, significant liver growth had occurred on the 12th day of 
pregnancy when placental development is known to be almost complete, but with 
only minor fetal development (Iguchi et al., 1993). Marked increases in hepatic 
expression of prolactin responsive growth hormone and prolactin receptor were 
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found during pregnancy. The placenta produces lactogens from relatively early in 
gestation (Ogren & Talamantes, 1988) and during weaning, a period where 
additional liver growth was also observed, lactogens are produced by the mammary 
gland. As such, it is plausible lactogens of placental origin drive gestational liver 
enlargement. A number of additional experiments are required to prove the 
involvement of placental lactogens in driving gestational liver growth in mice.   
 
There are no reports of gestational liver enlargement in humans. The fact that bile 
acids are raised in normal human pregnancy and that there are a number of 
pregnancy specific liver diseases suggests that gestation is a period of metabolic 
stress on the human maternal liver. There is no evidence in the literature, or 
presented in this thesis that suggests that maternal liver growth would not occur 
during pregnancy in humans. However, during late pregnancy, maternal liver weight 
in mice was found to be proportionate to maternal body weight. Because the fetal-
placental unit to body weight ratio is significantly larger in mice than in humans, it is 
likely that any liver growth that occurs in humans will be significantly smaller than 
that in mice. The dimensions of the liver can be established by ultrasound in humans 
but careful correction to maternal body weight and measurement of maternal liver 
size at a number of time points during gestation are likely to be required in order to 
determine whether liver growth occurs during pregnancy in humans.  
7.2 Entero-hepatic responses to LCA 
 
Lithocholic acid (LCA) is produced in the intestine by bacterial modification of 
primary bile acids. LCA is the most hydrophobic and hepatotoxic bile acid and it is 
implicated in the pathogenesis of cholestatic diseases. As such, there is a 
considerable body of research on the molecular pathogenesis of LCA-mediated 
hepatotoxicity and on the hepatoprotective mechanisms induced in response to LCA-
challenge.  
 
Several initial reports concluded that LCA induces hepatic cytochrome p450 
detoxification enzymes that hydroxylate the bile acid before it is sulfated and 
excreted in the urine (Staudinger et al., 2001b; Xie et al., 2001). These detoxification 
mechanisms were attributed to LCA-mediated activation of hepatic Pxr and Car. 
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However, there are examples in the literature of experiments where LCA has not 
induced the hepatic expression of drug metabolising enzymes (Kitada et al., 2003; 
Beilke et al., 2009) (Uppal et al., 2005). The reasons for these discrepancies are not 
known. However, findings presented here demonstrate that intraperitoneal 
administration of LCA induced hepatic cytochrome p450 enzymes whereas LCA-
feeding did not.  
 
LCA-feeding and LCA-injection experiments were conducted in wild type mice. 
Intraperitoneal injections are not physiologically relevant because they bypass the 
potential metabolic actions of the gut. LCA-feeding induced intestinal, but not 
hepatic, drug metabolizing enzymes while injection of LCA did induced these 
enzymes in the liver. This is an important finding because it demonstrates that the 
intestine, not the liver is the principal site of LCA hydroxylation. Furthermore, this 
finding demonstrates that a number of early reports on LCA-toxicity (Staudinger et 
al., 2001b; Xie et al., 2001) may have been miss-interpreted because they were 
conducted using intraperitoneal injections. It is also possible that this finding could 
be relevant to the detoxification of other xenobiotics including dietary toxins and 
orally administered pharmaceuticals.  
 
Pxr is strongly implicated in driving hepatoprotective gene expression in response to 
LCA (Staudinger et al., 2001b; Xie et al., 2001). There was little evidence that Pxr is 
activated in response to LCA-feeding. As such, the induction of intestinal 
cytochrome P450 enzymes was broadly maintained in mice lacking Pxr, as was the 
repression of these genes in the liver. An exception to this pattern was intestinal 
Cyp2b10, which was induced by LCA-feeding in wild type but not in Pxr-/- mice. 
Cyp2b10 is principally a Car target gene (Scheer et al., 2008) so its apparent 
regulation by Pxr was surprising. The apparent Pxr-dependent induction of intestinal 
Cyp2b10 but is an important finding and it warrants further investigation. 
 
Importantly, the induction of hepatic drug metabolizing enzymes in response to 
injection of LCA was largely Pxr-dependent. This is consistent with a number of 
reports (Staudinger et al., 2001b). However, the physiological significance of this 
effect seems to have been wrongly interpreted because Pxr does not mediate hepatic 
detoxification in response to gut-derived LCA.  
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A plausible explanation for the findings presented here is that Pxr-independent gut 
metabolism metabolises LCA and changes its structure such that it does not activate 
Pxr in the liver. In contrast, injecting LCA bypasses the metabolic action of the gut 
and hepatic detoxification enzymes are now induced in a Pxr-dependent manner.  
 
7.3  Hepatoprotection against LCA-mediated toxicity in 
mice Lacking Pxr 
 
Pxr-/- mice are reported to be both equally (Staudinger et al., 2001b) and more 
sensitive (Xie et al., 2001) to LCA-mediated hepatotoxicity than wild type mice. 
Furthermore, Pxr-/- mice are resistant to cholic acid-mediated hepatotoxicity (Teng & 
Piquette-Miller, 2007). Therefore, there are conflicting reports on the sensitivity of 
Pxr-/- mice to bile acid-mediated hepatotoxicity. Because of the marked differences 
in the role of Pxr in responding to LCA-feeding and LCA-injection, liver damage in 
these mice was assessed. Unexpectedly, independent of the route of administration, 
Pxr-/- mice were less sensitive to hepatotoxicity caused by LCA.  
 
The mechanism protecting Pxr-/- mice against LCA-toxicity is likely to be enhanced 
urinary bile acid excretion. Gene expression analysis revealed that Pxr-/- mice 
express elevated hepatic levels of Cyp3a11 and Cyp2c55 but that the response of 
these, and other cytochrome P450 enzymes and transporters in the liver and intestine, 
to LCA were not sufficient to explain the phenotype of protection. Both control and 
LCA-treated Pxr-/- mice express over 2-fold higher levels of the sulfate donor 
synthesis enzyme Papss2, compared to wild type mice. It is likely that the higher 
hepatic expression of Papss2 could result in a larger pool of cellular PAPS which, 
independent of changes in the expression of the sulfotransferase enzymes, could 
enhance the sulfation and subsequent urinary excretion of LCA in Pxr-/- mice.  
 
The phenotype of the Pxr-/- mouse reported here is in direct contrast to Xie et al who 
reported that Pxr-/- mice were hypersensitive to LCA-toxicity (Xie et al., 2001). 
However, these findings can be reconciled. Unlike the results presented here and in a 
report demonstrating protection of Pxr-/- mice against cholic acid (Teng & Piquette-
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Miller, 2007), Xie et al did not report enhanced basal expression of cytochrome P450 
enzymes in his Pxr-/- mice (Xie et al., 2000). This therefore supports the suggestion 
made in this thesis, that altered basal expression of drug metabolising enzymes can 
affect the phenotype of the Pxr-/- mice. The reason for the differences in basal gene 
expression reported by different labs is likely to be explained by a recent report in 
Cyp3a knockout mice which demonstrated that high hepatic exposure to plant 
phytoestrogens in standard diet, due to decreased intestinal metabolism, can 
upregulate hepatic enzymes other than Cyp3a (van Waterschoot et al., 2008). In the 
Pxr-/- mice, it could be extrapolated that reduced intestinal expression of drug 
metabolizing enzymes would expose the liver to higher concentrations of 
phytoestrogens and in turn, mechanisms independent of Pxr would upregulate 
cytochrome p450 enzymes. Therefore, altered standard diet composition between 
labs could affect basal gene expression and hence the phenotype of Pxr-/- mice 
challenged with bile acid.   
 
Enhanced urinary excretion of bile acid has been previously reported in LCA-fed 
Pxr-/- mice, but not in conjunction with hepatoprotection (Staudinger et al., 2001b). 
The hepatoprotective phenotype of the Pxr-/- mice could be masked by the dose or 
duration of the treatment. The finding that Pxr-/- mice can excrete more bile acid in 
their urine than wild type animals limits their use for the study of this receptor in 
mediating hepatoprotection but is a potentially clinically relevant finding. More 
extensive studies are required to confirm an active role for Papss2 in this process but 
these results indicate that targeting therapeutic treatments to Papss2 may be of 
potential benefit in treating cholestatic syndromes.   
 
7.4  Pro-cholestatic hepatic gene expression in pregnant 
mice 
 
In chapter 3, it was found that pregnancy causes a significant increase in serum bile 
acids in mice. This was consistent with a number of observations in humans (most 
recently (Castano et al., 2006)). No information is available regarding hepatic gene 
expression or hepatic bile acids in pregnant humans.  
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In Chapter 5, it was found that hepatic bile acids rise significantly during pregnancy 
in mice. Indeed, hepatic bile acids in pregnant mice reached a level comparable to 
those in cholate-fed and Fxr-/- mice. Cholate feeding is here considered a model 
response to bile acid overload while Fxr-/- mice were considered a pro-cholestatic 
genetic model. Intact tissue NMR experiments and hepatic microarrays were used to 
investigate the effects of pregnancy, cholate-feeding and absence of Fxr on the liver. 
Unbiased analysis showed circumstantial evidence of similarity between the effects 
of pregnancy and those in Fxr-/- mice. Subsequent supervised analysis of hepatic 
gene expression revealed that despite having raised serum and hepatic bile acids, the 
expression pattern in the liver of pregnant mice was pro-cholestatic and resembled a 
state of reduced Fxr function. Further evidence was presented for reduced Fxr 
function during gestation because potent activation of Fxr by cholate feeding 
prevented the gestational accumulation of hepatic bile acids. In addition, pregnancy 
did not increase hepatic bile acids in Fxr-/- mice.  
 
Despite having raised hepatic bile acids, gene expression in pregnant mice is pro-
cholestatic. Some evidence of reduced Fxr function during pregnancy is provided but 
further experiments are required to confirm this. Assessing hepatic bile acids in 
pregnant wild type and Fxr-/- mice treated with the highly specific Fxr agonist 
GW4064 would confirm a role for Fxr in preventing pro-cholestatic gene expression 
during pregnancy.  
 
The models of Milligan and Cohen were again used to assess whether pro-cholestatic 
gene expression was induced by physiologically relevant reproductive hormone 
treatments. No evidence was found that this was the case. As such, the signal driving 
the cholestatic effects of pregnancy was not identified here. Lithocholic acid (LCA) 
is a potential signal because its serum concentrations are raised in pregnant humans 
(Castano et al., 2006) and it can partially antagonise Fxr in mice (Yu et al., 2002). 
However, the rise in LCA levels in humans is small and its Fxr-antagonist effect 
seems to be selective because the expression of the Fxr target gene Bsep is repressed 
by LCA while another Fxr target, Shp is apparently not affected (Duran-Sandoval et 
al., 2005).  
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Insulin is another potential signal causing pro-cholestatic gene expression during 
pregnancy. In order to maintain a stable supply of glucose for fetal development, 
pregnancy is an insulin resistant state resulting in pancreatic islet cell proliferation 
and increased circulating levels of insulin (Weinhaus et al., 1996; Flamez et al., 
2002). There are conflicting reports on the effect of insulin of Fxr-function (Zhang et 
al., 2004b) (Duran-Sandoval et al., 2005). One report suggests that insulin can 
inhibit the expression and activity of Fxr (Zhang et al., 2004b). It is plausible that the 
increased circulating insulin that is a requirement of pregnancy could, as a secondary 
consequence, inhibit hepatic Fxr function and cause mild cholestasis.   
 
Testing potential signals causing pro-cholestatic gene expression during pregnancy 
in vitro or in vivo will prove difficult. Initial experiments could be conducted by 
treating primary cells with serum from non-pregnant and pregnant animals/humans 
and assessing Fxr-target gene expression. These experiments would at least allow 
conclusions to be drawn on whether the signal is a circulating factor. Subsequent 
experiments are speculative but the likely inter-individual variability on the effects of 
the serum could be used as an advantage by conducting high performance analytical 
techniques (e.g. gas chromatography mass spectrometry) on the sera to correlate 
individual metabolites with effect on Fxr-target gene expression.  
 
There are unpublished data from another laboratory that show that disrupting 
sleeping/waking hours can cause cyclical cholestasis in mice at the times when the 
animals would normally consume food. Pregnancy is largely accepted to cause 
alterations in sleep pattern and food consumption in humans and in mice. It is 
therefore possible that these alterations disturb the entero-hepatic homeostasis of bile 
acids.    
 
The data presented in this section do not definitively prove that Fxr function is 
reduced during pregnancy. However, the data demonstrate pro-cholestatic gene 
expression and a phenotype of mild cholestasis in pregnant mice. These findings are 
consistent with the genetic aetiology of intrahepatic cholestasis of pregnancy (ICP) 
(Dixon et. al. 2009). As such, if pregnancy is considered slightly cholestatic, 
individuals with function altering genetic variants of bile acid-protective genes or 
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experiencing unrelated biliary events would be at increased risk of developing 
cholestatic diseases when pregnant.    
 
7.5  Sequencing of hPXR in ICP and function of PXR 
variants 
 
Functional variants in the principal bile acid sensor FXR and its target genes are 
associated with ICP (Dixon et. al. 2009). It was hypothesized that variants of the 
xenobiotic sensor PXR, or its target gene SULT2A1, could also influence the 
aetiology of ICP. Furthermore, the drugs used to treat ICP are ligands of PXR so 
genetic variation in PXR could also explain the inter-individual variation in response 
to treatment.  
 
The entire coding region of PXR and SULT2A1 was sequenced in a Caucasian 
population. No coding variants in the SULT2A1 gene were identifies  and the two 
variants identified in PXR, P27A and G36R were present at frequencies similar to 
those reported in healthy populations (Zhang et al., 2001). Coding genetic variation 
in PXR or SULT2A1 does not therefore contribute to the aetiology of ICP. It remains 
possible that non-coding variation in these loci contribute to ICP, although this is 
unlikely. Furthermore, genetic variation in the upstream regulatory regions of genes 
can influence their transcription and function. No such genetic variation has been 
reported to be associated with ICP.  
 
There are difficulties in interpreting the results of transactivation assays assessing the 
function of PXR variants between labs. For example, despite no changes in protein 
expression, variant Q158K performs as wild-type protein in LS174T cells treated 
with coltrimazole but causes significantly reduced transactivation compared to WT 
PXR in HepG2 cells treated with the same ligand (Lim et al., 2005). Therefore the 
first comprehensive analysis of all known PXR variants in response to ligands used 
to treat ICP was conducted. While a number of variants did reduce the ability of PXR 
to transactivate the CYP3A4 promoter, the two variants identified in the ICP cohort 
were non-functional in this assay. Transactivation assays have limitations stemming 
from overexpression of target proteins, supraphysiological concentrations of ligands 
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and the semi-synthetic nature of reporter sequence. However, there is no data 
presented here that suggests that individuals harbouring P27S or G36R would have a 
perturbed treatment response in ICP.  
 
Thirteen non-synonymous polymorphisms have been reported in the PXR gene 
(Hustert et al., 2001; Zhang et al., 2001; Koyano et al., 2002; Lim et al., 2005; 
Bosch et al., 2006). This is significantly more than reported in the close relatives of 
PXR, namely FXR and CAR. Furthermore, the variants in PXR cluster in the LBD 
and this apparent plasticity suggest a strong evolutionary pressure on the receptor 
and its LBD. While most of the non-synonymous variants of PXR seem to be non-
functional, two variants are found to abolish all PXR function. These non-functional 
variants are rare and only ever found as heterozygous mutations, it is nevertheless 
interesting that the individuals harbouring these variants are reported to be normal 
(Koyano et al., 2004).  
 
Studies into the genetic aetiology of ICP have been hampered by a number of 
factors. Most notably, the limited sample size of most studies has prevented the 
identification of genetic variation with relatively subtle effects. Furthermore, the 
heterogeneity of the sample and control cohort can weaken the statistical significance 
of identified variation. Our group identifies ICP patients based on raised serum bile 
acid in combination with maternal puritus or abnormal liver function tests. This 
diagnosis is important for genetic studies because it eliminates individuals with 
asymptomatic hypercholaemia of pregnancy from being included in the ICP cohort. 
Future genome wide association studies will provide the most comprehensive 
information of the genetic aetiology of ICP, however, these experiments will require 
very large and well-defined patient and control cohorts.  
 
7.6  Overall conclusions 
 
Gestation is a period of increased metabolic demand on the maternal liver. This is 
highlighted in humans by pregnancy-specific liver diseases and in rodents by 
hepatomegaly. Gestational liver growth in rodents is intriguing because it precedes 
changes in maternal body weight and causes quiescent hepatocytes to enter the cell 
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cycle, progress through DNA synthesis but arrest prior to mitosis. Placental 
lactogens may mediate these events and could prove useful in transiently increasing 
liver metabolism without risking potentially harmful hyperplasia. Despite an increase 
in liver mass, pregnant mice also have raised hepatic bile acids and pro-cholestatic 
gene expression that resembles a state of reduced Fxr-function. The mechanism 
driving pro-cholestatic gene expression during gestation is not known. However, 
these findings are consistent with raised serum bile acids in pregnant humans and the 
fact that individuals with genetic variation in FXR are at increased risk of developing 
gestational cholestatic disease. Variation in PXR does not contribute to intrahepatic 
cholestasis of pregnancy and contrary to early reports, experiments using Pxr-/- mice 
suggest that this receptor may play only a limited role in mediating hepatic responses 
to intestinal-derived lithocholic acid.  
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Appendices 
 
(A) PXR (NR1I2) sequencing primers 
 
Exon Primer sequence Annealing oC 
PXRexon1.f CCCCTTTTCCTGTGTTTTTG 61 
PXRexon1 CAACATTAAGTGATTGTTTTCATGC 61 
PXRexon2.f AACAATTCCAACCCCCATTC 61 
PXRexon2.r TCTGGGATATAAATGGCTCCC 61 
PXRexon3.f  ACTCCCACCTACACCCTTCC 62 
PXRexon3.r CTCCCTCCATCTCCCAGAG 62 
PXRexon4.f  AGGGGAGAATTGCTTGTCAC 64 
PXRexon4.r ACTGGGGAACTGCCTAGCTT 64 
PXRexon5.f CAAGCAGGGATGTGTGTGAC 64 
PXRexon5.r GGAGGGTCTTCTGACACCAA 64 
PXRexon6.f GGTTGTGAGGGGAGAGATGA 61 
PXRexon6.r AGCCACCTGTGGATGGTAAC 61 
PXRexon7.f CTGCAGTTATGGGAGGAAGG 61 
PXRexon7.r GGCAAAGACAAGCTCAGTCC 61 
PXRexon8.f TATGGCCTTGCTCCTCATTC 64 
PXRexon8.r CCCCTGTTTGCTTGTGTTTT 64 
PXRexon9_1.f AAGCCTTGTCTCTTGGCTGA 64 
PXRexon9_1.r CATAGACCCCAGATGGCCTA 64 
PXRexon9_2.f ATGTCAGAAGCTTGGCATGA 64 
PXRexon9_2.r CCCACATTATTTTCCCCAGA 64 
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(B) SULT2A1 sequencing primers 
 
Exon Primer sequence Annealing 
oC 
SULT2A1 
exon1.f 
TGTAAAACGACGGCCAGTGGGACAAGGTTAAAGATCGTTTT 
ATC 
64 
SULT2A1 
exon1.r 
CAGGAAACAGCTATGACCAAGCATTGTACACTGTCTGAC 64 
SULT2A1 
exon2.f 
TGTAAAACGACGGCCAGTATGTCCGGCTGAGATGGTACA 62 
 
SULT2A1 
exon2.r 
CAGGAAACAGCTATGACCAACACAGACCTGTTGAAGGAG 62 
SULT2A1 
exon3.f 
TGTAAAACGACGGCCAGTATTGATATTATTAGGCATTATCC 
A 
62 
SULT2A1 
exon3.r 
CAGGAAACAGCTATGACCAGGTTTGGCCTCCAGGGGTGG 62 
SULT2A1 
exon4.f 
TGTAAAACGACGGCCAGTACATCTGTTATATACTGTAAA 64 
SULT2A1 
exon4.r 
CAGGAAACAGCTATGACCGGTGGAATGAAGACACAG 64 
SULT2A1 
exon5.f 
TGTAAAACGACGGCCAGTGGGATTACACGGTGAACCACC 62 
SULT2A1 
exon5.r 
CAGGAAACAGCTATGACCAAGCTCTCTTTCATCTCAACT 62 
SULT2A1 
exon6.f 
TGTAAAACGACGGCCAGTCTGCTATGTTAGCTACAATGTCC 
A 
62 
SULT2A1 
exon6.r 
CAGGAAACAGCTATGACCTTTTAACAAGGAAGGGATCAG 62 
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(C) hPXR mutagenesis primer sequences 
 
Variant Primer sequence 
P27S f CAGAGTCTGTTCCTGGAAABTCCAGTGTCAACGCAGATGAGG 
P27S r CCTCATCTGCGTTGACACACTGGACTTTCCAGGAACAGACTCTG 
G36R f CAACGCAGATGAGGAAGTCAGAGGTCCCCAAATCGTCCGT 
G36R r CACGGCAGATTTTGGGGACCTCTGACTTCCTCATCTGCGTTG 
A370T f CTGCAGGAGCAATTCACCATTACTCGAAGTCC 
A370T r GGACTTCAGAGTAATGGTGAATTGCTCCTGCAG 
V140M f CTCAGCCACTGGAATGCAGGGGCTGAC 
V140M r GTCAGCCCTGCATTCCCAGTGGCTGAC 
I403V f TATGCTCACCAGCTCCGCAGCGTAATGCTCAG 
I403V r CTGAGCATTGACGCTGCTGCGGAGCTCGGTGAGCATA 
R122Q f GTGGAGGAAGAGGCAGGCCTTGATCAAGCGC 
R122Q r CCGTTGATCAAGGCCYGCCTCGCCTCTCCTCCAC 
Q158K f GAGCTGATGGACGCTAAGATGAAAACCTTTGAG 
Q158K r GTCAAAGGTTTTCATCTTAGCGTCCATCAGCTC 
R381W f TCCTACATTGAATGCAATTGGCCCCAGCCTGCTCATAG 
R381W r CTCTGAGCAGGTGGGGCCAATTGCATTCAATGTAGGA 
E18K f GCTGACTTTGTACACTGTAAGACACAGAGTCTGTTCCTG 
E18K r CAGGAACAGACTCTGTGTCCTTACAGTGTACAAAGTCAGC 
R148Q f CTGACAGAGGAGCAGCACATAGATGATCGGAG 
R148Q r CTCCCTGATCATCTGCTTGCTCCTCTGTCAG 
D163G f CAGATGAAACCTTTGGCAATACCTTCTCCC 
D163G r GGGAGAAGGTAGTGCCAAAGGTTTTCATCTG 
R98C f TGCCAGGCCTGCTGCCTGCGCAAGTGC 
R98C r GACCTTGCGCAGGCAGCAGGCCTGGCA 
C379G f GTCCTACATTGAAGGAATCGGCCCCAG 
C379G r CTGGGCCGATTGCCTTCAATTAGGAC 
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(D) Generation and validation of Fxr-/- mice. 
 
Fxr-/- mice were generated and validated by Chitage Mataki in the laboratory of Dr 
Kristina Schoonjans and Professor Joan Auerx and supplied under an MTA with the 
university of Strasbourg.  
 
For the generation of Fxr knock-out (Fxr-/-) mice, genomic DNA covering the Fxr 
locus was amplified from the 129Sv strain using high fidelity PCR. The resulting 
DNA fragments were assembled into the targeting vector that after linearization was 
electroporated into 129Sv ES cells. G418-resistant colonies were selected and 
analyzed for homologous recombination. The karyotype was verified and several 
correctly targeted ES cell clones were injected into blastocysts from C57BL/6J mice. 
These blastocysts were transferred into pseudopregnant females, resulting in 
chimeric offspring that were mated to female C57BL/6J mice that express Flp 
recombinase under the control of the ubiquitous CMV promoter. Offspring that 
transmitted the mutated allele, in which the selection marker was excised and that 
lost the Flp transgene were selected, mated with CMV-Cre mice to excise the LoxP 
site (Fxr+/- mice) and intercrossed to generate wild type (Fxr+/+) and knock-out (Fxr-
/-) mice. For mice genotyping, PCR primer pair AHX118: 
5´GAAGCACACTCACAGATGTCA3´, AHX124: 
5’ATGTGTTCTAAGCTAGACATGG3’ (product size: 550 bp) and primer pair 
AHX118, AHX121: 5’AGATGCTGTTAGGTGGTCAGC3´ (product size: 380 bp) 
were used to identify excised (L-) and premutant (L2) alleles, respectively. RNA 
from liver was isolated using trizol method (Invitrogen, Carsland, CA). cDNAs were 
synthesized from total RNA with SuperScriptTM II Reverse Transcriptase 
(Invitrogen) and random hexamer primers (Roche, Basel, Switzerland). The real-time 
PCR measurement of individual cDNAs was performed using SYBR green dye 
(Qiagen, Courtaboeuf, France) to measure duplex DNA formation with Roche 
Lightcycler. Sequences of primers used to amplify Fxr are 
5’ACAGCTAATGAGGACGACAG 3’ and 5’ GATTTCCTGAGGCATTCTCTG 
3’. Nuclear extracts (100 µg) from liver of Fxr+/+, Fxr+/- and Fxr-/- mice were 
transferred to membrane following standard procedures. The membrane was then 
incubated overnight at 4°C with an anti-Fxr antibody (PPMX Perseus Proteomics 
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Inc) and next for 1 hour at 21°C with a peroxidase conjugate secondary antibody. 
Membranes were washed and proteins were visualized with the enhanced 
chemiluminescence kit (Amersham Pharmacia Biotech).
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(D) Mouse gene expression primer sequences 
 
Abca1 f TCCTCATCCTCGTCATTCAAA 
Abca1 r GGACTTGGTAGGACGGAACCT 
Abcg5 f TCAATGAGTTTTACGGCCTGAA 
Abcg5 r GCACATCGGGTGATTTAGCA 
Abcg8 f TGCCCACCTTCCACATGTC 
Abcg8 r ATGAAGCCGGCAGTAAGGTAGA 
Asbt f TCCTTGGCTGGACTAGCTGGTCAA 
Asbt r CTGAGTGTTCTGCATTCCAGTTTC 
Bsep f AAGGTACATCTGCCTTAGACACAGAA 
Bsep r CAATACAGGTCCGACCCTCTCT 
Car f GGAGGACCAGATCTCCCTTC 
Car r ATTTCATTGCCACTCCCAAG 
Ccnd1 f GGGCACCTGGATTGTTCT 
Ccnd1 r CACCGGAGACTCAGAGCA 
Cyp2b10 f CTGAATCCGCTCCTCCACACTC 
Cyp2b10 r TGAGCCAACCTTCAA GGAATAT 
Cyp2c55 f PROPRIETORY (QIAGEN) 
Cyp2c55 r PROPRIETORY (QIAGEN) 
Cyp7A1 f AGCAACTAAAACAACCTGCCAGT 
Cyp7A1 r GTCCGGATATTCAAGGATGCA 
Cyp8b1 f TAGCCCTCTTTCCTCCACTCATA 
Cyp8b1 r GAACCGATCGAACCTAAATTCCT 
Cyp3a11 f PROPRIETORY (QIAGEN) 
Cyp3a11 r PROPRIETORY (QIAGEN) 
Cyp17A1 f TAGCAATCGATGGGTAAAAT 
Cyp17A1 r TCCGAAGGGCAAATAACTGG 
Fgf15 f GAGGACCAAAACGAACGAAATT 
Fgf15 r ACGTCCTTGATGGCAATCG 
Gadd45b f GTTACTCAAGCAGTCACTCCCC 
Gadd45b r TCTTCAGGCTCACCTCTCTCTC 
Ghr f GATTTTACCCCCAGTCCCAGTC 
Ghr r GACCCTTCAGTCTTCTCATCCACA 
Hmgcr f CATTCCAGCCAAGGTGGTGAG 
Hmgcr r CAAGATGTCCTGCTGCCAAGG 
Ibabp f TGAGAGTGAGAAGAATTACGATGAGTTC 
Ibabp r TTACGTCCCCTTTCAATCACG 
Igfbp1 f CGCCTGCGTGCAGGAGTCTG 
Igfbp1 r AGAGCCTTCGAGCCATCATA 
Mdr1 f GG ATTGCCTACCTGTTGG 
Mdr1 r GCTTTCTGTGGACACTTCTG 
Mdr2 f CTCGTTAACATGCAGACAGCAG 
Mdr2 r GACCAGGGAGAACATGTTACAC 
Mrp2 f GGTTCCTGTCCATGTTCTGGATT 
Mrp2 r GCAGCTGAGGATTCAGAAACAAA 
Mrp3 f GCAGCAGAACCAAGCATCAAG 
Mrp3 r GACCGCATCCTCACCTGG 
Mrp4 f GGTTGGAATTGTGGGCAGAA 
Mrp4 r TCGTCCGTGTGCTCATTGAA 
Ntcp f GAAGTCCAAAAGGCCACACTATTGT 
Ntcp r ACAGCCACAGAGAGGGAGAAAAG 
Oatp1 f TGATACACGCTGGGTCGGTG 
Oatp1 r GCTGCTCCAGGTATTTGGGC 
Oatp2 f GTTGCAACCCATGGGGTCAGATG 
Oatp2 r GCTGGTCAGGATATTCACTCCTG 
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Ostα f CTGAGCATATAGTGGGCCTGTTC 
Ostα r AGCTGCGCTCTTCTCAGAAATT 
Ostβ f TGACAAGCATGTTCGTCCTGAG 
Ostβ r TTCTTTGTCTTGTGGCTGCTTC 
Papss2 f CATGCAGCTGTACTGGAGGA 
Papss2 r GGAGATGGAAAGATGGCAAC 
Prlr f CATCACAGTAAATGCCACGAACGAA 
Prlr r AAAGATGCAGGTCATCATGCTATAA 
Shp f CGATCCTCTTCAACCCAGATG 
Shp r AGGGCTCCAAGACTTCACACA 
Sult2a1 f GAAGGCATACCTTTTCCTGCCAT 
Sult2a1 r GTAACCAGACACAAGAATATCTCT 
Vdr f ATGACCTGTGAAGGCTGCAAG 
Vdr r GGCAGGTGAACAGGGCC 
 
 200 
Microarray gene expression Data 
 
Additional microarray data are presented on supplementary compact disk that 
accompanies this thesis. The files contain all liver expressed genes that are affected 
(p<0.05) under each condition.  
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